metformin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 387.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.64 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 67
kinase-selectivity-class ACVR2B,AXL,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP3K14,MAPK7,STK33,TEK,TTK 15
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.604 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 High 1

Approvals:

DateAgencyCompanyOrphan
March 3, 1995 FDA BRISTOL MYERS SQUIBB
July 28, 2006 EMA CHEPLAPHARM Arzneimittel GmbH
Jan. 1, 1961 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 21373.58 9.18 8502 464504 41961 90113480
Acute kidney injury 5768.04 9.18 7699 465307 312688 89842753
Hypoglycaemia 4746.16 9.18 3480 469526 66368 90089073
Metabolic acidosis 4229.41 9.18 2969 470037 52707 90102734
Diabetic ketoacidosis 2767.74 9.18 1674 471332 22733 90132708
Blood glucose increased 2379.69 9.18 2705 470301 92541 90062900
Euglycaemic diabetic ketoacidosis 1928.39 9.18 840 472166 5361 90150080
Ketoacidosis 1440.01 9.18 664 472342 4931 90150510
Hyperkalaemia 1412.57 9.18 1719 471287 63245 90092196
Diabetes mellitus inadequate control 1368.20 9.18 975 472031 17709 90137732
Glycosylated haemoglobin increased 1298.72 9.18 880 472126 14682 90140759
Hyperglycaemia 1144.37 9.18 1371 471635 49599 90105842
Systemic lupus erythematosus 1014.02 9.18 314 472692 361582 89793859
Pemphigus 898.90 9.18 293 472713 326571 89828870
Glossodynia 892.75 9.18 284 472722 321495 89833946
Shock 889.20 9.18 915 472091 27863 90127578
Hand deformity 884.09 9.18 228 472778 296134 89859307
Anti-cyclic citrullinated peptide antibody positive 752.46 9.18 158 472848 236275 89919166
Hyperlactacidaemia 737.34 9.18 382 472624 3754 90151687
Hypoglycaemic coma 732.63 9.18 343 472663 2647 90152794
Toxicity to various agents 697.88 9.18 3164 469842 284682 89870759
Infusion related reaction 675.96 9.18 707 472299 416073 89739368
Duodenal ulcer perforation 646.96 9.18 177 472829 221111 89934330
Arthropathy 644.05 9.18 578 472428 365664 89789777
Helicobacter infection 634.70 9.18 197 472809 226653 89928788
Synovitis 628.48 9.18 481 472525 329271 89826170
Renal failure 614.81 9.18 1787 471219 129220 90026221
Wound 608.58 9.18 418 472588 302562 89852879
Pericarditis 597.62 9.18 333 472673 269818 89885623
Drug intolerance 595.26 9.18 884 472122 446707 89708734
Rheumatoid factor positive 595.16 9.18 92 472914 171558 89983883
Pancreatitis acute 572.04 9.18 770 472236 31345 90124096
Swelling 556.83 9.18 828 472178 418230 89737211
Sleep disorder due to general medical condition, insomnia type 555.14 9.18 28 472978 128666 90026775
Alopecia 545.97 9.18 1101 471905 493970 89661471
Dehydration 517.74 9.18 2199 470807 192248 89963193
Joint swelling 506.34 9.18 1178 471828 502122 89653319
Blood glucose decreased 505.81 9.18 618 472388 22811 90132630
Anuria 503.29 9.18 496 472510 14322 90141119
Discomfort 489.24 9.18 427 472579 273908 89881533
Contraindicated product administered 484.84 9.18 574 472432 319565 89835876
Hypersensitivity 482.80 9.18 1033 471973 453644 89701797
Swollen joint count increased 480.28 9.18 24 472982 111182 90044259
Drug ineffective 475.89 9.18 4782 468224 1379516 88775925
Diarrhoea 462.54 9.18 7166 465840 932024 89223417
Infection 458.36 9.18 739 472267 361355 89794086
Muscle injury 453.46 9.18 177 472829 176477 89978964
Folliculitis 445.94 9.18 256 472750 204097 89951344
Treatment failure 442.22 9.18 562 472444 303366 89852075
Irritable bowel syndrome 437.04 9.18 271 472735 207177 89948264
Impaired healing 436.68 9.18 349 472657 233850 89921591
Hypothermia 434.42 9.18 469 472537 15106 90140335
Diabetic metabolic decompensation 429.12 9.18 208 472798 1749 90153692
Stomatitis 427.25 9.18 482 472524 274216 89881225
Drug interaction 422.05 9.18 2677 470329 273776 89881665
Blood glucose abnormal 419.60 9.18 368 472638 9124 90146317
Completed suicide 379.41 9.18 1632 471374 143426 90012015
Pemphigoid 371.32 9.18 336 472670 8690 90146751
Hepatic enzyme increased 364.33 9.18 842 472164 359894 89795547
Drug level increased 359.89 9.18 573 472433 27189 90128252
Pancreatitis 358.23 9.18 984 472022 68842 90086599
Therapeutic product effect decreased 358.21 9.18 559 472447 277012 89878429
Rhabdomyolysis 351.87 9.18 807 472199 50449 90104992
Rheumatic fever 351.26 9.18 180 472826 152941 90002500
Vomiting 342.04 9.18 5893 467113 782400 89373041
Rash 339.63 9.18 2598 470408 793502 89361939
Blood lactic acid increased 336.28 9.18 314 472692 8464 90146977
Off label use 333.88 9.18 3917 469089 1098335 89057106
Abdominal discomfort 329.23 9.18 1328 471678 476000 89679441
Diabetes mellitus 310.00 9.18 891 472115 63984 90091457
Musculoskeletal stiffness 308.39 9.18 681 472325 295851 89859590
Blister 283.29 9.18 564 472442 254434 89901007
Haemodialysis 279.02 9.18 283 472723 8464 90146977
Contusion 272.79 9.18 563 472443 250653 89904788
Ill-defined disorder 264.50 9.18 346 472660 184545 89970896
Fibromyalgia 257.93 9.18 424 472582 205845 89949596
Product use issue 256.00 9.18 874 472132 329045 89826396
Liver injury 252.50 9.18 311 472695 170256 89985185
Intentional overdose 248.57 9.18 1060 471946 92774 90062667
Deep vein thrombosis postoperative 245.24 9.18 38 472968 70771 90084670
Vitamin B12 deficiency 243.91 9.18 245 472761 7241 90148200
Acidosis 238.51 9.18 313 472693 12423 90143018
Pain 235.05 9.18 3724 469282 992617 89162824
Autoimmune disorder 234.49 9.18 56 472950 76688 90078753
Hypotension 229.67 9.18 2653 470353 322744 89832697
Drug level above therapeutic 224.84 9.18 209 472797 5600 90149841
Overdose 222.59 9.18 1498 471508 156211 89999230
Blood glucose fluctuation 218.54 9.18 194 472812 4889 90150552
Mobility decreased 216.39 9.18 633 472373 250101 89905340
Pyrexia 215.86 9.18 2305 470701 658180 89497261
Adjustment disorder with depressed mood 214.51 9.18 23 472983 56730 90098711
Renal impairment 212.57 9.18 1100 471906 104321 90051120
Maternal exposure during pregnancy 211.85 9.18 1062 471944 359001 89796440
Nausea 208.45 9.18 7406 465600 1102910 89052531
Lower limb fracture 205.51 9.18 93 472913 84920 90070521
Hip arthroplasty 204.51 9.18 71 472935 76137 90079304
Drug hypersensitivity 204.28 9.18 1498 471508 462111 89693330
Continuous haemodiafiltration 203.08 9.18 99 472907 844 90154597
Cardiac arrest 202.70 9.18 1082 471924 103853 90051588
Pancreatic carcinoma 200.62 9.18 233 472773 8144 90147297
Neurologic neglect syndrome 200.14 9.18 239 472767 8608 90146833
Carotid artery thrombosis 199.76 9.18 242 472764 8850 90146591
Injury 199.54 9.18 460 472546 196889 89958552
Personality disorder 194.14 9.18 280 472726 12164 90143277
Hemiplegia 193.78 9.18 322 472684 15838 90139603
C-reactive protein abnormal 192.12 9.18 229 472777 127200 90028241
Sinusitis 191.09 9.18 1031 471975 342057 89813384
Joint range of motion decreased 190.75 9.18 257 472749 135386 90020055
Prescribed overdose 190.11 9.18 139 472867 97486 90057955
Adjustment disorder 186.85 9.18 241 472765 9401 90146040
Rheumatoid arthritis 186.69 9.18 1118 471888 361496 89793945
Bone erosion 184.65 9.18 28 472978 52993 90102448
Psoriatic arthropathy 184.51 9.18 594 472412 227741 89927700
Hypomagnesaemia 183.96 9.18 503 472503 35085 90120356
Lip dry 178.75 9.18 158 472848 100797 90054644
Myocardial infarction 173.87 9.18 1046 471960 104926 90050515
Blood cholesterol increased 172.37 9.18 535 472471 207477 89947964
Ketosis 168.44 9.18 83 472923 726 90154715
Blood creatinine increased 167.14 9.18 1002 472004 100384 90055057
Pulmonary fibrosis 164.40 9.18 191 472815 107312 90048129
Wound infection 161.69 9.18 190 472816 106212 90049229
Dysarthria 161.26 9.18 637 472369 53845 90101596
Therapy non-responder 160.80 9.18 292 472714 136412 90019029
X-ray abnormal 160.47 9.18 23 472983 45401 90110040
Dislocation of vertebra 157.49 9.18 48 472958 55920 90099521
Wheezing 157.24 9.18 673 472333 237407 89918034
Tachypnoea 156.84 9.18 345 472661 20964 90134477
MELAS syndrome 156.06 9.18 54 472952 162 90155279
Bursitis 155.04 9.18 281 472725 131373 90024068
Motor dysfunction 150.30 9.18 319 472687 18911 90136530
Grip strength decreased 149.80 9.18 157 472849 92419 90063022
Oedema 148.94 9.18 540 472466 199755 89955686
Facet joint syndrome 148.10 9.18 177 472829 98212 90057229
Lupus vulgaris 147.63 9.18 28 472978 45031 90110410
Hyponatraemia 147.08 9.18 1196 471810 132342 90023099
Affect lability 146.25 9.18 304 472702 17759 90137682
Cerebrovascular accident 145.70 9.18 1124 471882 122409 90033032
Febrile neutropenia 145.27 9.18 388 472618 157961 89997480
Road traffic accident 145.23 9.18 210 472796 107416 90048025
Sensory loss 141.46 9.18 300 472706 17775 90137666
Polyuria 140.95 9.18 215 472791 9825 90145616
Lupus-like syndrome 140.90 9.18 40 472966 48806 90106635
Lower respiratory tract infection 139.63 9.18 753 472253 249906 89905535
Hepatic steatosis 135.47 9.18 463 472543 36482 90118959
C-reactive protein 134.67 9.18 7 472999 31360 90124081
Knee arthroplasty 134.66 9.18 141 472865 83041 90072400
Diabetic neuropathy 133.31 9.18 141 472865 4433 90151008
Arthralgia 131.51 9.18 3078 469928 775444 89379997
Multiple organ dysfunction syndrome 130.15 9.18 702 472304 67634 90087807
Hypovolaemia 129.80 9.18 233 472773 12198 90143243
Sciatica 127.03 9.18 208 472798 101174 90054267
Blindness transient 127.03 9.18 137 472869 4406 90151035
Fall 126.55 9.18 3351 469655 478459 89676982
Weight decreased 125.46 9.18 2727 470279 377183 89778258
Blood bicarbonate decreased 124.17 9.18 114 472892 3005 90152436
Anti-cyclic citrullinated peptide antibody 123.81 9.18 4 473002 27217 90128224
Suspected suicide 123.33 9.18 197 472809 9371 90146070
Eating disorder 123.05 9.18 374 472632 27699 90127742
Distributive shock 122.61 9.18 118 472888 3306 90152135
Foot deformity 121.33 9.18 81 472925 59570 90095871
Hypercholesterolaemia 120.89 9.18 213 472793 100679 90054762
Liver disorder 120.66 9.18 285 472721 120984 90034457
Bradycardia 117.37 9.18 795 472211 83052 90072389
General physical health deterioration 116.65 9.18 1237 471769 353878 89801563
Angina pectoris 115.19 9.18 457 472549 38703 90116738
Condition aggravated 113.29 9.18 2310 470696 593235 89562206
Nasopharyngitis 112.56 9.18 1473 471533 405631 89749810
Circulatory collapse 112.19 9.18 335 472671 24569 90130872
Hemiparesis 111.66 9.18 393 472613 31426 90124015
Myelosuppression 111.40 9.18 71 472935 53520 90101921
Migraine 111.02 9.18 563 472443 189829 89965612
Fatigue 110.96 9.18 4911 468095 1149112 89006329
Inflammation 110.57 9.18 517 472489 178075 89977366
Night sweats 110.34 9.18 326 472680 128440 90027001
Retinitis 109.99 9.18 32 472974 38426 90117015
Aphasia 109.77 9.18 479 472527 42333 90113108
Hypoaesthesia 109.57 9.18 1079 471927 313131 89842310
Urine ketone body present 108.92 9.18 97 472909 2455 90152986
Myopathy 108.85 9.18 227 472779 13291 90142150
Glomerular filtration rate decreased 107.90 9.18 259 472747 16673 90138768
Product residue present 105.52 9.18 121 472885 4170 90151271
Acetonaemia 103.30 9.18 45 472961 287 90155154
Hypovolaemic shock 102.55 9.18 154 472852 6940 90148501
Breast cancer stage III 102.34 9.18 177 472829 84270 90071171
Sleep disorder 101.04 9.18 612 472394 197418 89958023
Diabetic retinopathy 100.33 9.18 95 472911 2607 90152834
Anion gap increased 100.31 9.18 88 472918 2182 90153259
Hypoglycaemic encephalopathy 98.92 9.18 44 472962 297 90155144
Blood pressure increased 97.45 9.18 1508 471498 195709 89959732
Ketonuria 97.44 9.18 57 472949 724 90154717
Parkinsonism 97.11 9.18 222 472784 13843 90141598
Joint dislocation 96.95 9.18 56 472950 44526 90110915
Coordination abnormal 96.89 9.18 288 472718 21068 90134373
Injection site nodule 96.55 9.18 118 472888 4355 90151086
Tubulointerstitial nephritis 95.91 9.18 321 472685 25022 90130419
Macular degeneration 95.80 9.18 39 472967 37931 90117510
Accidental overdose 94.76 9.18 344 472662 27929 90127512
Choreoathetosis 92.29 9.18 50 472956 542 90154899
Breast cancer stage II 91.27 9.18 35 472971 35299 90120142
Lung disorder 90.94 9.18 437 472569 149446 90005995
Pregnancy 90.86 9.18 114 472892 61933 90093508
Exostosis 90.67 9.18 86 472920 53048 90102393
Urinary tract discomfort 89.28 9.18 57 472949 855 90154586
Blood potassium increased 87.75 9.18 273 472733 20476 90134965
Laryngitis 86.77 9.18 82 472924 50671 90104770
Intentional product use issue 86.39 9.18 720 472286 216172 89939269
Insulin resistance 86.07 9.18 61 472945 1097 90154344
Urticaria 84.76 9.18 1136 471870 311598 89843843
Renal tubular necrosis 84.66 9.18 215 472791 14340 90141101
Neutropenia 84.50 9.18 758 472248 224146 89931295
Suicide attempt 83.90 9.18 677 472329 74722 90080719
Anaemia vitamin B12 deficiency 83.72 9.18 49 472957 623 90154818
Hyperglycaemic hyperosmolar nonketotic syndrome 83.47 9.18 64 472942 1305 90154136
Product use in unapproved indication 82.45 9.18 1246 471760 334990 89820451
Psoriasis 81.28 9.18 1151 471855 146603 90008838
Sinus disorder 80.51 9.18 375 472631 34072 90121369
Skin haemorrhage 80.19 9.18 270 472736 21110 90134331
Sopor 79.36 9.18 296 472710 24348 90131093
Blood creatine phosphokinase increased 79.24 9.18 370 472636 33653 90121788
Peripheral venous disease 78.95 9.18 203 472803 83718 90071723
Gangrene 78.89 9.18 194 472812 12682 90142759
Unresponsive to stimuli 78.35 9.18 400 472606 37721 90117720
Oliguria 78.17 9.18 172 472834 10452 90144989
Peripheral swelling 77.07 9.18 1607 471399 411499 89743942
Hypophagia 76.61 9.18 381 472625 35556 90119885
Alveolar osteitis 76.13 9.18 57 472949 1120 90154321
Urinary tract infection 75.64 9.18 2110 470896 303522 89851919
Diabetic ketosis 75.47 9.18 43 472963 518 90154923
Vasoplegia syndrome 75.44 9.18 83 472923 2731 90152710
Adverse event 74.98 9.18 336 472670 117082 90038359
Arterial occlusive disease 74.65 9.18 186 472820 12260 90143181
Haemodynamic instability 74.19 9.18 179 472827 11560 90143881
Joint stiffness 74.02 9.18 188 472818 77854 90077587
Therapeutic product effect incomplete 73.93 9.18 651 472355 193245 89962196
Coma acidotic 73.14 9.18 27 472979 103 90155338
Blood triglycerides increased 72.61 9.18 196 472810 13565 90141876
Immunodeficiency 72.58 9.18 71 472935 43163 90112278
Athetosis 72.22 9.18 24 472982 61 90155380
Glycosylated haemoglobin decreased 72.21 9.18 44 472962 605 90154836
Atrial fibrillation 71.96 9.18 1037 471969 132574 90022867
Cholelithiasis 71.78 9.18 495 472511 52011 90103430
Polydipsia 71.62 9.18 99 472907 4132 90151309
Syncope 70.80 9.18 1028 471978 131635 90023806
Diabetic nephropathy 70.24 9.18 64 472942 1670 90153771
Postprandial hypoglycaemia 70.07 9.18 26 472980 101 90155340
Product prescribing error 69.60 9.18 327 472679 29818 90125623
Glycosylated haemoglobin abnormal 69.22 9.18 32 472974 239 90155202
Blood ketone body increased 69.15 9.18 35 472971 326 90155115
Porphyria acute 68.66 9.18 7 472999 17968 90137473
Prescribed underdose 68.64 9.18 184 472822 74835 90080606
Angioedema 68.15 9.18 575 472431 64301 90091140
Asthenia 67.91 9.18 3421 469585 530330 89625111
Chronic sinusitis 67.71 9.18 20 472986 23782 90131659
Type 2 diabetes mellitus 67.47 9.18 706 472300 202538 89952903
Seronegative arthritis 67.37 9.18 8 472998 18226 90137215
Microalbuminuria 67.25 9.18 40 472966 525 90154916
Disability 67.15 9.18 68 472938 40677 90114764
Chorea 66.81 9.18 68 472938 2042 90153399
Blood pressure systolic increased 66.07 9.18 526 472480 57819 90097622
Walking aid user 65.99 9.18 53 472953 35453 90119988
Osteoarthritis 65.33 9.18 679 472327 195051 89960390
Live birth 65.10 9.18 204 472802 78903 90076538
Palpitations 65.05 9.18 1039 471967 135689 90019752
Polymyalgia rheumatica 64.87 9.18 103 472903 4874 90150567
Red blood cell sedimentation rate increased 64.50 9.18 218 472788 82377 90073064
Coronary artery disease 64.41 9.18 346 472660 33277 90122164
Atrioventricular block 64.06 9.18 142 472864 8673 90146768
Colitis ulcerative 63.71 9.18 137 472869 60129 90095312
Bladder pain 63.66 9.18 75 472931 2662 90152779
Tunnel vision 63.53 9.18 60 472946 1641 90153800
Human rhinovirus test positive 63.52 9.18 46 472960 857 90154584
Gastroenteritis 63.10 9.18 311 472695 28918 90126523
Dysuria 62.74 9.18 386 472620 39015 90116426
Anaemia megaloblastic 62.52 9.18 36 472970 443 90154998
Dialysis 62.45 9.18 164 472842 11165 90144276
Thrombocytopenia 61.80 9.18 744 472262 207981 89947460
Product odour abnormal 61.73 9.18 57 472949 1514 90153927
Acute myocardial infarction 61.47 9.18 351 472655 34539 90120902
Musculoskeletal pain 61.36 9.18 584 472422 170667 89984774
Drug ineffective for unapproved indication 61.32 9.18 163 472843 66481 90088960
Disease progression 60.50 9.18 524 472482 156091 89999350
Acute coronary syndrome 60.08 9.18 157 472849 10656 90144785
Animal scratch 59.82 9.18 60 472946 1770 90153671
Cerebral venous thrombosis 59.55 9.18 67 472939 2261 90153180
Prerenal failure 59.52 9.18 64 472942 2051 90153390
Pollakiuria 59.44 9.18 334 472672 32671 90122770
Female genital tract fistula 58.75 9.18 11 472995 17857 90137584
Incorrect route of product administration 58.74 9.18 109 472897 50517 90104924
Cytomegalovirus infection 58.44 9.18 33 472973 26569 90128872
Myalgia 58.31 9.18 1259 471747 173866 89981575
Skin exfoliation 57.69 9.18 575 472431 67338 90088103
Lipase increased 57.37 9.18 157 472849 10954 90144487
Respiratory syncytial virus test positive 57.04 9.18 46 472960 1012 90154429
Blood lactic acid 56.92 9.18 22 472984 98 90155343
Blood urea increased 56.26 9.18 310 472696 30103 90125338
Insulin C-peptide decreased 56.15 9.18 18 472988 39 90155402
Osmolar gap 55.92 9.18 21 472985 85 90155356
Leukopenia 55.77 9.18 303 472703 100407 90055034
Immune-mediated myositis 55.75 9.18 66 472940 2355 90153086
High density lipoprotein decreased 55.71 9.18 69 472937 2582 90152859
Overweight 55.40 9.18 106 472900 5828 90149613
Dry mouth 55.28 9.18 654 472352 183405 89972036
Amylase increased 54.90 9.18 117 472889 6955 90148486
Cardiac failure 54.72 9.18 839 472167 108657 90046784
Abdominal pain 54.40 9.18 2556 470450 393165 89762276
Food allergy 53.99 9.18 33 472973 25445 90129996
Joint destruction 53.94 9.18 4 473002 13283 90142158
Maternal exposure timing unspecified 53.70 9.18 25 472981 22458 90132983
Pancreatic carcinoma metastatic 53.18 9.18 64 472942 2324 90153117
Adenocarcinoma pancreas 52.79 9.18 46 472960 1130 90154311
Kussmaul respiration 52.40 9.18 27 472979 262 90155179
Latent autoimmune diabetes in adults 51.73 9.18 15 472991 19 90155422
Glucose urine present 51.58 9.18 41 472965 883 90154558
Blood iron decreased 51.54 9.18 208 472798 17751 90137690
Potentiating drug interaction 51.46 9.18 100 472906 5562 90149879
Dyslipidaemia 51.38 9.18 142 472864 9965 90145476
Ear infection 50.59 9.18 190 472816 69585 90085856
Haemofiltration 50.49 9.18 13 472993 6 90155435
Sinus congestion 50.37 9.18 279 472727 27145 90128296
Amnesia 49.39 9.18 347 472659 108158 90047283
Gastrointestinal disorder 49.15 9.18 994 472012 255693 89899748
Weight increased 48.88 9.18 1737 471269 416190 89739251
Toothache 48.32 9.18 237 472769 21993 90133448
Ischaemic stroke 47.96 9.18 236 472770 21930 90133511
Dysentery 47.92 9.18 42 472964 1040 90154401
Hypertension 47.89 9.18 1927 471079 455605 89699836
Pancreatitis haemorrhagic 47.80 9.18 34 472972 615 90154826
Pharyngitis 47.72 9.18 234 472772 21713 90133728
Dyspepsia 47.61 9.18 737 472269 197423 89958018
Exposure via ingestion 47.56 9.18 64 472942 2603 90152838
Proctitis 46.87 9.18 11 472995 15248 90140193
Blindness 46.62 9.18 267 472739 26301 90129140
Urosepsis 46.61 9.18 227 472779 21005 90134436
Sneezing 45.92 9.18 290 472716 29579 90125862
Treatment noncompliance 45.91 9.18 442 472564 51285 90104156
Temperature regulation disorder 45.80 9.18 10 472996 14569 90140872
Viral test positive 45.79 9.18 33 472973 610 90154831
Anion gap abnormal 45.75 9.18 27 472979 349 90155092
Electrocardiogram QT prolonged 45.42 9.18 578 472428 71878 90083563
Delirium 44.97 9.18 339 472667 104020 90051421
Left ventricular hypertrophy 44.67 9.18 99 472907 6045 90149396
Cytokine release syndrome 44.61 9.18 48 472958 27925 90127516
Cataract 44.31 9.18 573 472433 71519 90083922
Product substitution issue 44.28 9.18 199 472807 17809 90137632
Anhidrosis 43.89 9.18 21 472985 171 90155270
Vitamin B12 decreased 43.73 9.18 90 472916 5220 90150221
Blood pH decreased 43.52 9.18 60 472946 2498 90152943
Electrocardiogram T wave peaked 43.21 9.18 23 472983 240 90155201
Neutrophilia 43.03 9.18 94 472912 5684 90149757
Respiratory tract congestion 42.68 9.18 267 472739 27143 90128298
Altered state of consciousness 42.35 9.18 296 472710 31236 90124205
Wrong patient received product 41.31 9.18 69 472937 3408 90152033
Cold sweat 41.14 9.18 164 472842 13917 90141524
Persistent cloaca 41.13 9.18 22 472984 232 90155209
Ulcer haemorrhage 41.06 9.18 46 472960 26275 90129166
Radiculopathy 40.58 9.18 23 472983 18482 90136959
Cutaneous vasculitis 40.54 9.18 105 472901 7088 90148353
Blood insulin increased 40.54 9.18 19 472987 147 90155294
Pneumonia 40.35 9.18 2827 470179 635232 89520209
Malignant mediastinal neoplasm 40.32 9.18 43 472963 1365 90154076
Inappropriate antidiuretic hormone secretion 39.61 9.18 204 472802 19301 90136140
Conjoined twins 39.58 9.18 28 472978 502 90154939
Transplant rejection 39.58 9.18 9 472997 12749 90142692
Wound complication 39.54 9.18 81 472925 4682 90150759
Influenza 39.48 9.18 979 472027 138285 90017156
Cholecystitis chronic 39.46 9.18 127 472879 9699 90145742
Autoimmune myositis 39.45 9.18 24 472982 329 90155112
Leukocytosis 39.35 9.18 287 472719 30703 90124738
Hypertriglyceridaemia 39.27 9.18 110 472896 7779 90147662
Ear congestion 39.16 9.18 67 472939 3375 90152066
Respiratory alkalosis 39.07 9.18 67 472939 3381 90152060
Osteoporosis 39.06 9.18 319 472687 96212 90059229
Hypoglycaemia neonatal 38.92 9.18 38 472968 1084 90154357
Osmolar gap increased 38.87 9.18 19 472987 163 90155278
Heart rate increased 38.64 9.18 815 472191 112087 90043354
Nephropathy 38.58 9.18 121 472885 9114 90146327
Hospitalisation 38.52 9.18 455 472551 127645 90027796
Coma 38.01 9.18 561 472445 72071 90083370
Thirst 37.79 9.18 177 472829 16118 90139323
Coeliac disease 37.44 9.18 114 472892 44496 90110945
Macroangiopathy 36.98 9.18 20 472986 216 90155225
Atrioventricular block complete 36.88 9.18 124 472882 9687 90145754
Device expulsion 36.86 9.18 101 472905 40785 90114656
Headache 36.67 9.18 3943 469063 858803 89296638
Anion gap 36.52 9.18 37 472969 1105 90154336
Azotaemia 36.46 9.18 84 472922 5264 90150177
Body mass index increased 36.45 9.18 42 472964 1455 90153986
Respiratory disorder 36.44 9.18 194 472812 64622 90090819
Albuminuria 36.43 9.18 23 472983 338 90155103
Vision blurred 36.40 9.18 792 472214 109501 90045940
Cystitis 36.37 9.18 519 472487 66199 90089242
Blood pressure inadequately controlled 36.26 9.18 92 472914 6132 90149309
Anaemia macrocytic 35.91 9.18 76 472930 4496 90150945
Gait inability 35.75 9.18 543 472463 145913 90009528
Pneumocystis jirovecii pneumonia 35.70 9.18 36 472970 21580 90133861
Frequent bowel movements 35.69 9.18 164 472842 56771 90098670
Electrolyte imbalance 35.55 9.18 229 472777 23516 90131925
Pulseless electrical activity 35.46 9.18 115 472891 8817 90146624
Neutrophil count decreased 35.45 9.18 223 472783 71309 90084132
Cleft lip 34.99 9.18 18 472988 174 90155267
Epstein-Barr virus infection 34.81 9.18 6 473000 10338 90145103
White blood cell count decreased 34.76 9.18 638 472368 166471 89988970
Coma scale abnormal 34.71 9.18 85 472921 5541 90149900
Pneumonia haemophilus 34.65 9.18 41 472965 1462 90153979
Intestinal malrotation 34.32 9.18 24 472982 422 90155019
Loss of consciousness 34.31 9.18 967 472039 139271 90016170
Blood cholesterol decreased 33.92 9.18 46 472960 1885 90153556
Muscle necrosis 33.89 9.18 31 472975 813 90154628
Urine output decreased 33.83 9.18 143 472863 12460 90142981
Abnormal loss of weight 33.83 9.18 95 472911 6728 90148713
Hyperinsulinaemic hypoglycaemia 33.79 9.18 16 472990 127 90155314
Insulinoma 33.79 9.18 16 472990 127 90155314
Calculus urinary 33.78 9.18 43 472963 1655 90153786
Fungal infection 33.75 9.18 356 472650 42305 90113136
Incorrect dose administered 33.57 9.18 589 472417 78341 90077100
Drug tolerance decreased 33.17 9.18 74 472932 32056 90123385
Renal tubular acidosis 33.10 9.18 50 472956 2265 90153176
Loss of personal independence in daily activities 33.09 9.18 505 472501 135600 90019841
Disorientation 32.98 9.18 364 472642 43750 90111691
Drug tolerance 32.97 9.18 27 472979 17889 90137552
Pancreatic mass 32.95 9.18 36 472970 1175 90154266
Wound secretion 32.52 9.18 77 472929 4913 90150528
Hypokinesia 32.46 9.18 165 472841 15532 90139909
Body temperature decreased 32.24 9.18 224 472782 23592 90131849
Transient ischaemic attack 32.16 9.18 356 472650 42820 90112621
Bladder sphincter atony 32.09 9.18 18 472988 210 90155231
Needle issue 32.05 9.18 151 472855 13783 90141658
Spondylitis 32.00 9.18 17 472989 14161 90141280
Pancreatitis chronic 31.90 9.18 55 472951 2788 90152653
Nephrolithiasis 31.80 9.18 394 472612 48691 90106750
Hyperventilation 31.73 9.18 92 472914 6636 90148805
Malabsorption 31.70 9.18 78 472928 5100 90150341
Flatulence 31.70 9.18 343 472663 41024 90114417
Renal abscess 31.69 9.18 34 472972 1087 90154354
Pernicious anaemia 31.60 9.18 30 472976 826 90154615
Pruritus genital 31.53 9.18 72 472934 4486 90150955
Vaginal discharge 31.49 9.18 33 472973 19431 90136010
Breast cancer stage I 31.48 9.18 6 473000 9618 90145823
Swollen joint count 31.47 9.18 4 473002 8649 90146792
Haemophagocytic lymphohistiocytosis 31.42 9.18 21 472985 15438 90140003
Blood pressure abnormal 30.99 9.18 192 472814 19453 90135988
Anovulatory cycle 30.90 9.18 16 472990 157 90155284
Metabolic encephalopathy 30.57 9.18 91 472915 6661 90148780
Blood urine present 30.55 9.18 174 472832 17104 90138337
Diabetic foot 30.41 9.18 40 472966 1591 90153850
Metabolic syndrome 30.31 9.18 43 472963 1839 90153602
Electrocardiogram abnormal 30.14 9.18 120 472886 10178 90145263
Poisoning 30.11 9.18 158 472848 15059 90140382
Fluid retention 30.03 9.18 304 472702 87787 90067654
Dysphagia 29.97 9.18 783 472223 111495 90043946
Drug resistance 29.92 9.18 72 472934 30377 90125064
Haematotoxicity 29.84 9.18 14 472992 12521 90142920
C-reactive protein increased 29.67 9.18 720 472286 180669 89974772
Osmolar gap abnormal 29.66 9.18 10 472996 27 90155414
Hypertensive heart disease 29.52 9.18 51 472955 2589 90152852
Oral candidiasis 29.47 9.18 91 472915 35364 90120077
Hypertensive crisis 29.44 9.18 176 472830 17608 90137833
Diabetic coma 29.31 9.18 27 472979 715 90154726
Pancreatic neoplasm 29.30 9.18 31 472975 975 90154466
Liver function test increased 29.27 9.18 292 472714 84563 90070878
Eosinophilic myocarditis 29.16 9.18 26 472980 659 90154782
Multiple sclerosis relapse 29.15 9.18 157 472849 52148 90103293
Hypoglycaemic unconsciousness 29.05 9.18 28 472978 786 90154655
Tongue biting 28.99 9.18 45 472961 2088 90153353
Corneal reflex decreased 28.82 9.18 19 472987 302 90155139
Antipsychotic drug level increased 28.74 9.18 62 472944 3717 90151724
Blood pressure systolic decreased 28.74 9.18 110 472896 9160 90146281
Cardiovascular disorder 28.73 9.18 143 472863 13349 90142092
Somnolence 28.36 9.18 1349 471657 207735 89947706
Cough 28.24 9.18 2264 470742 366698 89788743
Impaired gastric emptying 28.15 9.18 137 472869 12672 90142769
Malignant neoplasm progression 27.90 9.18 391 472615 106479 90048962
Prescription drug used without a prescription 27.79 9.18 56 472950 3199 90152242
Insomnia 27.67 9.18 1440 471566 332034 89823407
Paranasal sinus discomfort 27.46 9.18 83 472923 6127 90149314
Sickle cell anaemia with crisis 27.46 9.18 3 473003 7294 90148147
Diabetic hyperosmolar coma 27.46 9.18 20 472986 376 90155065
Non-alcoholic steatohepatitis 27.41 9.18 41 472965 1841 90153600
Mucosal inflammation 27.35 9.18 182 472824 57443 90097998
Hyperinsulinaemia 27.33 9.18 14 472992 134 90155307
Renal injury 27.32 9.18 116 472890 10127 90145314
Shock hypoglycaemic 27.26 9.18 13 472993 105 90155336
Hyperphagia 27.13 9.18 51 472955 2767 90152674
Crush syndrome 27.04 9.18 18 472988 291 90155150
Starvation ketoacidosis 26.97 9.18 16 472990 209 90155232
Bradyarrhythmia 26.82 9.18 47 472959 2414 90153027
Necrotising myositis 26.71 9.18 27 472979 804 90154637
Decreased vibratory sense 26.60 9.18 19 472987 346 90155095
Blood growth hormone increased 26.39 9.18 22 472984 508 90154933
Diabetic ketoacidotic hyperglycaemic coma 26.37 9.18 11 472995 62 90155379
Respiratory tract infection 26.36 9.18 190 472816 58888 90096553
Thrombotic microangiopathy 26.25 9.18 26 472980 15717 90139724
Postmenopausal haemorrhage 25.95 9.18 46 472960 2384 90153057
Progressive multifocal leukoencephalopathy 25.94 9.18 26 472980 15629 90139812
Blood pressure diastolic decreased 25.69 9.18 233 472773 26593 90128848
Pancreatic enzymes increased 25.68 9.18 27 472979 843 90154598
Subcutaneous drug absorption impaired 25.44 9.18 20 472986 13525 90141916
Necrotising fasciitis 25.42 9.18 60 472946 3820 90151621
Product blister packaging issue 25.38 9.18 18 472988 324 90155117
Hypoglycaemic seizure 25.33 9.18 22 472984 538 90154903
Increased appetite 25.26 9.18 125 472881 11640 90143801
Infective pulmonary exacerbation of cystic fibrosis 25.22 9.18 11 472995 10268 90145173
Encephalopathy 25.20 9.18 361 472645 46083 90109358
Rales 25.16 9.18 155 472851 15672 90139769
Blood ketone body 25.14 9.18 11 472995 71 90155370
Multiple-drug resistance 25.12 9.18 5 473001 7771 90147670
Temperature perception test abnormal 25.06 9.18 8 472998 17 90155424
Death 24.98 9.18 2047 470959 454504 89700937
Peripheral circulatory failure 24.89 9.18 36 472970 1568 90153873
Hypoperfusion 24.76 9.18 38 472968 1746 90153695
Apolipoprotein A-I decreased 24.75 9.18 8 472998 18 90155423
Blood insulin decreased 24.75 9.18 8 472998 18 90155423
Pruritus 24.70 9.18 2462 470544 539063 89616378
Pyelonephritis 24.58 9.18 193 472813 21123 90134318
Spinal fusion surgery 24.55 9.18 17 472989 12266 90143175
Cardiac failure congestive 24.55 9.18 682 472324 98012 90057429
Ischaemic contracture of the left ventricle 24.47 9.18 13 472993 135 90155306
IIIrd nerve paresis 24.39 9.18 13 472993 136 90155305
Tenosynovitis 24.36 9.18 24 472982 14543 90140898
Myocardial ischaemia 24.35 9.18 139 472867 13675 90141766
Blood immunoglobulin E increased 24.33 9.18 64 472942 4361 90151080
Cytomegalovirus viraemia 24.25 9.18 5 473001 7581 90147860
Pancreatic injury 24.18 9.18 10 472996 55 90155386
Foreign body aspiration 24.14 9.18 15 472991 214 90155227
Macular oedema 24.00 9.18 68 472938 4841 90150600
Cardio-respiratory arrest 23.99 9.18 463 472543 62677 90092764
Mouth ulceration 23.97 9.18 117 472889 39857 90115584
Congenital bladder anomaly 23.90 9.18 15 472991 218 90155223
Mechanical ventilation complication 23.89 9.18 8 472998 21 90155420
Bronchopulmonary aspergillosis 23.82 9.18 15 472991 11383 90144058
Pleural effusion 23.78 9.18 426 472580 111565 90043876
Chronic kidney disease 23.70 9.18 381 472625 49810 90105631
General symptom 23.58 9.18 25 472981 14643 90140798
Glomerular filtration rate abnormal 23.57 9.18 32 472974 1313 90154128
Influenza like illness 23.53 9.18 569 472437 80042 90075399
Therapeutic response decreased 23.53 9.18 328 472678 89401 90066040
Urachal abnormality 23.44 9.18 15 472991 226 90155215
Base excess decreased 23.37 9.18 11 472995 86 90155355
Anal incontinence 23.37 9.18 155 472851 16075 90139366
Pancreatic neuroendocrine tumour 23.34 9.18 22 472984 600 90154841
Cytomegalovirus infection reactivation 23.22 9.18 6 473000 7794 90147647
Cutaneous T-cell dyscrasia 23.19 9.18 10 472996 62 90155379
Alopecia scarring 23.13 9.18 14 472992 190 90155251
Differential white blood cell count abnormal 23.08 9.18 27 472979 951 90154490
Product administration error 23.06 9.18 225 472781 26198 90129243
Orbital swelling 23.06 9.18 10 472996 63 90155378
Acidosis hyperchloraemic 23.05 9.18 26 472980 880 90154561
Infusion site reaction 22.97 9.18 40 472966 18999 90136442
Aspergillus infection 22.96 9.18 14 472992 10809 90144632
Microcytic anaemia 22.83 9.18 57 472949 3761 90151680
Urinary incontinence 22.83 9.18 298 472708 37268 90118173
Diabetic ulcer 22.79 9.18 13 472993 157 90155284
Carcinoid tumour of the stomach 22.79 9.18 13 472993 157 90155284
Cardiogenic shock 22.66 9.18 211 472795 24257 90131184
Skin turgor decreased 22.61 9.18 21 472985 562 90154879
Oedematous pancreatitis 22.52 9.18 24 472982 761 90154680
Diabetes mellitus management 22.52 9.18 6 473000 4 90155437
Neurotoxicity 22.52 9.18 49 472957 21418 90134023
Respiratory acidosis 22.48 9.18 93 472913 8026 90147415
Rash erythematous 22.47 9.18 224 472782 64880 90090561
Mouth haemorrhage 22.47 9.18 96 472910 8405 90147036
Hepatic failure 22.44 9.18 311 472695 39417 90116024
C3 glomerulopathy 22.30 9.18 13 472993 164 90155277
Systemic infection 22.24 9.18 65 472941 4710 90150731
Mitochondrial enzyme deficiency 22.20 9.18 8 472998 28 90155413
Upper respiratory tract infection 22.19 9.18 505 472501 127813 90027628
Brugada syndrome 22.17 9.18 19 472987 456 90154985
Exercise tolerance decreased 22.10 9.18 88 472918 7463 90147978
Cerebral infarction 22.01 9.18 224 472782 26372 90129069
Cholestatic liver injury 21.99 9.18 56 472950 3741 90151700
Metastases to retroperitoneum 21.96 9.18 13 472993 169 90155272
Base excess negative 21.95 9.18 6 473000 5 90155436
Carbuncle 21.94 9.18 32 472974 1404 90154037
Low density lipoprotein increased 21.91 9.18 92 472914 7993 90147448
Impaired work ability 21.75 9.18 174 472832 19152 90136289
Unintentional medical device removal 21.73 9.18 5 473001 7025 90148416
Lip swelling 21.71 9.18 302 472704 38308 90117133
Cytopenia 21.66 9.18 36 472970 17413 90138028
Pyelonephritis acute 21.62 9.18 70 472936 5362 90150079
Congenital absence of bile ducts 21.57 9.18 8 472998 31 90155410
Diabetic complication 21.54 9.18 26 472980 947 90154494
Insulin-like growth factor increased 21.52 9.18 26 472980 948 90154493
Lichen planus 21.46 9.18 46 472960 2745 90152696
Hyperhidrosis 21.46 9.18 893 472113 135412 90020029
Resuscitation 21.45 9.18 30 472976 1266 90154175
Renal cyst 21.33 9.18 128 472878 12822 90142619
Multiple cardiac defects 21.30 9.18 5 473001 0 90155441
Hepatosplenomegaly neonatal 21.30 9.18 5 473001 0 90155441
Lactate pyruvate ratio abnormal 21.30 9.18 5 473001 0 90155441
Blood phosphorus increased 21.29 9.18 60 472946 4258 90151183
Bone marrow failure 21.29 9.18 91 472915 32130 90123311
Heart sounds 21.24 9.18 28 472978 1116 90154325
Injection site mass 21.22 9.18 192 472814 21898 90133543
Genital infection 21.20 9.18 13 472993 181 90155260
Insulin C-peptide increased 21.05 9.18 10 472996 80 90155361
Sedation complication 21.00 9.18 35 472971 16909 90138532
Bundle branch block left 20.80 9.18 89 472917 7796 90147645
Periorbital inflammation 20.77 9.18 13 472993 188 90155253
Decreased appetite 20.75 9.18 2257 470749 374283 89781158
Urine albumin/creatinine ratio abnormal 20.73 9.18 11 472995 114 90155327
Prolonged expiration 20.66 9.18 29 472977 1228 90154213
Jaundice hepatocellular 20.64 9.18 8 472998 36 90155405
Ventricular extrasystoles 20.59 9.18 129 472877 13121 90142320
Salivary hypersecretion 20.53 9.18 98 472908 8994 90146447
Tachycardia 20.47 9.18 1013 471993 156660 89998781
Prothrombin consumption time prolonged 20.46 9.18 8 472998 37 90155404
Retinopathy proliferative 20.45 9.18 9 472997 59 90155382
Hepatic cirrhosis 20.45 9.18 221 472785 63032 90092409
Congenital aortic valve stenosis 20.33 9.18 9 472997 60 90155381
Tongue injury 20.30 9.18 20 472986 577 90154864
Swollen tongue 20.28 9.18 345 472661 45611 90109830
Neuroglycopenia 20.26 9.18 27 472979 1088 90154353
Vulvovaginal pruritus 20.20 9.18 56 472950 3937 90151504
Blood pressure decreased 20.18 9.18 523 472483 74372 90081069
Muscle spasticity 20.15 9.18 277 472729 35045 90120396
Product complaint 20.09 9.18 130 472876 13370 90142071
Decreased bronchial secretion 20.08 9.18 9 472997 62 90155379
Chest discomfort 19.89 9.18 898 472108 137467 90017974
Dermatitis artefacta 19.84 9.18 9 472997 64 90155377
Feeling hot 19.80 9.18 287 472719 77721 90077720
Immune reconstitution inflammatory syndrome 19.78 9.18 6 473000 7013 90148428
Obesity 19.75 9.18 410 472596 105097 90050344
Nasal oedema 19.73 9.18 5 473001 6579 90148862
Hunger 19.63 9.18 77 472929 6486 90148955
Sedation 19.57 9.18 159 472847 48012 90107429
Genital infection fungal 19.54 9.18 13 472993 210 90155231
Eructation 19.51 9.18 110 472896 10772 90144669
Eyelid bleeding 19.49 9.18 8 472998 43 90155398
Stupor 19.48 9.18 68 472938 5414 90150027
Paraesthesia 19.43 9.18 1088 471918 249238 89906203
Depressed mood 19.33 9.18 369 472637 49853 90105588
Ear pain 19.31 9.18 200 472806 57502 90097939
Bronchopulmonary aspergillosis allergic 19.23 9.18 53 472953 3713 90151728
Device difficult to use 19.23 9.18 39 472967 17486 90137955
Accidental underdose 19.18 9.18 26 472980 1065 90154376
Limb injury 19.17 9.18 250 472756 31258 90124183
Lethargy 19.14 9.18 448 472558 62691 90092750
Foreign body in reproductive tract 19.12 9.18 27 472979 1150 90154291
Abdominal distension 19.08 9.18 849 472157 129752 90025689
Glycosuria 19.01 9.18 30 472976 1412 90154029
Thalamic infarction 19.01 9.18 18 472988 494 90154947
Allergic reaction to excipient 19.01 9.18 22 472984 766 90154675
Premature delivery 18.97 9.18 296 472710 38466 90116975
Hypoaesthesia oral 18.97 9.18 143 472863 15457 90139984
Rhinovirus infection 18.92 9.18 4 473002 5959 90149482
Fluid intake reduced 18.84 9.18 56 472950 4096 90151345
Neuropathy, ataxia, retinitis pigmentosa syndrome 18.77 9.18 8 472998 48 90155393
Hypocapnia 18.74 9.18 18 472988 503 90154938
Urogenital infection fungal 18.51 9.18 7 472999 29 90155412
PCO2 decreased 18.48 9.18 28 472978 1272 90154169
Blood sodium decreased 18.47 9.18 223 472783 27390 90128051
Central obesity 18.44 9.18 29 472977 1361 90154080
Sinus pain 18.42 9.18 66 472940 5323 90150118
Sinus arrest 18.42 9.18 37 472969 2109 90153332
Device dislocation 18.38 9.18 93 472913 31389 90124052
Genital swelling 18.32 9.18 11 472995 147 90155294
Insulin-like growth factor decreased 18.26 9.18 16 472990 396 90155045
Overlap syndrome 18.21 9.18 11 472995 8537 90146904
Food craving 18.19 9.18 35 472971 1932 90153509
Metabolic alkalosis 18.18 9.18 50 472956 3499 90151942
Asthma 18.16 9.18 1056 471950 241104 89914337
Product dispensing error 18.15 9.18 118 472888 12155 90143286
Bladder cancer 18.12 9.18 69 472937 5732 90149709
Bronchostenosis 18.11 9.18 18 472988 525 90154916
Intestinal ischaemia 18.10 9.18 93 472913 8790 90146651
Mast cell activation syndrome 18.10 9.18 31 472975 1563 90153878
Vulvovaginal candidiasis 18.08 9.18 53 472953 3847 90151594
Hormone receptor positive HER2 negative breast cancer 18.07 9.18 14 472992 290 90155151
Hyperlipasaemia 18.06 9.18 22 472984 809 90154632
Metastases to kidney 18.05 9.18 13 472993 240 90155201
Myopathy toxic 18.02 9.18 19 472987 595 90154846
Blood chloride decreased 17.98 9.18 73 472933 6246 90149195
Atrioventricular block first degree 17.97 9.18 90 472916 8421 90147020
Drug level abnormal 17.95 9.18 14 472992 293 90155148
Pain in jaw 17.88 9.18 162 472844 47823 90107618
Faeces discoloured 17.85 9.18 180 472826 21140 90134301
Hyperparathyroidism secondary 17.84 9.18 33 472973 1768 90153673
Leukocyturia 17.70 9.18 31 472975 1591 90153850
Urine albumin/creatinine ratio increased 17.70 9.18 18 472988 540 90154901
Arrhythmia 17.68 9.18 315 472691 42017 90113424
Angina unstable 17.61 9.18 79 472927 7064 90148377
Adrenal adenoma 17.57 9.18 26 472980 1156 90154285
Enthesopathy 17.52 9.18 14 472992 9390 90146051
Dysgeusia 17.52 9.18 378 472628 52182 90103259
Persistent left superior vena cava 17.47 9.18 7 472999 35 90155406
Pulmonary hypoplasia 17.44 9.18 15 472991 362 90155079
Basilar artery thrombosis 17.40 9.18 11 472995 162 90155279
Thyroid cancer recurrent 17.39 9.18 8 472998 59 90155382
Brain stem infarction 17.18 9.18 22 472984 852 90154589
Haematuria 17.17 9.18 267 472739 34670 90120771
Diet failure 17.15 9.18 7 472999 37 90155404
Blood lactic acid abnormal 17.15 9.18 7 472999 37 90155404
Movement disorder 17.14 9.18 229 472777 28790 90126651
Venoocclusive liver disease 17.11 9.18 5 473001 5988 90149453
Oxygen saturation immeasurable 17.10 9.18 6 473000 19 90155422
CD30 expression 17.06 9.18 8 472998 62 90155379
Anaemia 17.05 9.18 2097 470909 350705 89804736
Pleural mesothelioma 17.04 9.18 4 473002 0 90155441
Leukocyte vacuolisation 17.04 9.18 4 473002 0 90155441
Pancreatic islets hyperplasia 17.04 9.18 4 473002 0 90155441
Skinfold measurement 17.04 9.18 4 473002 0 90155441
Reactive psychosis 17.04 9.18 4 473002 0 90155441
Epileptic encephalopathy 17.03 9.18 15 472991 374 90155067
Stevens-Johnson syndrome 17.03 9.18 87 472919 29289 90126152
Hallucination, auditory 16.99 9.18 142 472864 15833 90139608
Colitis microscopic 16.94 9.18 108 472898 11051 90144390
Hypernatraemia 16.91 9.18 95 472911 9292 90146149
Scleroedema 16.89 9.18 10 472996 130 90155311
Multiple drug therapy 16.89 9.18 77 472929 6932 90148509
Metastases to central nervous system 16.83 9.18 42 472964 17500 90137941
Choking 16.77 9.18 114 472892 11919 90143522
Posterior reversible encephalopathy syndrome 16.74 9.18 60 472946 22279 90133162
Vertigo 16.68 9.18 480 472526 69331 90086110
Bradykinesia 16.68 9.18 75 472931 6713 90148728
Neuroendocrine tumour 16.65 9.18 22 472984 879 90154562
Product dose omission issue 16.56 9.18 1752 471254 289935 89865506
Vitreous haemorrhage 16.55 9.18 40 472966 2586 90152855
Blood electrolytes abnormal 16.54 9.18 25 472981 1133 90154308
Pathogen resistance 16.53 9.18 11 472995 8104 90147337
Hepatic function abnormal 16.50 9.18 158 472848 46130 90109311
Binge eating 16.49 9.18 18 472988 587 90154854
Clostridium difficile infection 16.45 9.18 116 472890 36129 90119312
Ballismus 16.44 9.18 10 472996 137 90155304
Hidradenitis 16.39 9.18 55 472951 4292 90151149
Coronary artery occlusion 16.36 9.18 88 472918 8466 90146975
Thyroglobulin increased 16.33 9.18 8 472998 69 90155372
Toxic encephalopathy 16.31 9.18 89 472917 8610 90146831
Myxoedema coma 16.29 9.18 15 472991 397 90155044
Antipsychotic drug level decreased 16.26 9.18 15 472991 398 90155043
Creatinine renal clearance abnormal 16.23 9.18 16 472990 462 90154979
Deformity 16.16 9.18 24 472982 12146 90143295
Skin sensitisation 16.07 9.18 23 472983 992 90154449
Gallbladder oedema 16.06 9.18 12 472994 235 90155206
Platelet count decreased 16.03 9.18 569 472437 136400 90019041
Bicuspid aortic valve 16.01 9.18 10 472996 144 90155297
Malaise 15.96 9.18 3375 469631 582611 89572830
Neurofibrosarcoma 15.95 9.18 11 472995 189 90155252
No adverse event 15.92 9.18 254 472752 67728 90087713
Aortic disorder 15.89 9.18 21 472985 839 90154602
Pustular psoriasis 15.87 9.18 47 472959 18509 90136932
Nail disorder 15.81 9.18 215 472791 58852 90096589
Hypochromic anaemia 15.81 9.18 35 472971 2136 90153305
Acute myeloid leukaemia 15.75 9.18 55 472951 20585 90134856
Congenital uterine anomaly 15.66 9.18 10 472996 150 90155291
Herpes simplex 15.65 9.18 18 472988 10163 90145278
Autoimmune hepatitis 15.60 9.18 100 472906 10251 90145190
Hypochloraemia 15.53 9.18 39 472967 2583 90152858
Bezoar 15.50 9.18 40 472966 2694 90152747
Retinal artery thrombosis 15.49 9.18 8 472998 78 90155363
Papillary thyroid cancer 15.48 9.18 39 472967 2588 90152853
Rhinitis allergic 15.48 9.18 41 472965 16744 90138697
Renal replacement therapy 15.41 9.18 8 472998 79 90155362
Rhinorrhoea 15.39 9.18 585 472421 87731 90067710
Eye injury 15.36 9.18 21 472985 10999 90144442
Creatinine renal clearance decreased 15.36 9.18 49 472957 18850 90136591
Red cell distribution width abnormal 15.32 9.18 11 472995 202 90155239
Shock haemorrhagic 15.31 9.18 113 472893 12132 90143309
Enterochromaffin cell hyperplasia 15.29 9.18 7 472999 51 90155390
Patella fracture 15.25 9.18 38 472968 2505 90152936
Laryngitis viral 15.23 9.18 8 472998 81 90155360
Hypocalcaemia 15.20 9.18 308 472698 42060 90113381
Hypertensive angiopathy 15.15 9.18 8 472998 82 90155359
Blepharospasm 15.14 9.18 201 472805 55244 90100197
Cerebral haematoma 15.07 9.18 53 472953 4236 90151205
International normalised ratio increased 15.04 9.18 338 472668 46978 90108463
Pancreatic atrophy 15.03 9.18 13 472993 316 90155125
Visceral congestion 15.03 9.18 14 472992 376 90155065
Catarrh 15.02 9.18 29 472977 1605 90153836
Adverse drug reaction 15.02 9.18 479 472527 116222 90039219
Left atrial dilatation 14.99 9.18 32 472974 1904 90153537
Blood growth hormone abnormal 14.97 9.18 6 473000 30 90155411
Aerophagia 14.97 9.18 6 473000 30 90155411
Vascular purpura 14.96 9.18 30 472976 1708 90153733
Respiratory rate increased 14.83 9.18 138 472868 15863 90139578
Diffuse idiopathic skeletal hyperostosis 14.82 9.18 4 473002 3 90155438
Diabetic cheiroarthropathy 14.82 9.18 4 473002 3 90155438
Haematemesis 14.81 9.18 253 472753 33473 90121968
Benign pancreatic neoplasm 14.81 9.18 6 473000 31 90155410
Dementia 14.80 9.18 190 472816 23671 90131770
Multiple fractures 14.80 9.18 93 472913 9469 90145972
Product size issue 14.75 9.18 15 472991 450 90154991
Mineral metabolism disorder 14.74 9.18 7 472999 56 90155385
Hypoglobulinaemia 14.64 9.18 10 472996 169 90155272
Sinus bradycardia 14.62 9.18 144 472862 16808 90138633
Polyarthritis 14.62 9.18 48 472958 18302 90137139
Blood calcium decreased 14.49 9.18 95 472911 30087 90125354
Oral herpes 14.39 9.18 109 472897 33415 90122026
Macrosomia 14.33 9.18 7 472999 60 90155381
Feeling cold 14.31 9.18 212 472794 27253 90128188
Renal tubular disorder 14.31 9.18 43 472963 3164 90152277
Venous aneurysm 14.29 9.18 4 473002 4 90155437
Inner ear operation 14.29 9.18 4 473002 4 90155437
Empty sella syndrome 14.23 9.18 7 472999 61 90155380
Polyp 14.19 9.18 78 472928 7566 90147875
Hypoxic-ischaemic encephalopathy 14.15 9.18 55 472951 4613 90150828
Arthritis 14.14 9.18 721 472285 166594 89988847
Metastases to fallopian tube 14.13 9.18 7 472999 62 90155379
Duodenal ulcer haemorrhage 14.09 9.18 37 472969 2519 90152922
Device related infection 14.04 9.18 78 472928 25708 90129733
Hypereosinophilic syndrome 14.02 9.18 13 472993 347 90155094
Hyporesponsive to stimuli 14.02 9.18 28 472978 1589 90153852
Malignant polyp 13.91 9.18 10 472996 184 90155257
Injection site hypersensitivity 13.90 9.18 38 472968 2649 90152792
Synovial cyst 13.90 9.18 25 472981 11727 90143714
Melaena 13.85 9.18 257 472749 34540 90120901
Left ventricular dysfunction 13.84 9.18 127 472879 14542 90140899
Vulvovaginal discomfort 13.82 9.18 38 472968 2659 90152782
Hyponatraemic encephalopathy 13.80 9.18 12 472994 294 90155147
Glucose urine 13.77 9.18 5 473001 18 90155423
Large intestine polyp 13.73 9.18 90 472916 9296 90146145
Metabolic disorder 13.72 9.18 76 472930 7394 90148047
Gallbladder disorder 13.72 9.18 161 472845 19642 90135799
Haematoma 13.72 9.18 283 472723 38765 90116676
Diabetic foot infection 13.72 9.18 11 472995 240 90155201
Scleritis 13.72 9.18 5 473001 5203 90150238
Foaming at mouth 13.71 9.18 25 472981 1325 90154116
Peripheral artery haematoma 13.68 9.18 6 473000 39 90155402
Steatohepatitis 13.67 9.18 19 472987 797 90154644
Thyroid cancer 13.66 9.18 67 472939 6217 90149224
Electrocardiogram QRS complex prolonged 13.66 9.18 75 472931 7273 90148168
Optic ischaemic neuropathy 13.62 9.18 29 472977 1723 90153718
Cataract operation 13.61 9.18 66 472940 6097 90149344
Tumour compression 13.58 9.18 7 472999 68 90155373
Aspartate aminotransferase decreased 13.57 9.18 21 472985 972 90154469
Vascular access site haemorrhage 13.55 9.18 10 472996 192 90155249
Mental status changes 13.53 9.18 317 472689 44362 90111079
Polyhydramnios 13.51 9.18 36 472970 2472 90152969
Vulvovaginal mycotic infection 13.50 9.18 67 472939 6247 90149194
Hypoparathyroidism 13.44 9.18 21 472985 980 90154461
Pseudomonal sepsis 13.42 9.18 3 473003 4299 90151142
Blood magnesium decreased 13.39 9.18 133 472873 15560 90139881
Embolic cerebellar infarction 13.36 9.18 5 473001 20 90155421
Hernia 13.32 9.18 123 472883 14108 90141333
Angioplasty 13.32 9.18 26 472980 1451 90153990
Discoloured vomit 13.30 9.18 23 472983 1169 90154272
Nodular rash 13.29 9.18 10 472996 198 90155243
Antipsychotic drug level above therapeutic 13.26 9.18 25 472981 1359 90154082
Epilepsy 13.24 9.18 327 472679 81879 90073562
Rash maculo-papular 13.24 9.18 143 472863 40790 90114651
Injection site erythema 13.24 9.18 402 472604 98100 90057341
Product coating issue 13.19 9.18 8 472998 109 90155332
Creatinine urine increased 13.16 9.18 11 472995 255 90155186
Transcription medication error 13.12 9.18 11 472995 256 90155185
Vaccination site pain 13.11 9.18 13 472993 378 90155063
Glycosylated haemoglobin 13.07 9.18 7 472999 74 90155367
Memory impairment 13.07 9.18 870 472136 196374 89959067
Agitation 13.05 9.18 450 472556 66648 90088793
Diaphragmatic spasm 13.03 9.18 4 473002 7 90155434
Gait disturbance 13.03 9.18 1176 471830 259320 89896121
Hypokalaemia 13.03 9.18 822 472184 130294 90025147
Micturition disorder 13.01 9.18 40 472966 2980 90152461
Inappropriate schedule of product administration 12.95 9.18 929 472077 149004 90006437
Chronic gastritis 12.95 9.18 46 472960 3695 90151746
Breath sounds abnormal 12.93 9.18 130 472876 15256 90140185
Blood ketone body present 12.91 9.18 7 472999 76 90155365
Disturbance in social behaviour 12.90 9.18 3 473003 4185 90151256
Phaeochromocytoma 12.87 9.18 16 472990 601 90154840
Total cholesterol/HDL ratio abnormal 12.83 9.18 7 472999 77 90155364
Psychogenic tremor 12.81 9.18 5 473001 23 90155418
Vulvovaginitis 12.81 9.18 13 472993 389 90155052
Complication associated with device 12.81 9.18 55 472951 19394 90136047
Peritonitis 12.81 9.18 56 472950 19649 90135792
Drug dose omission by device 12.80 9.18 21 472985 10210 90145231
Fat tissue increased 12.79 9.18 18 472988 764 90154677
Monogenic diabetes 12.78 9.18 3 473003 0 90155441
Non-high-density lipoprotein cholesterol decreased 12.78 9.18 3 473003 0 90155441
Insulin resistant diabetes 12.78 9.18 3 473003 0 90155441
Eyelid myokymia 12.78 9.18 3 473003 0 90155441
Abdominal compartment syndrome 12.78 9.18 18 472988 765 90154676
Lymphocyte count decreased 12.77 9.18 119 472887 34931 90120510
Urticarial vasculitis 12.77 9.18 21 472985 1024 90154417
Lactate pyruvate ratio increased 12.75 9.18 7 472999 78 90155363
Cholangiectasis acquired 12.69 9.18 4 473002 8 90155433
Foetal hypokinesia 12.67 9.18 16 472990 611 90154830
Hyperkinetic heart syndrome 12.64 9.18 5 473001 24 90155417
Creatinine renal clearance 12.64 9.18 5 473001 24 90155417
Carotid arteriosclerosis 12.64 9.18 23 472983 1217 90154224
Cardiovascular insufficiency 12.63 9.18 27 472979 1608 90153833
Bladder neoplasm 12.58 9.18 17 472989 694 90154747
Drug use disorder 12.56 9.18 15 472991 8328 90147113
Nephrogenic systemic fibrosis 12.54 9.18 3 473003 4105 90151336
Pancreatic disorder 12.48 9.18 39 472967 2932 90152509
Maximal voluntary ventilation abnormal 12.48 9.18 5 473001 25 90155416
Cholecystitis 12.46 9.18 140 472866 16900 90138541
Systemic inflammatory response syndrome 12.44 9.18 67 472939 6449 90148992
Infected dermal cyst 12.43 9.18 14 472992 473 90154968
Exposure during pregnancy 12.43 9.18 1424 471582 236986 89918455
Pulmonary embolism 12.43 9.18 817 472189 130003 90025438
Pancreatic duct stenosis 12.42 9.18 6 473000 50 90155391
Endometrial hyperplasia 12.40 9.18 20 472986 959 90154482
Catheter site erythema 12.39 9.18 5 473001 4889 90150552
Electrocardiogram P wave abnormal 12.29 9.18 10 472996 223 90155218
Autoimmune nephritis 12.28 9.18 13 472993 409 90155032
Wrong dose 12.27 9.18 30 472976 1954 90153487
Product solubility abnormal 12.25 9.18 20 472986 969 90154472
Emphysematous pyelonephritis 12.19 9.18 12 472994 346 90155095
Hypernatriuria 12.16 9.18 5 473001 27 90155414
Genital rash 12.15 9.18 16 472990 637 90154804
Blood iron abnormal 12.15 9.18 3 473003 4017 90151424
Barotrauma 12.14 9.18 9 472997 174 90155267
Blood triglycerides abnormal 12.13 9.18 13 472993 415 90155026
Lupus nephritis 12.13 9.18 5 473001 4827 90150614
Ectopia cordis 12.10 9.18 7 472999 87 90155354
Biopsy skin abnormal 12.09 9.18 8 472998 128 90155313
Premature labour 12.09 9.18 33 472973 13343 90142098
Stress 12.08 9.18 530 472476 80865 90074576
Extrasystoles 12.07 9.18 60 472946 5597 90149844
Pyelonephritis chronic 12.06 9.18 10 472996 229 90155212
Enzyme abnormality 12.06 9.18 9 472997 176 90155265
Tremor 12.04 9.18 942 472064 152231 90003210
Urine ketone body 12.03 9.18 8 472998 129 90155312
Lymphopenia 12.03 9.18 70 472936 22811 90132630
Cortisol increased 11.99 9.18 14 472992 492 90154949
Rebound effect 11.99 9.18 19 472987 9365 90146076
Hypovitaminosis 11.98 9.18 20 472986 987 90154454
Device use error 11.96 9.18 12 472994 7209 90148232
Glucose tolerance impaired 11.95 9.18 77 472929 7908 90147533
Urine protein/creatinine ratio increased 11.91 9.18 20 472986 992 90154449
Gingival oedema 11.89 9.18 7 472999 90 90155351
Fear of falling 11.89 9.18 16 472990 651 90154790
Alkalosis hypochloraemic 11.88 9.18 10 472996 234 90155207
Cardiac death 11.87 9.18 15 472991 573 90154868
Tenosynovitis stenosans 11.85 9.18 3 473003 3950 90151491
Cholangiocarcinoma 11.83 9.18 23 472983 1280 90154161
Hypergastrinaemia 11.83 9.18 8 472998 133 90155308
Full blood count abnormal 11.81 9.18 262 472744 36335 90119106
Cystic fibrosis 11.79 9.18 3 473003 3938 90151503
Respiratory syncytial virus infection 11.77 9.18 23 472983 10457 90144984
Adrenal neoplasm 11.76 9.18 13 472993 430 90155011
Granuloma annulare 11.74 9.18 18 472988 826 90154615
Grandiosity 11.73 9.18 11 472995 298 90155143
Diabetic vascular disorder 11.73 9.18 5 473001 30 90155411
Blindness cortical 11.73 9.18 15 472991 580 90154861
Foot operation 11.71 9.18 18 472988 8983 90146458
Foetal death 11.66 9.18 62 472944 20661 90134780
Ischaemic cardiomyopathy 11.63 9.18 35 472971 2578 90152863
Sudden death 11.62 9.18 97 472909 10812 90144629
Injection site hypertrophy 11.57 9.18 7 472999 95 90155346
Blood osmolarity abnormal 11.56 9.18 4 473002 12 90155429
Dizziness 11.46 9.18 3344 469662 585940 89569501
Sprue-like enteropathy 11.44 9.18 19 472987 934 90154507
Hormone level abnormal 11.41 9.18 37 472969 2836 90152605
Gastrointestinal toxicity 11.32 9.18 20 472986 9447 90145994
Pituitary apoplexy 11.28 9.18 8 472998 144 90155297
Hypothyroidism 11.28 9.18 360 472646 52767 90102674
Medullary thyroid cancer 11.26 9.18 10 472996 252 90155189
Depressed level of consciousness 11.26 9.18 476 472530 72308 90083133
Ureterolithiasis 11.25 9.18 31 472975 2171 90153270
Dry skin 11.25 9.18 565 472441 87508 90067933
Sinonasal obstruction 11.23 9.18 10 472996 253 90155188
Fibrosis 11.23 9.18 61 472945 5891 90149550
Seizure 11.18 9.18 667 472339 151962 90003479
Bradyphrenia 11.14 9.18 73 472933 7539 90147902
Resting tremor 11.13 9.18 18 472988 865 90154576
Oesophageal rupture 11.09 9.18 15 472991 613 90154828
Urethral pain 11.07 9.18 12 472994 388 90155053
Bundle branch block right 11.05 9.18 57 472949 5396 90150045
Hypoplastic left heart syndrome 11.01 9.18 9 472997 202 90155239
B-lymphocyte abnormalities 11.01 9.18 10 472996 260 90155181
Craniofacial fracture 10.98 9.18 13 472993 464 90154977
Monoclonal immunoglobulin present 10.95 9.18 30 472976 2094 90153347
Cell death 10.95 9.18 38 472968 3017 90152424
Anticoagulation drug level above therapeutic 10.87 9.18 29 472977 1993 90153448
Retinal haemorrhage 10.83 9.18 59 472947 5705 90149736
Pancreatic pseudocyst 10.81 9.18 17 472989 798 90154643
Respiratory distress 10.79 9.18 273 472733 38673 90116768
Colitis 10.79 9.18 280 472726 69662 90085779
Gout 10.78 9.18 135 472871 16724 90138717
Toxic epidermal necrolysis 10.78 9.18 113 472893 32415 90123026
Therapy partial responder 10.77 9.18 69 472937 21974 90133467
Blood uric acid increased 10.75 9.18 73 472933 7631 90147810
Clear cell endometrial carcinoma 10.72 9.18 3 473003 3 90155438
Castleman's disease 10.72 9.18 3 473003 3 90155438
Aerococcus urinae infection 10.72 9.18 3 473003 3 90155438
Acquired perforating dermatosis 10.72 9.18 3 473003 3 90155438
Biliary neoplasm 10.72 9.18 3 473003 3 90155438
Musculoskeletal disorder 10.71 9.18 68 472938 21701 90133740
Intestinal transit time abnormal 10.70 9.18 6 473000 70 90155371
Supraventricular extrasystoles 10.69 9.18 55 472951 5202 90150239
Genital infection female 10.69 9.18 7 472999 110 90155331
Wheelchair user 10.69 9.18 15 472991 7770 90147671
Pelvic fracture 10.67 9.18 42 472964 15177 90140264
Aplasia pure red cell 10.63 9.18 7 472999 5187 90150254
Meningitis candida 10.62 9.18 6 473000 71 90155370
Dermatitis exfoliative 10.62 9.18 57 472949 5479 90149962
Serum serotonin increased 10.61 9.18 9 472997 213 90155228
Thirst decreased 10.60 9.18 11 472995 338 90155103
Internal haemorrhage 10.58 9.18 62 472944 6158 90149283
Incision site swelling 10.57 9.18 10 472996 274 90155167
Joint effusion 10.53 9.18 60 472946 19650 90135791
Ultrasound antenatal screen 10.47 9.18 9 472997 217 90155224
Carcinoid tumour 10.43 9.18 12 472994 415 90155026
Nervousness 10.43 9.18 242 472764 33814 90121627
Vascular device infection 10.42 9.18 30 472976 11922 90143519
Sputum retention 10.41 9.18 15 472991 651 90154790
Blood urea abnormal 10.39 9.18 18 472988 916 90154525
Staphylococcal infection 10.36 9.18 184 472822 48255 90107186
Methaemoglobinaemia 10.33 9.18 4 473002 4011 90151430
Blood creatine increased 10.31 9.18 67 472939 6900 90148541
Intestinal angioedema 10.30 9.18 17 472989 831 90154610
Therapeutic response unexpected 10.30 9.18 166 472840 21714 90133727
Dry eye 10.29 9.18 227 472779 57704 90097737
pH body fluid abnormal 10.27 9.18 6 473000 76 90155365
Nipple swelling 10.26 9.18 3 473003 4 90155437
Delusion 10.25 9.18 114 472892 13726 90141715
Jaundice 10.25 9.18 232 472774 32285 90123156
Cytomegalovirus test positive 10.25 9.18 3 473003 3588 90151853
Vascular stent stenosis 10.24 9.18 15 472991 661 90154780
Injection site pain 10.23 9.18 1046 471960 172653 89982788
Mucosal membrane hyperplasia 10.22 9.18 5 473001 43 90155398
Burning feet syndrome 10.21 9.18 7 472999 119 90155322
Pancreatic cyst 10.21 9.18 30 472976 2180 90153261
Mucosal dryness 10.16 9.18 38 472968 3129 90152312
Hypertensive emergency 10.15 9.18 30 472976 2187 90153254
Blood sodium increased 10.06 9.18 38 472968 3144 90152297
Cardio-respiratory distress 10.04 9.18 8 472998 173 90155268
Neck pain 10.03 9.18 489 472517 113474 90041967
Bezold-Jarisch reflex 10.03 9.18 5 473001 45 90155396
Cerebral artery occlusion 9.99 9.18 19 472987 1040 90154401
Benign neoplasm of bladder 9.98 9.18 4 473002 20 90155421
Dysstasia 9.96 9.18 185 472821 24867 90130574
Deprescribing error 9.93 9.18 5 473001 46 90155395
Product administered to patient of inappropriate age 9.90 9.18 6 473000 4647 90150794
Device occlusion 9.89 9.18 21 472985 9261 90146180
Hepatorenal failure 9.89 9.18 15 472991 682 90154759
Hypothalamo-pituitary disorder 9.87 9.18 30 472976 2222 90153219
Blood immunoglobulin M increased 9.85 9.18 22 472984 1350 90154091
Pulmonary oedema 9.83 9.18 407 472599 61673 90093768
Squamous cell carcinoma of the vagina 9.82 9.18 4 473002 21 90155420
Bacteraemia 9.81 9.18 72 472934 22228 90133213
Calcification metastatic 9.81 9.18 8 472998 179 90155262
Helicobacter gastritis 9.77 9.18 25 472981 1675 90153766
Electrocardiogram change 9.76 9.18 16 472990 778 90154663
Complication of pregnancy 9.76 9.18 15 472991 690 90154751
Blood bicarbonate abnormal 9.75 9.18 5 473001 48 90155393
Atelectasis 9.72 9.18 81 472925 24328 90131113
Cerebellar ischaemia 9.72 9.18 9 472997 240 90155201
Tumour lysis syndrome 9.72 9.18 28 472978 11124 90144317
Scleroderma 9.70 9.18 11 472995 6250 90149191
Cellulitis 9.70 9.18 576 472430 90761 90064680
Pancreatic failure 9.70 9.18 23 472983 1469 90153972
Thyroid atrophy 9.67 9.18 10 472996 306 90155135
Anosmia 9.67 9.18 86 472920 9762 90145679
Stool analysis abnormal 9.66 9.18 5 473001 49 90155392
Candida endophthalmitis 9.66 9.18 5 473001 49 90155392
Retching 9.64 9.18 147 472859 19012 90136429
Postmortem blood drug level increased 9.60 9.18 15 472991 700 90154741
Increased viscosity of bronchial secretion 9.59 9.18 11 472995 379 90155062
Laboratory test abnormal 9.59 9.18 157 472849 41697 90113744
Respiratory failure 9.59 9.18 730 472276 117688 90037753
Febrile bone marrow aplasia 9.59 9.18 23 472983 9715 90145726
Fungal pharyngitis 9.59 9.18 8 472998 185 90155256
Sleep disorder due to a general medical condition 9.55 9.18 170 472836 44568 90110873
pH urine decreased 9.52 9.18 3 473003 6 90155435
Asplenia 9.52 9.18 3 473003 6 90155435
Oedema due to hepatic disease 9.52 9.18 3 473003 6 90155435
Eye oedema 9.50 9.18 27 472979 1925 90153516
Pharyngeal mass 9.46 9.18 10 472996 314 90155127
Small fibre neuropathy 9.46 9.18 15 472991 709 90154732
Hypopnoea 9.46 9.18 47 472959 4384 90151057
Blood magnesium increased 9.45 9.18 3 473003 3405 90152036
Collagen disorder 9.41 9.18 9 472997 250 90155191
Transferrin saturation decreased 9.41 9.18 17 472989 894 90154547
Occult blood 9.39 9.18 21 472985 1290 90154151
Retroperitoneal oedema 9.38 9.18 4 473002 24 90155417
Intracranial haematoma 9.37 9.18 11 472995 389 90155052
Iris neovascularisation 9.33 9.18 5 473001 53 90155388
Blood citric acid increased 9.33 9.18 5 473001 53 90155388
Ventricular tachycardia 9.32 9.18 181 472825 24527 90130914
Biliary colic 9.32 9.18 44 472962 4019 90151422
Antipsychotic drug level below therapeutic 9.31 9.18 10 472996 320 90155121
Micturition frequency decreased 9.30 9.18 14 472992 632 90154809
Mental disability 9.30 9.18 8 472998 193 90155248
Retinal vascular disorder 9.27 9.18 9 472997 255 90155186
Cardiac disorder 9.27 9.18 374 472632 56498 90098943
Base excess 9.25 9.18 5 473001 54 90155387
Medication error 9.21 9.18 535 472471 84117 90071324
Urine output increased 9.20 9.18 25 472981 1737 90153704
Depressive symptom 9.20 9.18 53 472953 5232 90150209
Hypoacusis 9.19 9.18 200 472806 27650 90127791

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 14786.94 11.27 7401 362574 37860 42213500
Acute kidney injury 2875.34 11.27 8311 361664 359026 41892334
Metabolic acidosis 2642.51 11.27 2727 367248 49131 42202229
Hypoglycaemia 2387.30 11.27 2767 367208 57087 42194273
Diabetic ketoacidosis 1829.18 11.27 1532 368443 20835 42230525
Euglycaemic diabetic ketoacidosis 1330.35 11.27 745 369230 4915 42246445
Blood glucose increased 1214.07 11.27 2243 367732 71456 42179904
Glycosylated haemoglobin increased 1047.63 11.27 881 369094 12043 42239317
Hyperkalaemia 997.10 11.27 2175 367800 78283 42173077
Diabetes mellitus inadequate control 978.07 11.27 914 369061 14476 42236884
Off label use 825.07 11.27 2822 367153 635513 41615847
Ketoacidosis 782.71 11.27 520 369455 4832 42246528
Hyperglycaemia 572.51 11.27 1244 368731 44615 42206745
Pancreatitis 504.34 11.27 1142 368833 42126 42209234
Completed suicide 450.45 11.27 1844 368131 94621 42156739
Shock 434.06 11.27 850 369125 28271 42223089
Drug ineffective 421.77 11.27 3480 366495 626717 41624643
Hyperlactacidaemia 418.75 11.27 333 369642 4183 42247177
Drug abuse 358.42 11.27 234 369741 104537 42146823
Pancreatitis acute 357.25 11.27 855 369120 32709 42218651
Hypoglycaemic coma 313.16 11.27 229 369746 2515 42248845
Blood lactic acid increased 303.84 11.27 362 369613 7677 42243683
Diabetic metabolic decompensation 285.25 11.27 195 369780 1907 42249453
Febrile neutropenia 280.78 11.27 761 369214 184942 42066418
Intentional overdose 278.53 11.27 1031 368944 50425 42200935
Product use in unapproved indication 272.08 11.27 765 369210 183691 42067669
Death 253.31 11.27 2744 367231 468441 41782919
Neutropenia 251.99 11.27 887 369088 198544 42052816
Vitamin B12 deficiency 250.52 11.27 259 369716 4663 42246697
Pemphigoid 247.72 11.27 394 369581 11073 42240287
Pyrexia 247.62 11.27 2209 367766 391833 41859527
Blood glucose abnormal 241.26 11.27 302 369673 6751 42244609
Disease progression 237.73 11.27 562 369413 143094 42108266
Blood glucose decreased 229.00 11.27 429 369546 13790 42237570
Toxicity to various agents 226.23 11.27 3007 366968 226129 42025231
Myelosuppression 203.88 11.27 50 369925 40411 42210949
Blood glucose fluctuation 201.06 11.27 223 369752 4364 42246996
Suspected suicide 184.80 11.27 248 369727 5951 42245409
Pneumonia 183.97 11.27 2571 367404 419578 41831782
MELAS syndrome 180.99 11.27 55 369920 33 42251327
Pancreatic carcinoma 177.62 11.27 306 369669 9200 42242160
Hypomagnesaemia 170.49 11.27 590 369385 27898 42223462
Cytomegalovirus infection 168.57 11.27 37 369938 32269 42219091
Thrombocytopenia 167.11 11.27 968 369007 189311 42062049
Renal failure 166.46 11.27 1944 368031 141782 42109578
Acidosis 158.74 11.27 338 369637 11941 42239419
Diabetic neuropathy 155.95 11.27 194 369781 4308 42247052
Platelet count decreased 154.49 11.27 648 369327 137933 42113427
Pancytopenia 151.70 11.27 519 369456 117224 42134136
Ketonuria 149.51 11.27 85 369890 579 42250781
Anuria 148.57 11.27 317 369658 11215 42240145
Leukopenia 148.54 11.27 263 369712 74483 42176877
Distributive shock 135.50 11.27 136 369839 2360 42249000
Immune-mediated myositis 135.50 11.27 166 369809 3627 42247733
Type 2 diabetes mellitus 135.36 11.27 410 369565 18061 42233299
Drug resistance 135.07 11.27 64 369911 34184 42217176
Diarrhoea 130.66 11.27 5059 364916 455790 41795570
Drug dependence 129.99 11.27 45 369930 29049 42222311
Vomiting 128.98 11.27 3359 366616 286364 41964996
Drug level above therapeutic 124.92 11.27 201 369774 5705 42245655
Treatment failure 123.84 11.27 221 369754 62403 42188957
Dehydration 123.69 11.27 1821 368154 139946 42111414
Weight decreased 123.57 11.27 2511 367464 205437 42045923
Malignant neoplasm progression 121.94 11.27 505 369470 107895 42143465
Infusion related reaction 118.97 11.27 216 369759 60590 42190770
Anion gap increased 111.67 11.27 113 369862 1981 42249379
Seizure 110.25 11.27 605 369370 119956 42131404
Continuous haemodiafiltration 109.73 11.27 80 369895 874 42250486
White blood cell count decreased 104.82 11.27 547 369428 109849 42141511
Drug ineffective for unapproved indication 104.40 11.27 149 369826 46014 42205346
Ketosis 102.08 11.27 75 369900 830 42250530
Pneumocystis jirovecii pneumonia 100.93 11.27 46 369929 25135 42226225
Drug level increased 100.87 11.27 473 369502 25727 42225633
Bone marrow failure 100.04 11.27 84 369891 33009 42218351
Toxic epidermal necrolysis 99.48 11.27 54 369921 26696 42224664
Stomatitis 94.73 11.27 183 369792 50146 42201214
Overdose 94.08 11.27 1358 368617 103906 42147454
Cytokine release syndrome 93.67 11.27 151 369824 44376 42206984
Graft versus host disease 91.66 11.27 5 369970 12920 42238440
Haemodialysis 89.00 11.27 242 369733 10018 42241342
Diabetes mellitus 88.31 11.27 853 369122 59234 42192126
Product monitoring error 87.42 11.27 146 369829 4277 42247083
Diabetic retinopathy 86.49 11.27 98 369877 1965 42249395
Hypotension 85.14 11.27 2879 367096 254752 41996608
Mucosal inflammation 84.92 11.27 189 369786 49185 42202175
Glycosylated haemoglobin abnormal 84.72 11.27 45 369930 263 42251097
Drug intolerance 81.76 11.27 389 369586 80035 42171325
Lipase increased 79.74 11.27 237 369738 10329 42241031
Product residue present 79.15 11.27 110 369865 2731 42248629
Glomerular filtration rate decreased 78.89 11.27 316 369659 16035 42235325
Neuropathy peripheral 78.05 11.27 540 369435 101313 42150047
Urine ketone body present 77.60 11.27 77 369898 1317 42250043
Bronchopulmonary aspergillosis 75.55 11.27 37 369938 19392 42231968
Posterior reversible encephalopathy syndrome 74.85 11.27 11 369964 12810 42238550
Myocardial infarction 73.72 11.27 1498 368477 122511 42128849
BRASH syndrome 73.65 11.27 85 369890 1740 42249620
Product use issue 73.55 11.27 379 369596 76372 42174988
Condition aggravated 72.71 11.27 1716 368259 259038 41992322
Blood phosphorus increased 72.54 11.27 11 369964 12514 42238846
Therapy non-responder 72.25 11.27 230 369745 53129 42198231
Toe amputation 72.20 11.27 107 369868 2822 42248538
Transplant rejection 72.03 11.27 15 369960 13573 42237787
Sepsis 71.91 11.27 1257 368718 198077 42053283
Acetonaemia 71.42 11.27 38 369937 223 42251137
Drug hypersensitivity 71.29 11.27 537 369438 98852 42152508
Hypothermia 71.25 11.27 255 369720 12260 42239100
Myocardial ischaemia 70.83 11.27 324 369651 17438 42233922
Cytomegalovirus viraemia 70.63 11.27 5 369970 10372 42240988
Appendicitis 70.47 11.27 46 369929 20567 42230793
Neutrophil count decreased 70.30 11.27 297 369678 63118 42188242
Anion gap 70.00 11.27 58 369917 775 42250585
Aspergillus infection 69.88 11.27 25 369950 15812 42235548
Hyperphosphataemia 69.67 11.27 14 369961 12990 42238370
Blood lactic acid 69.17 11.27 41 369934 305 42251055
Diabetic nephropathy 68.78 11.27 93 369882 2248 42249112
Blood ketone body increased 68.51 11.27 48 369927 490 42250870
Hyperglycaemic hyperosmolar nonketotic syndrome 68.07 11.27 77 369898 1541 42249819
Polyuria 65.78 11.27 214 369761 9797 42241563
Pancreatitis chronic 65.44 11.27 90 369885 2212 42249148
Pancreatic carcinoma metastatic 64.58 11.27 106 369869 3060 42248300
Bladder cancer 64.33 11.27 306 369669 16741 42234619
Anaemia vitamin B12 deficiency 64.28 11.27 47 369928 516 42250844
Injection site nodule 63.72 11.27 86 369889 2075 42249285
Drug reaction with eosinophilia and systemic symptoms 62.27 11.27 174 369801 41901 42209459
Bacterial infection 62.03 11.27 91 369884 27788 42223572
Microalbuminuria 61.54 11.27 55 369920 819 42250541
Haemophagocytic lymphohistiocytosis 60.50 11.27 42 369933 18180 42233180
Renal tubular necrosis 60.44 11.27 317 369658 18037 42233323
Epstein-Barr virus infection 59.94 11.27 7 369968 9711 42241649
Suicide attempt 59.84 11.27 638 369337 45462 42205898
Diabetic ketosis 59.64 11.27 34 369941 233 42251127
Kidney transplant rejection 59.64 11.27 4 369971 8679 42242681
Balanoposthitis 59.62 11.27 72 369903 1549 42249811
Hepatic steatosis 59.05 11.27 353 369622 21095 42230265
Latent autoimmune diabetes in adults 58.51 11.27 28 369947 126 42251234
Syncope 58.13 11.27 1198 368777 98208 42153152
Hepatic function abnormal 58.09 11.27 240 369735 51327 42200033
Pseudomonas infection 57.97 11.27 33 369942 15890 42235470
Cytomegalovirus infection reactivation 57.91 11.27 13 369962 11165 42240195
Coronary artery disease 57.86 11.27 717 369258 53003 42198357
Adenocarcinoma pancreas 57.65 11.27 68 369907 1426 42249934
Acute myocardial infarction 57.44 11.27 764 369211 57401 42193959
Blood pH decreased 56.72 11.27 84 369891 2214 42249146
Neoplasm progression 56.72 11.27 103 369872 28897 42222463
Therapy partial responder 56.69 11.27 54 369921 19967 42231393
Progressive multifocal leukoencephalopathy 56.67 11.27 15 369960 11521 42239839
Infection 56.51 11.27 661 369314 111407 42139953
Pathogen resistance 56.04 11.27 15 369960 11435 42239925
Ascites 55.93 11.27 277 369698 56401 42194959
Intentional product use issue 55.93 11.27 379 369596 71454 42179906
Acute graft versus host disease 55.79 11.27 4 369971 8211 42243149
Drug interaction 54.23 11.27 2835 367140 264164 41987196
Hypovolaemic shock 54.13 11.27 182 369793 8477 42242883
Aplastic anaemia 53.88 11.27 20 369955 12364 42238996
Incorrect route of product administration 53.42 11.27 80 369895 24225 42227135
Aggression 53.27 11.27 200 369775 43963 42207397
Exposure via ingestion 53 11.27 78 369897 2044 42249316
Post transplant lymphoproliferative disorder 52.84 11.27 8 369967 9112 42242248
Rash 52.71 11.27 1920 368055 275034 41976326
Macroangiopathy 52.70 11.27 17 369958 16 42251344
Hospitalisation 52.63 11.27 403 369572 73927 42177433
Haematotoxicity 52.62 11.27 15 369960 10970 42240390
Vitamin B1 deficiency 52.55 11.27 37 369938 381 42250979
Infective pulmonary exacerbation of cystic fibrosis 52.55 11.27 4 369971 7814 42243546
BK virus infection 52.54 11.27 7 369968 8777 42242583
Haemodynamic instability 52.27 11.27 232 369743 12325 42239035
Immune reconstitution inflammatory syndrome 52.14 11.27 12 369963 10131 42241229
Neurotoxicity 51.84 11.27 78 369897 23573 42227787
Drug use disorder 51.60 11.27 13 369962 10320 42241040
Anaemia 51.34 11.27 1952 368023 278326 41973034
Genital infection fungal 50.48 11.27 29 369946 202 42251158
Diabetic ketoacidotic hyperglycaemic coma 50.40 11.27 27 369948 161 42251199
Staphylococcal infection 49.74 11.27 164 369811 37479 42213881
Product odour abnormal 49.61 11.27 50 369925 872 42250488
Lumbosacral radiculoplexus neuropathy 48.46 11.27 21 369954 71 42251289
Medication error 48.37 11.27 470 369505 32684 42218676
Glycosylated haemoglobin decreased 48.08 11.27 36 369939 411 42250949
Arthralgia 46.79 11.27 1390 368585 203848 42047512
Haemorrhage 46.42 11.27 321 369654 60242 42191118
Multiple-drug resistance 45.85 11.27 5 369970 7317 42244043
Blood bicarbonate decreased 45.33 11.27 87 369888 2848 42248512
Plasma cell myeloma 44.97 11.27 236 369739 47342 42204018
Diabetic foot infection 44.88 11.27 43 369932 703 42250657
No adverse event 44.33 11.27 181 369794 38840 42212520
Thrombotic microangiopathy 44.08 11.27 38 369937 14744 42236616
Pneumothorax 43.95 11.27 86 369889 23457 42227903
Hypovolaemia 43.95 11.27 207 369768 11278 42240082
Interstitial lung disease 43.02 11.27 454 369521 78008 42173352
Glycosuria 42.67 11.27 56 369919 1314 42250046
Tumour lysis syndrome 42.55 11.27 80 369895 22151 42229209
Musculoskeletal stiffness 42.40 11.27 310 369665 57455 42193905
Pulmonary vasculitis 42.12 11.27 135 369840 6131 42245229
Clostridium difficile infection 42.10 11.27 83 369892 22576 42228784
Pancreatic neoplasm 42.08 11.27 47 369928 927 42250433
Renal impairment 41.57 11.27 1252 368723 108976 42142384
Rheumatoid arthritis 41.54 11.27 208 369767 42232 42209128
Coma 41.30 11.27 674 369301 52880 42198480
Cardiac failure 41.19 11.27 1217 368758 105639 42145721
Neuralgia 41.03 11.27 102 369873 25545 42225815
Urine albumin/creatinine ratio abnormal 40.95 11.27 13 369962 11 42251349
Aspartate aminotransferase increased 40.89 11.27 450 369525 76713 42174647
Dizziness 39.56 11.27 2589 367386 246665 42004695
Intercepted product preparation error 39.49 11.27 8 369967 7381 42243979
Septic shock 39.43 11.27 559 369416 91113 42160247
Clostridium difficile colitis 39.35 11.27 78 369897 21174 42230186
Blood cholesterol 39.21 11.27 25 369950 215 42251145
Osteoporosis 39.03 11.27 43 369932 14863 42236497
Acute painful neuropathy of rapid glycaemic control 39.00 11.27 12 369963 8 42251352
Cerebrovascular accident 38.94 11.27 1112 368863 96048 42155312
Vitamin B12 decreased 38.64 11.27 59 369916 1599 42249761
Therapeutic product effect decreased 38.24 11.27 192 369783 38958 42212402
Neurological symptom 38.17 11.27 180 369795 9811 42241549
Pleural effusion 38.17 11.27 603 369372 96563 42154797
Gangrene 37.75 11.27 114 369861 5012 42246348
Sinusitis 37.56 11.27 248 369727 47044 42204316
Sedation 37.41 11.27 137 369838 30338 42221022
Potentiating drug interaction 36.99 11.27 132 369843 6336 42245024
Myelodysplastic syndrome 36.75 11.27 90 369885 22655 42228705
Deep vein thrombosis 36.46 11.27 460 369515 76497 42174863
Abdominal discomfort 36.43 11.27 883 369092 74372 42176988
Immunosuppressant drug level increased 36.22 11.27 11 369964 7720 42243640
Alanine aminotransferase increased 35.96 11.27 545 369430 87861 42163499
Chronic obstructive pulmonary disease 35.90 11.27 362 369613 62752 42188608
Urine ketone body 35.69 11.27 15 369960 46 42251314
Dystonia 35.63 11.27 35 369940 12755 42238605
Blood mercury abnormal 35.54 11.27 25 369950 257 42251103
Blood triglycerides increased 35.40 11.27 248 369727 15648 42235712
Immune effector cell-associated neurotoxicity syndrome 35.32 11.27 19 369956 9442 42241918
Psoriasis 35.02 11.27 605 369370 47999 42203361
Accidental overdose 34.88 11.27 388 369587 27942 42223418
Tongue oedema 34.85 11.27 84 369891 3226 42248134
Diabetic foot 34.54 11.27 80 369895 2993 42248367
Cholelithiasis 34.07 11.27 331 369644 23015 42228345
Peritonitis 33.97 11.27 69 369906 18564 42232796
Rhabdomyolysis 33.81 11.27 902 369073 77117 42174243
Angina pectoris 33.68 11.27 435 369540 32461 42218899
Myasthenia gravis 33.67 11.27 55 369920 16082 42235278
Graft versus host disease in gastrointestinal tract 33.55 11.27 3 369972 5140 42246220
Anxiety 33.30 11.27 779 369196 117781 42133579
Hyperlipasaemia 33.28 11.27 33 369942 564 42250796
Low density lipoprotein abnormal 33.26 11.27 28 369947 383 42250977
Osteonecrosis 33.17 11.27 54 369921 15811 42235549
Acute coronary syndrome 33.15 11.27 232 369743 14633 42236727
Blood ketone body 33.11 11.27 18 369957 111 42251249
Substance abuse 33.07 11.27 18 369957 8887 42242473
Chills 32.96 11.27 596 369379 93470 42157890
Lymphocyte count decreased 32.85 11.27 127 369848 27682 42223678
Obesity 32.77 11.27 250 369725 16209 42235151
Pernicious anaemia 32.60 11.27 18 369957 115 42251245
Neuritis 32.27 11.27 123 369852 6097 42245263
Hallucination 32.23 11.27 331 369644 57176 42194184
Stevens-Johnson syndrome 31.87 11.27 93 369882 22085 42229275
Insomnia 31.83 11.27 782 369193 117471 42133889
Anion gap abnormal 31.77 11.27 28 369947 409 42250951
Leukocytosis 31.76 11.27 396 369579 29312 42222048
Cerebral hypoperfusion 31.50 11.27 42 369933 1001 42250359
Acute myeloid leukaemia 31.49 11.27 94 369881 22162 42229198
Hepatojugular reflux 31.48 11.27 34 369941 645 42250715
Diffuse large B-cell lymphoma recurrent 31.47 11.27 3 369972 4883 42246477
Polydipsia 31.37 11.27 98 369877 4390 42246970
Epilepsy 31.25 11.27 119 369856 26052 42225308
Thirst 31.16 11.27 159 369816 8949 42242411
Contraindicated product administered 31.05 11.27 346 369629 24926 42226434
Pneumonitis 31.04 11.27 223 369752 41495 42209865
Bradycardia 30.90 11.27 966 369009 84518 42166842
Hypocalcaemia 30.90 11.27 399 369576 29774 42221586
Pancreatic neuroendocrine tumour 30.53 11.27 24 369951 296 42251064
Respiratory syncytial virus infection 30.36 11.27 12 369963 7140 42244220
Dumping syndrome 30.29 11.27 12 369963 30 42251330
Leg amputation 30.27 11.27 69 369906 2554 42248806
Obstructive pancreatitis 30.19 11.27 35 369940 720 42250640
Intentional product misuse 30.07 11.27 368 369607 61532 42189828
Cytopenia 30.06 11.27 67 369908 17430 42233930
Diabetic macroangiopathy 29.87 11.27 9 369966 5 42251355
Product prescribing error 29.62 11.27 352 369623 25760 42225600
Methaemoglobinaemia 29.34 11.27 7 369968 5767 42245593
Klebsiella infection 29.33 11.27 33 369942 11299 42240061
Haematuria 29.13 11.27 682 369293 57117 42194243
Enterococcal infection 29.09 11.27 37 369938 12002 42239358
Status epilepticus 28.99 11.27 57 369918 15521 42235839
Malaise 28.99 11.27 2177 367798 209979 42041381
Osmolar gap 28.94 11.27 13 369962 49 42251311
Aplasia pure red cell 28.86 11.27 13 369962 7153 42244207
Bronchitis 28.85 11.27 266 369709 46935 42204425
Pulmonary toxicity 28.66 11.27 20 369955 8635 42242725
Adrenal cyst 28.55 11.27 19 369956 177 42251183
Osmolar gap increased 28.52 11.27 10 369965 15 42251345
Cystitis haemorrhagic 28.43 11.27 14 369961 7315 42244045
Alopecia 28.35 11.27 144 369831 29132 42222228
Thrombosis 28.32 11.27 421 369554 68090 42183270
Upper respiratory tract infection 28.29 11.27 232 369743 41941 42209419
Bladder transitional cell carcinoma 28.27 11.27 68 369907 2608 42248752
Hypoglycaemic encephalopathy 28.27 11.27 23 369952 299 42251061
Hypogammaglobulinaemia 28.27 11.27 37 369938 11854 42239506
Pleuritic pain 28.25 11.27 13 369962 7064 42244296
Body temperature decreased 28.18 11.27 218 369757 14195 42237165
Therapeutic drug monitoring analysis incorrectly performed 28.08 11.27 23 369952 302 42251058
Glucose urine present 28.00 11.27 46 369929 1329 42250031
Product administered to patient of inappropriate age 27.99 11.27 4 369971 4757 42246603
Abnormal loss of weight 27.86 11.27 101 369874 4886 42246474
Kussmaul respiration 27.79 11.27 15 369960 91 42251269
Naevus flammeus 27.77 11.27 19 369956 186 42251174
Coma scale abnormal 27.70 11.27 95 369880 4470 42246890
Restlessness 27.68 11.27 145 369830 29104 42222256
Necrotising oesophagitis 27.66 11.27 38 369937 933 42250427
Akathisia 27.53 11.27 30 369945 10421 42240939
Total lung capacity abnormal 27.43 11.27 93 369882 4350 42247010
Vitreous haemorrhage 27.11 11.27 68 369907 2679 42248681
Viral infection 26.99 11.27 102 369873 22381 42228979
Miosis 26.97 11.27 47 369928 13399 42237961
Serotonin syndrome 26.84 11.27 124 369851 25721 42225639
Abdominal pain 26.78 11.27 1959 368016 188512 42062848
Dry skin 26.77 11.27 279 369696 48059 42203301
Tremor 26.63 11.27 639 369336 96290 42155070
Hepatitis B reactivation 26.56 11.27 4 369971 4574 42246786
Device related infection 26.34 11.27 89 369886 20190 42231170
Diabetic eye disease 26.33 11.27 14 369961 82 42251278
Clear cell renal cell carcinoma 26.28 11.27 43 369932 1238 42250122
Pollakiuria 26.25 11.27 305 369670 22200 42229160
Drug level below therapeutic 26.16 11.27 12 369963 6533 42244827
Neuropathic arthropathy 25.83 11.27 18 369957 182 42251178
Foetal exposure during pregnancy 25.82 11.27 274 369701 47037 42204323
Antipsychotic drug level decreased 25.77 11.27 41 369934 1152 42250208
Liver disorder 25.73 11.27 220 369755 39424 42211936
Melaena 25.68 11.27 476 369499 38270 42213090
Albumin urine present 25.67 11.27 24 369951 380 42250980
Mydriasis 25.60 11.27 23 369952 8747 42242613
Body mass index abnormal 25.58 11.27 17 369958 158 42251202
Herpes zoster 25.56 11.27 215 369760 38662 42212698
Anaphylactic shock 25.52 11.27 111 369864 23406 42227954
Alcoholic ketoacidosis 25.42 11.27 11 369964 37 42251323
Conjunctivitis 25.26 11.27 46 369929 12893 42238467
Actinic elastosis 25.25 11.27 12 369963 53 42251307
Haemolytic anaemia 25.15 11.27 186 369789 11941 42239419
Hypoxia 25.13 11.27 440 369535 69346 42182014
Psychomotor skills impaired 25.12 11.27 7 369968 5197 42246163
Neuropathy vitamin B12 deficiency 25.04 11.27 18 369957 192 42251168
Pancreatitis necrotising 24.88 11.27 79 369896 3570 42247790
Oxygen saturation decreased 24.54 11.27 404 369571 64283 42187077
Gastroenteritis 24.39 11.27 234 369741 16215 42235145
Bacteraemia 24.34 11.27 123 369852 24917 42226443
Palmar-plantar erythrodysaesthesia syndrome 24.31 11.27 94 369881 20488 42230872
Suicidal ideation 24.28 11.27 284 369691 47877 42203483
Cytomegalovirus colitis 24.23 11.27 3 369972 3978 42247382
Therapeutic response decreased 24.19 11.27 205 369770 36807 42214553
Colitis 24.11 11.27 273 369702 46299 42205061
End stage renal disease 24.10 11.27 69 369906 16489 42234871
Pancreatic pseudocyst 24.05 11.27 34 369941 858 42250502
Pericardial disease 23.96 11.27 26 369949 496 42250864
Blood cholesterol abnormal 23.89 11.27 53 369922 1926 42249434
Nasopharyngitis 23.83 11.27 551 369424 83445 42167915
Alveolar capillary dysplasia 23.82 11.27 7 369968 3 42251357
Mucosal dryness 23.81 11.27 48 369927 1630 42249730
Sopor 23.80 11.27 196 369779 13006 42238354
Drug effective for unapproved indication 23.78 11.27 14 369961 6619 42244741
5-hydroxyindolacetic acid in urine increased 23.68 11.27 17 369958 181 42251179
Pulmonary haemorrhage 23.63 11.27 39 369936 11358 42240002
Left ventricular dysfunction 23.63 11.27 176 369799 11325 42240035
Needle issue 23.62 11.27 143 369832 8584 42242776
Paradoxical drug reaction 23.58 11.27 6 369969 4732 42246628
Nausea 23.56 11.27 3853 366122 392946 41858414
Arteriosclerosis coronary artery 23.54 11.27 257 369718 18420 42232940
Blood creatinine increased 23.48 11.27 1174 368801 108829 42142531
Blood uric acid increased 23.22 11.27 64 369911 15483 42235877
Drug withdrawal syndrome 23.21 11.27 102 369873 21447 42229913
Drug dose omission by device 23.20 11.27 11 369964 5875 42245485
Arthropathy 23.10 11.27 156 369819 29441 42221919
Autoimmune pancreatitis 23.06 11.27 23 369952 396 42250964
Pneumonia cytomegaloviral 23.05 11.27 4 369971 4122 42247238
Flushing 22.91 11.27 208 369767 36820 42214540
Disease recurrence 22.88 11.27 157 369818 29521 42221839
Ulcer 22.86 11.27 70 369905 16371 42234989
Unevaluable event 22.82 11.27 189 369786 34099 42217261
Bundle branch block left 22.82 11.27 114 369861 6362 42244998
Starvation ketoacidosis 22.78 11.27 15 369960 137 42251223
Intestinal perforation 22.74 11.27 37 369938 10837 42240523
Complications of transplanted kidney 22.67 11.27 9 369966 5341 42246019
Renal artery thrombosis 22.64 11.27 21 369954 329 42251031
Bronchopulmonary aspergillosis allergic 22.55 11.27 6 369969 4592 42246768
Swelling 22.43 11.27 338 369637 54547 42196813
Blindness transient 22.43 11.27 64 369911 2725 42248635
Cytomegalovirus test positive 22.42 11.27 5 369970 4314 42247046
Cardiotoxicity 22.37 11.27 19 369956 7426 42243934
Anaphylactic reaction 22.35 11.27 250 369725 42493 42208867
Disseminated intravascular coagulation 22.32 11.27 125 369850 24669 42226691
Phimosis 22.28 11.27 38 369937 1133 42250227
Food aversion 22.27 11.27 25 369950 496 42250864
Postmortem blood drug level increased 22.27 11.27 25 369950 496 42250864
Basilar artery thrombosis 22.19 11.27 18 369957 233 42251127
Haemoglobin decreased 22.16 11.27 932 369043 131539 42119821
Expired product administered 22.16 11.27 83 369892 4080 42247280
Balanitis candida 22.08 11.27 16 369959 173 42251187
Stenotrophomonas infection 22.04 11.27 3 369972 3701 42247659
Exposure during pregnancy 22.01 11.27 25 369950 8523 42242837
Rebound effect 21.97 11.27 19 369956 7360 42244000
Diabetic complication 21.88 11.27 30 369945 735 42250625
Osteonecrosis of jaw 21.86 11.27 88 369887 18961 42232399
Erythema 21.82 11.27 749 369226 108044 42143316
Electrocardiogram Q wave abnormal 21.77 11.27 25 369950 509 42250851
Ischaemic cardiomyopathy 21.72 11.27 113 369862 6409 42244951
Retroperitoneal fibrosis 21.60 11.27 23 369952 429 42250931
Large for dates baby 21.54 11.27 33 369942 897 42250463
Hypophosphataemia 21.45 11.27 101 369874 20844 42230516
Inflammation 21.44 11.27 189 369786 33658 42217702
Tenosynovitis 21.43 11.27 7 369968 4688 42246672
Vasoplegia syndrome 21.42 11.27 61 369914 2594 42248766
Epistaxis 21.38 11.27 430 369545 66396 42184964
Hyperammonaemia 21.37 11.27 22 369953 7844 42243516
Hypoglycaemic unconsciousness 21.31 11.27 30 369945 754 42250606
Echocardiogram abnormal 21.30 11.27 39 369936 1231 42250129
Staphylococcal bacteraemia 21.30 11.27 40 369935 11081 42240279
Pulmonary valve disease 21.15 11.27 22 369953 399 42250961
Bradyarrhythmia 21.14 11.27 61 369914 2614 42248746
Body mass index increased 21.12 11.27 38 369937 1183 42250177
Acquired phimosis 21.10 11.27 15 369960 157 42251203
Diabetic coma 21.08 11.27 34 369941 967 42250393
High density lipoprotein decreased 20.99 11.27 78 369897 3819 42247541
Ileus 20.97 11.27 90 369885 19049 42232311
Coronary artery stenosis 20.86 11.27 158 369817 10221 42241139
Herbal interaction 20.85 11.27 22 369953 406 42250954
Neoplasm malignant 20.83 11.27 114 369861 22629 42228731
Cytomegalovirus chorioretinitis 20.82 11.27 7 369968 4604 42246756
Joint swelling 20.78 11.27 441 369534 67581 42183779
Type V hyperlipidaemia 20.75 11.27 33 369942 927 42250433
Optic ischaemic neuropathy 20.71 11.27 62 369913 2713 42248647
Hypoalbuminaemia 20.62 11.27 68 369907 15542 42235818
Lymphoma 20.61 11.27 60 369915 14261 42237099
Genital candidiasis 20.50 11.27 12 369963 87 42251273
Insulin resistance 20.47 11.27 30 369945 783 42250577
Confusional state 20.46 11.27 1705 368270 165892 42085468
Back pain 20.37 11.27 1014 368961 140762 42110598
Lymphopenia 20.35 11.27 107 369868 21456 42229904
Hepatic neoplasm 20.34 11.27 53 369922 2138 42249222
Diabetic foetopathy 20.31 11.27 16 369959 198 42251162
Drug-disease interaction 20.25 11.27 32 369943 894 42250466
Intentional self-injury 20.24 11.27 66 369909 15136 42236224
Normochromic normocytic anaemia 20.17 11.27 141 369834 8890 42242470
Dysphagia 20.07 11.27 479 369496 72240 42179120
Paranoia 20.02 11.27 59 369916 13967 42237393
Headache 20.01 11.27 1797 368178 237572 42013788
Urine albumin/creatinine ratio increased 19.96 11.27 24 369951 514 42250846
Leukoencephalopathy 19.93 11.27 9 369966 4945 42246415
Insulin C-peptide decreased 19.82 11.27 9 369966 35 42251325
Arteriosclerosis 19.75 11.27 241 369734 17748 42233612
Prerenal failure 19.73 11.27 56 369919 2377 42248983
Premature baby 19.62 11.27 119 369856 23034 42228326
Nipple inflammation 19.61 11.27 10 369965 53 42251307
Decreased appetite 19.50 11.27 1938 368037 191199 42060161
Product substitution issue 19.49 11.27 166 369809 11124 42240236
Atrioventricular block first degree 19.27 11.27 109 369866 6382 42244978
Pneumonia fungal 19.24 11.27 31 369944 9115 42242245
Activated partial thromboplastin time prolonged 19.19 11.27 72 369903 15831 42235529
Peritonitis bacterial 19.17 11.27 19 369956 6896 42244464
Necrotising myositis 19.09 11.27 35 369940 1106 42250254
Hypersensitivity 19.08 11.27 480 369495 71890 42179470
Pulmonary embolism 19.07 11.27 846 369129 118766 42132594
Vitamin B1 decreased 19.04 11.27 20 369955 367 42250993
Mitral valve incompetence 19.02 11.27 223 369752 16266 42235094
Diffuse large B-cell lymphoma 19.01 11.27 33 369942 9421 42241939
Blood pressure fluctuation 18.98 11.27 146 369829 26762 42224598
Hyperoxaluria 18.98 11.27 14 369961 156 42251204
Pneumonia bacterial 18.96 11.27 71 369904 15621 42235739
Poor venous access 18.90 11.27 21 369954 7231 42244129
Cardiac arrest 18.85 11.27 1144 368831 108176 42143184
Ballismus 18.84 11.27 12 369963 103 42251257
Dyspnoea at rest 18.83 11.27 80 369895 4169 42247191
Device leakage 18.82 11.27 38 369937 10247 42241113
Total lung capacity decreased 18.80 11.27 4 369971 3566 42247794
Blood insulin decreased 18.78 11.27 5 369970 0 42251360
Birt-Hogg-Dube syndrome 18.78 11.27 5 369970 0 42251360
Atrioventricular node dysfunction 18.78 11.27 5 369970 0 42251360
Blood lactic acid decreased 18.75 11.27 10 369965 59 42251301
pH body fluid abnormal 18.72 11.27 7 369968 14 42251346
Product dose omission issue 18.66 11.27 1123 368852 153242 42098118
Intercapillary glomerulosclerosis 18.48 11.27 10 369965 61 42251299
Pulmonary fibrosis 18.46 11.27 330 369645 26351 42225009
Arteriospasm coronary 18.45 11.27 9 369966 4729 42246631
Cardiovascular disorder 18.29 11.27 187 369788 13178 42238182
Irritability 18.29 11.27 156 369819 27972 42223388
Helicobacter gastritis 18.29 11.27 38 369937 1319 42250041
Cardiac discomfort 18.28 11.27 27 369948 710 42250650
Product commingling 18.25 11.27 8 369967 28 42251332
Swollen tongue 18.19 11.27 272 369703 20959 42230401
Substance use disorder 18.17 11.27 12 369963 5333 42246027
Schizophrenia 18.15 11.27 155 369820 10395 42240965
Rhinovirus infection 18.14 11.27 18 369957 6530 42244830
Blood bilirubin increased 18.03 11.27 258 369717 41994 42209366
Respiratory arrest 17.88 11.27 159 369816 28265 42223095
Clostridium test positive 17.87 11.27 13 369962 5492 42245868
Product solubility abnormal 17.75 11.27 24 369951 580 42250780
Gingival hypertrophy 17.73 11.27 54 369921 2385 42248975
Bradypnoea 17.64 11.27 8 369967 4385 42246975
Liver palpable 17.60 11.27 17 369958 281 42251079
Cleft lip and palate 17.41 11.27 30 369945 902 42250458
Pain 17.40 11.27 1860 368115 242988 42008372
Parainfluenzae virus infection 17.40 11.27 5 369970 3638 42247722
Anaemia megaloblastic 17.32 11.27 19 369956 367 42250993
Faecal calprotectin increased 17.28 11.27 3 369972 3091 42248269
Mouth ulceration 17.25 11.27 69 369906 14894 42236466
Insulin C-peptide increased 17.21 11.27 11 369964 95 42251265
Hepatic vein dilatation 17.19 11.27 15 369960 216 42251144
Synovitis 17.18 11.27 73 369902 15494 42235866
Oliguria 17.18 11.27 139 369836 9174 42242186
Brain natriuretic peptide abnormal 17.16 11.27 19 369956 371 42250989
Cough 17.15 11.27 1322 368653 176781 42074579
Tongue disorder 17.10 11.27 13 369962 5370 42245990
Pneumatosis intestinalis 17.08 11.27 10 369965 4742 42246618
Atrial enlargement 17.07 11.27 26 369949 703 42250657
Spirometry abnormal 17.02 11.27 89 369886 5057 42246303
Multiple sclerosis relapse 16.94 11.27 65 369910 14199 42237161
Depression 16.87 11.27 792 369183 110571 42140789
Lichen sclerosus 16.77 11.27 7 369968 21 42251339
Erythromelalgia 16.75 11.27 9 369966 54 42251306
Product contamination chemical 16.73 11.27 6 369969 10 42251350
Encephalitis toxic 16.73 11.27 16 369959 261 42251099
Hypoglycaemic seizure 16.73 11.27 19 369956 382 42250978
Necrotising fasciitis 16.71 11.27 81 369894 4465 42246895
Abdominal pain upper 16.67 11.27 877 369098 81732 42169628
Ejection fraction decreased 16.66 11.27 277 369698 21810 42229550
Blood pressure systolic increased 16.64 11.27 338 369637 27630 42223730
Abnormal behaviour 16.62 11.27 148 369827 26303 42225057
Cornea verticillata 16.57 11.27 11 369964 102 42251258
Drug specific antibody present 16.55 11.27 7 369968 3999 42247361
Prostate cancer 16.54 11.27 280 369695 44363 42206997
Dermatitis acneiform 16.50 11.27 26 369949 7713 42243647
Burkholderia pseudomallei infection 16.48 11.27 10 369965 78 42251282
Coronary artery bypass 16.48 11.27 84 369891 4726 42246634
Psychiatric decompensation 16.48 11.27 8 369967 4214 42247146
Virologic failure 16.47 11.27 7 369968 3987 42247373
Tachypnoea 16.46 11.27 272 369703 21390 42229970
Generalised tonic-clonic seizure 16.40 11.27 148 369827 26231 42225129
Pancreatitis haemorrhagic 16.38 11.27 19 369956 391 42250969
Coma acidotic 16.38 11.27 6 369969 11 42251349
Malignant spinal cord compression 16.32 11.27 12 369963 133 42251227
Oedematous pancreatitis 16.23 11.27 26 369949 735 42250625
Drug dose titration not performed 16.20 11.27 19 369956 396 42250964
Physical examination abnormal 16.18 11.27 20 369955 441 42250919
Ureterolithiasis 16.12 11.27 54 369921 2510 42248850
Pancreaticoduodenectomy 16.11 11.27 9 369966 59 42251301
Cryptococcosis 16.11 11.27 4 369971 3207 42248153
Tendonitis 16.10 11.27 39 369936 9855 42241505
Anti-GAD antibody positive 16.08 11.27 7 369968 24 42251336
Body temperature increased 16.04 11.27 107 369868 20251 42231109
Graft versus host disease in skin 16.03 11.27 13 369962 5199 42246161
Device use error 16.00 11.27 4 369971 3193 42248167
Conduction disorder 15.80 11.27 53 369922 2465 42248895
Enteritis 15.80 11.27 45 369930 10771 42240589
Diabetic vascular disorder 15.75 11.27 9 369966 62 42251298
COVID-19 15.75 11.27 834 369141 115114 42136246
Chronic pigmented purpura 15.74 11.27 12 369963 141 42251219
Extrapyramidal disorder 15.73 11.27 81 369894 16331 42235029
Periarthritis calcarea 15.68 11.27 10 369965 86 42251274
Hypoaesthesia eye 15.66 11.27 7 369968 26 42251334
Adrenal insufficiency 15.66 11.27 98 369877 18826 42232534
Bacterial sepsis 15.58 11.27 20 369955 6462 42244898
Chronic sinusitis 15.58 11.27 5 369970 3387 42247973
Neonatal respiratory distress syndrome 15.52 11.27 10 369965 4503 42246857
Metabolic syndrome 15.46 11.27 45 369930 1938 42249422
Therapeutic drug monitoring analysis not performed 15.42 11.27 22 369953 560 42250800
Atrioventricular block 15.37 11.27 139 369836 9476 42241884
Pneumonia viral 15.35 11.27 9 369966 4265 42247095
Articular calcification 15.31 11.27 10 369965 90 42251270
Productive cough 15.26 11.27 336 369639 51231 42200129
Circulatory collapse 15.19 11.27 289 369686 23347 42228013
Transferrin saturation decreased 15.18 11.27 21 369954 519 42250841
Plasmapheresis 15.13 11.27 19 369956 426 42250934
Lung opacity 15.10 11.27 17 369958 5820 42245540
Blood lactate dehydrogenase increased 15.07 11.27 149 369826 25932 42225428
Pulseless electrical activity 15.07 11.27 125 369850 8312 42243048
Urine output increased 15.05 11.27 37 369938 1439 42249921
Anaemia macrocytic 15.04 11.27 66 369909 3489 42247871
Pancreatic enzymes abnormal 15.02 11.27 4 369971 0 42251360
Diabetes mellitus management 15.02 11.27 4 369971 0 42251360
Skinfold measurement 15.02 11.27 4 369971 0 42251360
Hyperventilation 14.95 11.27 61 369914 3121 42248239
Glomerular filtration rate increased 14.94 11.27 26 369949 788 42250572
Skin toxicity 14.94 11.27 21 369954 6528 42244832
Loss of consciousness 14.91 11.27 961 369014 91393 42159967
Benign neoplasm of adrenal gland 14.89 11.27 5 369970 6 42251354
Non-proliferative retinopathy 14.89 11.27 5 369970 6 42251354
Intraductal papillary-mucinous carcinoma of pancreas 14.89 11.27 5 369970 6 42251354
Atrial fibrillation 14.85 11.27 1406 368569 138187 42113173
Psychotic disorder 14.81 11.27 172 369803 29036 42222324
Psychomotor retardation 14.79 11.27 10 369965 4389 42246971
Full blood count decreased 14.76 11.27 111 369864 20449 42230911
Extrasystoles 14.76 11.27 74 369901 4135 42247225
Hemiplegia 14.76 11.27 118 369857 7761 42243599
Low density lipoprotein decreased 14.72 11.27 34 369941 1270 42250090
Ischaemic stroke 14.68 11.27 273 369702 21960 42229400
Tearfulness 14.65 11.27 6 369969 3494 42247866
Tubulointerstitial nephritis 14.61 11.27 368 369607 31180 42220180
Hyperbilirubinaemia 14.54 11.27 112 369863 20523 42230837
Cardiorenal syndrome 14.45 11.27 27 369948 866 42250494
Product complaint 14.35 11.27 95 369880 5882 42245478
Exercise tolerance decreased 14.31 11.27 96 369879 5970 42245390
Acute lung injury 14.30 11.27 38 369937 1551 42249809
Post-traumatic amnestic disorder 14.25 11.27 8 369967 53 42251307
Conjunctivitis allergic 14.22 11.27 94 369881 5817 42245543
Dust allergy 14.19 11.27 87 369888 5245 42246115
Constipation 14.18 11.27 1214 368761 161077 42090283
Lip oedema 14.15 11.27 60 369915 3124 42248236
Choluria 14.14 11.27 12 369963 166 42251194
Forced expiratory volume decreased 14.14 11.27 114 369861 7516 42243844
Unintentional medical device removal 14.14 11.27 5 369970 3186 42248174
Microcytic anaemia 14.12 11.27 58 369917 2977 42248383
Nasal congestion 14.09 11.27 176 369799 29325 42222035
Fungal balanitis 14.07 11.27 5 369970 8 42251352
Hypertensive crisis 14.06 11.27 143 369832 10063 42241297
Stem cell transplant 14.06 11.27 3 369972 2669 42248691
Iron deficiency 14.06 11.27 49 369926 11012 42240348
Brain abscess 14.05 11.27 10 369965 4274 42247086
Product appearance confusion 14.05 11.27 7 369968 35 42251325
Foetal macrosomia 14.03 11.27 12 369963 168 42251192
Low density lipoprotein increased 14.02 11.27 87 369888 5268 42246092
Respiratory tract infection viral 14.00 11.27 6 369969 3400 42247960
Intracranial pressure increased 13.96 11.27 12 369963 4662 42246698
Blood test abnormal 13.95 11.27 61 369914 12845 42238515
Cardiac failure chronic 13.95 11.27 136 369839 9465 42241895
Neutropenic colitis 13.94 11.27 11 369964 4459 42246901
C-reactive protein abnormal 13.92 11.27 38 369937 9223 42242137
Deprescribing error 13.91 11.27 6 369969 20 42251340
5-hydroxyindolacetic acid increased 13.89 11.27 10 369965 107 42251253
Liver function test increased 13.87 11.27 109 369866 19889 42231471
Central obesity 13.85 11.27 24 369951 725 42250635
Fistula 13.83 11.27 30 369945 7882 42243478
Trisomy 18 13.80 11.27 26 369949 839 42250521
Diabetic gangrene 13.76 11.27 14 369961 247 42251113
Skin cancer 13.76 11.27 52 369923 11410 42239950
Intestinal obstruction 13.74 11.27 160 369815 26998 42224362
Pseudomembranous colitis 13.73 11.27 5 369970 3128 42248232
Tachyarrhythmia 13.70 11.27 69 369906 3863 42247497
Stress 13.69 11.27 286 369689 43926 42207434
Scoliosis 13.68 11.27 5 369970 3121 42248239
Anaemia of malignant disease 13.68 11.27 20 369955 521 42250839
Overweight 13.60 11.27 49 369926 2363 42248997
Blood triglycerides abnormal 13.59 11.27 14 369961 251 42251109
Expiratory reserve volume decreased 13.59 11.27 10 369965 111 42251249
Sleep disorder due to a general medical condition 13.58 11.27 220 369755 17233 42234127
Fibrillary glomerulonephritis 13.55 11.27 8 369967 59 42251301
Angioedema 13.54 11.27 473 369502 42004 42209356
Folliculitis 13.52 11.27 17 369958 5541 42245819
Arterial spasm 13.51 11.27 9 369966 84 42251276
Respiratory depression 13.48 11.27 102 369873 18766 42232594
Hereditary motor and sensory neuropathy 13.48 11.27 6 369969 22 42251338
Lymphadenopathy 13.45 11.27 206 369769 33159 42218201
Electrocardiogram QT interval 13.45 11.27 7 369968 39 42251321
Antineutrophil cytoplasmic antibody positive 13.43 11.27 74 369901 4291 42247069
Amputation 13.35 11.27 25 369950 803 42250557
Blood alkaline phosphatase increased 13.35 11.27 208 369767 33389 42217971
Anhedonia 13.33 11.27 29 369946 7611 42243749
Discoloured vomit 13.32 11.27 24 369951 748 42250612
Coma uraemic 13.31 11.27 7 369968 40 42251320
Myoclonus 13.29 11.27 90 369885 16975 42234385
Small intestinal obstruction 13.28 11.27 90 369885 16971 42234389
Malnutrition 13.26 11.27 73 369902 14469 42236891
Hypophagia 13.25 11.27 317 369658 26639 42224721
Acute myeloid leukaemia recurrent 13.19 11.27 7 369968 3505 42247855
Amylase decreased 13.17 11.27 9 369966 88 42251272
Proctalgia 13.16 11.27 26 369949 7067 42244293
Second primary malignancy 13.15 11.27 41 369934 9534 42241826
Obsessive-compulsive disorder 13.14 11.27 24 369951 6719 42244641
Blood albumin decreased 13.14 11.27 79 369896 15323 42236037
Aspiration 13.11 11.27 96 369879 17790 42233570
Vascular resistance systemic decreased 13.08 11.27 9 369966 89 42251271
Wrong dose 13.05 11.27 29 369946 1055 42250305
Ultrasound antenatal screen 13.04 11.27 20 369955 544 42250816
Helicobacter test false negative 13.02 11.27 8 369967 64 42251296
Hydrops foetalis 12.97 11.27 26 369949 879 42250481
Acute lymphocytic leukaemia recurrent 12.94 11.27 8 369967 3683 42247677
Diabetic microangiopathy 12.90 11.27 6 369969 25 42251335
Hepatobiliary scan abnormal 12.81 11.27 4 369971 3 42251357
Carotid artery stenosis 12.81 11.27 86 369889 5350 42246010
Clostridial infection 12.77 11.27 9 369966 3865 42247495
Foot amputation 12.74 11.27 25 369950 832 42250528
Bladder papilloma 12.71 11.27 6 369969 26 42251334
Inner ear disorder 12.71 11.27 13 369962 231 42251129
Agranulocytosis 12.68 11.27 188 369787 30424 42220936
Abdominal tenderness 12.66 11.27 78 369897 4711 42246649
Rales 12.63 11.27 153 369822 11247 42240113
Enterocolitis 12.61 11.27 44 369931 9885 42241475
Multiple use of single-use product 12.60 11.27 17 369958 410 42250950
Product taste abnormal 12.57 11.27 31 369944 1208 42250152
Enthesopathy 12.56 11.27 14 369961 4814 42246546
Osteopenia 12.54 11.27 22 369953 6256 42245104
Granuloma 12.53 11.27 10 369965 4031 42247329
Groin abscess 12.52 11.27 25 369950 843 42250517
Circumcision 12.52 11.27 7 369968 46 42251314
Dry eye 12.47 11.27 81 369894 15425 42235935
Base excess decreased 12.44 11.27 12 369963 198 42251162
Pelvic neoplasm 12.39 11.27 7 369968 47 42251313
Hepatic enzyme decreased 12.37 11.27 9 369966 98 42251262
Adrenal adenoma 12.36 11.27 19 369956 518 42250842
Asthenia 12.35 11.27 2686 367289 278107 41973253
Febrile bone marrow aplasia 12.34 11.27 46 369929 10135 42241225
Respiratory failure 12.33 11.27 951 369024 127181 42124179
Paraplegia 12.30 11.27 59 369916 3238 42248122
Ventricular arrhythmia 12.29 11.27 95 369880 6184 42245176
Growth retardation 12.26 11.27 3 369972 2429 42248931
Escherichia infection 12.24 11.27 54 369921 11342 42240018
Scrotal gangrene 12.20 11.27 6 369969 29 42251331
Joint injury 12.14 11.27 76 369899 14600 42236760
Plasmacytoma 12.09 11.27 12 369963 4352 42247008
Cellulitis of male external genital organ 12.07 11.27 8 369967 74 42251286
Troponin T increased 12.05 11.27 52 369923 2728 42248632
Blood potassium increased 12.03 11.27 227 369748 18309 42233051
Pneumomediastinum 12.01 11.27 6 369969 3110 42248250
Hepatic cirrhosis 12.01 11.27 239 369736 19463 42231897
Binocular eye movement disorder 12.00 11.27 14 369961 290 42251070
Macular oedema 12.00 11.27 62 369913 3507 42247853
Angina unstable 11.98 11.27 152 369823 11296 42240064
Endometriosis male 11.98 11.27 5 369970 15 42251345
Blindness 11.96 11.27 221 369754 17757 42233603
Erectile dysfunction 11.95 11.27 292 369683 24621 42226739
Atrioventricular block complete 11.94 11.27 151 369824 11213 42240147
Orbital oedema 11.93 11.27 11 369964 171 42251189
Cerebellar ischaemia 11.92 11.27 10 369965 136 42251224
Pneumonia aspiration 11.92 11.27 337 369638 49741 42201619
Renal aplasia 11.84 11.27 23 369952 760 42250600
Lung infiltration 11.80 11.27 72 369903 13917 42237443
Stress urinary incontinence 11.79 11.27 9 369966 106 42251254
Mucormycosis 11.75 11.27 28 369947 7115 42244245
Nipple disorder 11.69 11.27 12 369963 214 42251146
Vascular device infection 11.68 11.27 22 369953 6088 42245272
Disinhibition 11.63 11.27 10 369965 3885 42247475
Migraine 11.62 11.27 153 369822 25261 42226099
Dyslipidaemia 11.59 11.27 129 369846 9289 42242071
Aplasia 11.58 11.27 15 369960 4828 42246532
Disseminated tuberculosis 11.57 11.27 5 369970 2819 42248541
Squamous cell carcinoma of skin 11.54 11.27 64 369911 12662 42238698
Peripheral arterial occlusive disease 11.52 11.27 100 369875 6738 42244622
Nocardiosis 11.49 11.27 17 369958 5173 42246187
Ototoxicity 11.46 11.27 3 369972 2322 42249038
Neuroleptic malignant syndrome 11.45 11.27 125 369850 21347 42230013
Intestinal stenosis 11.43 11.27 5 369970 2799 42248561
Depression suicidal 11.42 11.27 7 369968 3238 42248122
Base excess negative 11.41 11.27 4 369971 6 42251354
Blood glucose 11.41 11.27 4 369971 6 42251354
Tricuspid valve incompetence 11.39 11.27 147 369828 10966 42240394
Serum ferritin abnormal 11.38 11.27 13 369962 263 42251097
Leukaemoid reaction 11.35 11.27 10 369965 146 42251214
Behaviour disorder 11.33 11.27 28 369947 7026 42244334
Brain oedema 11.32 11.27 89 369886 16238 42235122
Spondylolysis 11.31 11.27 8 369967 83 42251277
Cardioactive drug level increased 11.29 11.27 37 369938 1700 42249660
Peripheral vascular disorder 11.28 11.27 82 369893 5235 42246125
Metabolic alkalosis 11.27 11.27 42 369933 2059 42249301

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 35786.83 10.04 15645 715724 77166 109780764
Acute kidney injury 8989.46 10.04 15476 715893 619954 109237976
Metabolic acidosis 7021.61 10.04 5585 725784 94159 109763771
Hypoglycaemia 6717.05 10.04 5802 725567 110302 109747628
Diabetic ketoacidosis 4157.92 10.04 2890 728479 39168 109818762
Euglycaemic diabetic ketoacidosis 3139.43 10.04 1535 729834 10088 109847842
Hyperkalaemia 2624.52 10.04 3827 727542 131969 109725961
Blood glucose increased 2605.79 10.04 3765 727604 128731 109729199
Ketoacidosis 1975.06 10.04 1073 730296 9014 109848916
Diabetes mellitus inadequate control 1973.36 10.04 1611 729758 28164 109829766
Glycosylated haemoglobin increased 1858.37 10.04 1414 729955 22205 109835725
Hyperglycaemia 1566.78 10.04 2345 729024 82745 109775185
Shock 1366.95 10.04 1729 729640 51859 109806071
Hyperlactacidaemia 1102.74 10.04 686 730683 7600 109850330
Toxicity to various agents 1028.62 10.04 6050 725319 474505 109383425
Off label use 992.55 10.04 5850 725519 1494335 108363595
Hypoglycaemic coma 980.04 10.04 551 730818 4982 109852948
Drug ineffective 866.83 10.04 6202 725167 1514338 108343592
Completed suicide 859.09 10.04 3526 727843 238855 109619075
Renal failure 841.17 10.04 3344 728025 223230 109634700
Pancreatitis acute 838.65 10.04 1463 729906 58811 109799119
Infusion related reaction 758.51 10.04 841 730528 380321 109477609
Hand deformity 752.18 10.04 253 731116 218253 109639677
Systemic lupus erythematosus 729.02 10.04 386 730983 253952 109603978
Glossodynia 699.11 10.04 296 731073 221708 109636222
Drug intolerance 683.74 10.04 1018 730351 405494 109452436
Blood lactic acid increased 671.52 10.04 666 730703 15155 109842775
Anti-cyclic citrullinated peptide antibody positive 669.06 10.04 187 731182 181797 109676133
Dehydration 647.53 10.04 3596 727773 275915 109582015
Pemphigus 636.80 10.04 311 731058 214259 109643671
Pemphigoid 636.06 10.04 717 730652 18990 109838940
Helicobacter infection 628.73 10.04 209 731160 181668 109676262
Duodenal ulcer perforation 625.23 10.04 198 731171 177502 109680428
Synovitis 617.43 10.04 542 730827 273550 109584380
Diabetic metabolic decompensation 586.92 10.04 349 731020 3540 109854390
Arthropathy 583.32 10.04 624 730745 286898 109571032
Pancreatitis 583.24 10.04 1645 729724 91888 109766042
Anuria 580.79 10.04 760 730609 23581 109834349
Sleep disorder due to general medical condition, insomnia type 577.69 10.04 29 731340 105614 109752316
Rheumatoid factor positive 567.77 10.04 94 731275 131546 109726384
Stomatitis 566.85 10.04 570 730799 269672 109588258
Intentional overdose 566.14 10.04 2046 729323 130455 109727475
Blood glucose decreased 557.31 10.04 823 730546 28665 109829265
Vitamin B12 deficiency 535.39 10.04 480 730889 9575 109848355
Treatment failure 525.07 10.04 636 730733 276598 109581332
Blood glucose abnormal 524.80 10.04 531 730838 12385 109845545
Alopecia 522.54 10.04 1012 730357 363741 109494189
Joint swelling 518.75 10.04 1371 729998 441474 109416456
Drug level increased 504.31 10.04 1030 730339 46689 109811241
Pericarditis 494.96 10.04 432 730937 218682 109639248
Hypersensitivity 491.40 10.04 1227 730142 402771 109455159
Swelling 482.21 10.04 998 730371 350043 109507887
Folliculitis 476.54 10.04 257 731112 167396 109690534
Drug interaction 470.78 10.04 5218 726151 494965 109362965
Wound 460.89 10.04 522 730847 233915 109624015
Swollen joint count increased 447.97 10.04 26 731343 83635 109774295
Muscle injury 447.61 10.04 185 731184 140622 109717308
Diarrhoea 447.29 10.04 10261 721108 1129244 108728686
Irritable bowel syndrome 444.87 10.04 267 731102 163948 109693982
Hypothermia 439.06 10.04 693 730676 25609 109832321
Drug hypersensitivity 422.78 10.04 1560 729809 452530 109405400
Infection 418.98 10.04 1128 730241 361072 109496858
Impaired healing 407.77 10.04 419 730950 196298 109661632
Acidosis 403.17 10.04 613 730756 21918 109836012
Therapeutic product effect decreased 397.80 10.04 625 730744 243691 109614239
Overdose 384.14 10.04 2756 728613 231038 109626892
Product use in unapproved indication 377.60 10.04 1598 729771 445779 109412151
Drug level above therapeutic 376.33 10.04 423 730946 11165 109846765
Vomiting 370.65 10.04 8245 723124 902430 108955500
Hypomagnesaemia 364.85 10.04 1050 730319 59320 109798610
Pyrexia 363.11 10.04 3995 727374 894270 108963660
Hypotension 357.31 10.04 5148 726221 518701 109339229
Rheumatic fever 354.07 10.04 184 731185 122395 109735535
Musculoskeletal stiffness 344.64 10.04 844 730525 278978 109578952
Haemodialysis 342.72 10.04 500 730869 17219 109840711
Rash 341.81 10.04 3626 727743 817338 109040592
Blood glucose fluctuation 332.15 10.04 327 731042 7371 109850559
Hepatic enzyme increased 326.43 10.04 1061 730308 319831 109538099
Rhabdomyolysis 324.50 10.04 1616 729753 118785 109739145
Maternal exposure during pregnancy 320.03 10.04 761 730608 254122 109603808
Febrile neutropenia 317.64 10.04 1054 730315 315713 109542217
Fibromyalgia 317.23 10.04 398 730971 170511 109687419
Discomfort 314.89 10.04 587 730782 214120 109643810
MELAS syndrome 311.99 10.04 107 731262 222 109857708
Pancreatic carcinoma 308.69 10.04 434 730935 14438 109843492
Myelosuppression 307.91 10.04 119 731250 94221 109763709
Suspected suicide 305.81 10.04 437 730932 14762 109843168
Anion gap increased 302.47 10.04 242 731127 4102 109853828
Sinusitis 294.84 10.04 991 730378 295697 109562233
Continuous haemodiafiltration 285.13 10.04 171 731198 1764 109856166
C-reactive protein abnormal 281.71 10.04 265 731104 129430 109728500
Product use issue 273.66 10.04 1096 730273 310599 109547331
Lip dry 273.45 10.04 161 731208 99922 109758008
Arthralgia 269.17 10.04 3587 727782 776045 109081885
Ill-defined disorder 268.06 10.04 388 730981 156465 109701465
Distributive shock 262.60 10.04 255 731114 5649 109852281
Deep vein thrombosis postoperative 260.89 10.04 40 731329 59251 109798679
Autoimmune disorder 256.55 10.04 59 731310 65424 109792506
Renal impairment 255.21 10.04 2124 729245 186321 109671609
Diabetic neuropathy 252.48 10.04 270 731099 6729 109851201
Contusion 251.09 10.04 752 730617 232609 109625321
Neutropenia 250.41 10.04 1452 729917 373168 109484762
Diabetes mellitus 246.95 10.04 1304 730065 98077 109759853
Hypovolaemia 241.12 10.04 478 730891 21196 109836734
Therapy non-responder 240.55 10.04 419 730950 156888 109701042
Blister 238.72 10.04 741 730628 226635 109631295
Bursitis 238.52 10.04 305 731064 129613 109728317
Ketosis 237.91 10.04 147 731222 1607 109856323
Facet joint syndrome 230.81 10.04 181 731188 96647 109761283
Myocardial infarction 230.44 10.04 2108 729261 189975 109667955
Blood bicarbonate decreased 229.45 10.04 235 731134 5562 109852368
Pain 226.63 10.04 4707 726662 950248 108907682
Mobility decreased 225.08 10.04 809 730560 236613 109621317
Lower limb fracture 222.23 10.04 110 731259 75238 109782692
Joint range of motion decreased 221.62 10.04 288 731081 121544 109736386
Inflammation 220.11 10.04 606 730763 192632 109665298
Ketonuria 219.75 10.04 130 731239 1305 109856625
Contraindicated product administered 219.11 10.04 871 730498 247396 109610534
Drug abuse 218.43 10.04 535 730834 176876 109681054
Blood creatinine increased 214.29 10.04 1997 729372 180892 109677038
Immune-mediated myositis 209.80 10.04 231 731138 5955 109851975
Adjustment disorder with depressed mood 208.96 10.04 23 731346 43860 109814070
Polyuria 208.03 10.04 400 730969 17338 109840592
Rheumatoid arthritis 199.77 10.04 1162 730207 298451 109559479
Psoriatic arthropathy 196.92 10.04 655 730714 196106 109661824
Injury 195.90 10.04 564 730805 176701 109681229
Lower respiratory tract infection 193.57 10.04 887 730482 242219 109615711
Cardiac arrest 192.16 10.04 2069 729300 194684 109663246
Cytomegalovirus infection 183.85 10.04 65 731304 54379 109803551
Liver injury 183.26 10.04 456 730913 149957 109707973
Liver disorder 180.61 10.04 422 730947 141821 109716109
Urine ketone body present 180.30 10.04 171 731198 3675 109854255
Disease progression 179.41 10.04 916 730453 243118 109614812
Glomerular filtration rate decreased 178.20 10.04 507 730862 28449 109829481
Cerebrovascular accident 175.94 10.04 1904 729465 179380 109678550
Bradycardia 175.62 10.04 1685 729684 153832 109704098
Wound infection 175.48 10.04 228 731141 96237 109761693
Blood cholesterol increased 174.88 10.04 630 730739 184155 109673775
Road traffic accident 174.46 10.04 275 731094 107123 109750807
Suicide attempt 173.81 10.04 1226 730143 102168 109755762
Acute myocardial infarction 172.92 10.04 1046 730323 82731 109775199
Hypovolaemic shock 172.43 10.04 330 731039 14253 109843677
Condition aggravated 172.02 10.04 3629 727740 731207 109126723
Hepatic steatosis 171.59 10.04 709 730660 48122 109809808
Nasopharyngitis 171.35 10.04 1723 729646 392638 109465292
Anaemia vitamin B12 deficiency 169.40 10.04 104 731265 1123 109856807
X-ray abnormal 169.35 10.04 25 731344 38092 109819838
Hemiplegia 168.53 10.04 427 730942 22355 109835575
Abdominal discomfort 167.74 10.04 1729 729640 392129 109465801
C-reactive protein 166.84 10.04 8 731361 30323 109827607
Grip strength decreased 165.80 10.04 171 731198 80003 109777927
Blood pH decreased 164.70 10.04 178 731191 4491 109853439
Hypoaesthesia 164.49 10.04 1309 730060 312914 109545016
Weight decreased 163.78 10.04 4153 727216 463904 109394026
Wheezing 161.62 10.04 1006 730363 254224 109603706
Renal tubular necrosis 160.48 10.04 505 730864 29970 109827960
Acetonaemia 159.72 10.04 77 731292 488 109857442
Bone erosion 158.93 10.04 54 731315 46317 109811613
Diabetic retinopathy 158.64 10.04 154 731215 3410 109854520
Drug ineffective for unapproved indication 158.03 10.04 273 731096 102565 109755365
Tachypnoea 156.15 10.04 594 730775 38801 109819129
Neurologic neglect syndrome 155.19 10.04 245 731124 9053 109848877
Thrombocytopenia 155.01 10.04 1516 729853 347369 109510561
Breast cancer stage III 154.47 10.04 177 731192 78940 109778990
Carotid artery thrombosis 154.06 10.04 249 731120 9389 109848541
Migraine 153.46 10.04 599 730770 171053 109686877
Dislocation of vertebra 153.20 10.04 49 731320 43672 109814258
Pregnancy 152.95 10.04 73 731296 50994 109806936
Exposure during pregnancy 151.76 10.04 581 730788 166843 109691087
Hip arthroplasty 149.35 10.04 92 731277 55721 109802209
Night sweats 148.97 10.04 425 730944 133558 109724372
Oedema 148.81 10.04 798 730571 209178 109648752
Sciatica 148.75 10.04 238 731131 92161 109765769
Accidental overdose 146.96 10.04 706 730663 51128 109806802
Personality disorder 145.08 10.04 285 731084 12552 109845378
Haemodynamic instability 142.06 10.04 402 730967 22486 109835444
Syncope 141.13 10.04 1999 729370 200537 109657393
Angina pectoris 141.01 10.04 797 730572 61498 109796432
Intentional product use issue 140.49 10.04 1010 730359 246896 109611034
Lupus-like syndrome 138.94 10.04 48 731321 40744 109817186
Lupus vulgaris 137.87 10.04 28 731341 33855 109824075
Blindness transient 135.96 10.04 182 731187 5774 109852156
Base excess decreased 135.63 10.04 62 731307 342 109857588
Blood lactic acid 134.69 10.04 65 731304 413 109857517
Pneumonia 134.06 10.04 4601 726768 872113 108985817
Hyperglycaemic hyperosmolar nonketotic syndrome 133.90 10.04 130 731239 2879 109855051
Injection site nodule 133.10 10.04 159 731210 4487 109853443
Blood ketone body increased 132.21 10.04 79 731290 809 109857121
Leukopenia 131.86 10.04 521 730848 148270 109709660
Adjustment disorder 129.75 10.04 246 731123 10549 109847381
Peripheral venous disease 129.52 10.04 223 731146 83894 109774036
Osteoarthritis 127.77 10.04 697 730672 181926 109676004
Prescribed overdose 126.09 10.04 242 731127 87339 109770591
Diabetic nephropathy 124.20 10.04 134 731235 3374 109854556
Cardiac failure 124.04 10.04 1835 729534 185791 109672139
Knee arthroplasty 123.89 10.04 148 731221 64800 109793130
Glycosylated haemoglobin abnormal 122.00 10.04 61 731308 423 109857507
Diabetic ketosis 120.79 10.04 76 731293 860 109857070
Dry mouth 119.98 10.04 801 730568 199147 109658783
Drug resistance 117.97 10.04 119 731250 56255 109801675
Retinitis 117.30 10.04 34 731335 32293 109825637
Chronic sinusitis 117.29 10.04 14 731355 25070 109832860
Coronary artery disease 115.22 10.04 841 730528 70849 109787081
Anti-cyclic citrullinated peptide antibody 114.05 10.04 4 731365 19960 109837970
White blood cell count decreased 113.89 10.04 969 730400 228421 109629509
Hypoglycaemic encephalopathy 112.88 10.04 66 731303 647 109857283
Headache 110.56 10.04 4741 726628 877636 108980294
Atrial fibrillation 110.14 10.04 2132 729237 227510 109630420
Sleep disorder 109.78 10.04 815 730554 197829 109660101
Lipase increased 109.17 10.04 321 731048 18351 109839579
Incorrect route of product administration 107.91 10.04 160 731209 63901 109794029
Affect lability 106.68 10.04 318 731051 18319 109839611
Live birth 106.26 10.04 185 731184 69299 109788631
Cytokine release syndrome 105.87 10.04 189 731180 70117 109787813
Bladder cancer 105.69 10.04 335 731034 19957 109837973
Pneumocystis jirovecii pneumonia 104.23 10.04 78 731291 42657 109815273
Product residue present 103.38 10.04 129 731240 3812 109854118
Graft versus host disease 103.31 10.04 5 731364 18801 109839129
Product prescribing error 102.82 10.04 636 730733 50695 109807235
Tubulointerstitial nephritis 102.78 10.04 663 730706 53621 109804309
Circulatory collapse 102.60 10.04 558 730811 42435 109815495
Peripheral swelling 102.21 10.04 1969 729400 402065 109455865
Blood potassium increased 100.94 10.04 462 730907 32787 109825143
Eating disorder 99.86 10.04 437 730932 30421 109827509
Lung disorder 99.82 10.04 738 730631 179309 109678621
Hypercholesterolaemia 98.88 10.04 291 731078 90546 109767384
Exposure via ingestion 98.74 10.04 141 731228 4759 109853171
Microalbuminuria 98.72 10.04 75 731294 1174 109856756
Anion gap 98.32 10.04 91 731278 1894 109856036
Platelet count decreased 98.27 10.04 1011 730358 229432 109628498
Nausea 97.98 10.04 9462 721907 1226228 108631702
Bone marrow failure 97.91 10.04 144 731225 57704 109800226
Hypocapnia 97.30 10.04 66 731303 856 109857074
Breast cancer stage II 97.13 10.04 30 731339 27345 109830585
Gangrene 96.57 10.04 282 731087 16059 109841871
Potentiating drug interaction 96.52 10.04 228 731141 11415 109846515
Transplant rejection 96.50 10.04 22 731347 24545 109833385
Malignant neoplasm progression 95.61 10.04 718 730651 173849 109684081
Insulin resistance 94.74 10.04 84 731285 1650 109856280
Polydipsia 94.64 10.04 177 731192 7511 109850419
Porphyria acute 94.27 10.04 8 731361 18772 109839158
Macroangiopathy 93.82 10.04 37 731332 131 109857799
Latent autoimmune diabetes in adults 93.79 10.04 38 731331 147 109857783
Myocardial ischaemia 93.40 10.04 387 730982 26297 109831633
Urticaria 93.00 10.04 1515 729854 317342 109540588
Acute coronary syndrome 92.85 10.04 350 731019 22762 109835168
Parkinsonism 92.47 10.04 340 731029 21847 109836083
Product monitoring error 92.30 10.04 191 731178 8736 109849194
Fatigue 92.05 10.04 6862 724507 1209096 108648834
Epstein-Barr virus infection 91.33 10.04 9 731360 18729 109839201
Dysarthria 90.79 10.04 903 730466 83218 109774712
Vasoplegia syndrome 90.34 10.04 143 731226 5296 109852634
Sopor 89.70 10.04 478 730891 36068 109821862
Mucosal inflammation 89.46 10.04 330 731039 95811 109762119
Musculoskeletal pain 88.67 10.04 778 730591 182245 109675685
Foot deformity 87.73 10.04 115 731254 48365 109809565
Leukocytosis 87.38 10.04 633 730736 53195 109804735
Hypophagia 87.24 10.04 622 730747 52004 109805926
Red blood cell sedimentation rate increased 86.57 10.04 249 731120 78053 109779877
Adenocarcinoma pancreas 86.43 10.04 90 731279 2173 109855757
Bronchopulmonary aspergillosis 85.95 10.04 45 731324 29818 109828112
Anaemia megaloblastic 85.39 10.04 59 731310 790 109857140
Neutrophil count decreased 84.90 10.04 461 730908 120480 109737450
Blood triglycerides increased 84.53 10.04 348 731021 23578 109834352
Pancreatic carcinoma metastatic 84.17 10.04 120 731249 4044 109853886
Oliguria 83.81 10.04 293 731076 18364 109839566
Adverse event 83.61 10.04 402 730967 108407 109749523
Toe amputation 83.29 10.04 122 731247 4216 109853714
Coma 83.12 10.04 1166 730203 116703 109741227
Coma acidotic 83.01 10.04 33 731336 120 109857810
Gastroenteritis 82.97 10.04 489 730880 38311 109819619
Cytomegalovirus viraemia 82.85 10.04 10 731359 17754 109840176
Aphasia 82.49 10.04 670 730699 58327 109799603
Aspergillus infection 82.44 10.04 33 731336 25583 109832347
Osmolar gap 81.71 10.04 34 731335 143 109857787
Joint dislocation 81.35 10.04 64 731305 34126 109823804
Hemiparesis 81.16 10.04 533 730836 43370 109814560
BRASH syndrome 80.78 10.04 111 731258 3612 109854318
Sensory loss 80.52 10.04 318 731051 21139 109836791
Insomnia 80.33 10.04 1794 729575 358796 109499134
Vitamin B12 decreased 80.22 10.04 133 731236 5124 109852806
Fall 80.01 10.04 4814 726555 598668 109259262
Coordination abnormal 79.16 10.04 354 731015 24874 109833056
Exostosis 79.15 10.04 113 731256 45843 109812087
Toxic epidermal necrolysis 78.84 10.04 160 731209 56567 109801363
Diabetic ketoacidotic hyperglycaemic coma 78.80 10.04 38 731331 241 109857689
Female genital tract fistula 77.79 10.04 9 731360 16510 109841420
Therapeutic product effect incomplete 77.54 10.04 1028 730341 222777 109635153
Maternal exposure timing unspecified 76.43 10.04 22 731347 20991 109836939
Laryngitis 76.34 10.04 101 731268 42310 109815620
Motor dysfunction 76.23 10.04 342 731027 24064 109833866
Posterior reversible encephalopathy syndrome 76.11 10.04 67 731302 33794 109824136
Cholelithiasis 75.47 10.04 695 730674 62727 109795203
Infective pulmonary exacerbation of cystic fibrosis 74.95 10.04 6 731363 14765 109843165
Venoocclusive liver disease 74.92 10.04 7 731362 15200 109842730
Atrioventricular block 74.91 10.04 264 731105 16613 109841317
Pollakiuria 74.22 10.04 524 730845 43671 109814259
Osteoporosis 74.16 10.04 310 731059 86842 109771088
Insulin C-peptide decreased 73.81 10.04 27 731342 73 109857857
Product odour abnormal 73.48 10.04 70 731299 1513 109856417
Urinary tract discomfort 73.41 10.04 57 731312 923 109857007
Blood creatine phosphokinase increased 72.93 10.04 772 730597 72305 109785625
Dialysis 72.21 10.04 289 731080 19330 109838600
Acute graft versus host disease 72.15 10.04 3 731366 12878 109845052
Glucose urine present 71.68 10.04 82 731287 2207 109855723
Progressive multifocal leukoencephalopathy 71.25 10.04 38 731331 24918 109833012
Haemophagocytic lymphohistiocytosis 70.26 10.04 63 731306 31496 109826434
Anion gap abnormal 70.08 10.04 52 731317 784 109857146
Myopathy 70.05 10.04 339 731030 24621 109833309
Post transplant lymphoproliferative disorder 69.92 10.04 10 731359 15603 109842327
Hyponatraemia 69.84 10.04 1910 729459 215743 109642187
Haematuria 69.79 10.04 848 730521 82157 109775773
Haematotoxicity 69.77 10.04 26 731343 21056 109836874
Joint stiffness 69.21 10.04 221 731148 67022 109790908
Cytomegalovirus infection reactivation 68.92 10.04 18 731351 18315 109839615
Kussmaul respiration 68.36 10.04 41 731328 423 109857507
Dysuria 68.15 10.04 653 730716 59578 109798352
High density lipoprotein decreased 68.11 10.04 130 731239 5603 109852327
Pathogen resistance 67.11 10.04 17 731352 17655 109840275
Angioedema 66.89 10.04 968 730401 97532 109760398
Pancreatitis chronic 66.84 10.04 112 731257 4353 109853577
Glycosylated haemoglobin decreased 65.93 10.04 51 731318 821 109857109
Glycosuria 65.67 10.04 84 731285 2546 109855384
Genital infection fungal 65.27 10.04 33 731336 235 109857695
PCO2 decreased 65.23 10.04 92 731277 3069 109854861
Multiple organ dysfunction syndrome 64.60 10.04 1384 729985 150326 109707604
Pernicious anaemia 64.56 10.04 48 731321 726 109857204
Alveolar osteitis 64.19 10.04 55 731314 1030 109856900
Thirst 63.95 10.04 299 731070 21408 109836522
Coeliac disease 62.45 10.04 119 731250 43068 109814862
BK virus infection 62.07 10.04 7 731362 13099 109844831
Paraesthesia 62.05 10.04 1374 729995 275147 109582783
Death 61.99 10.04 3888 727481 694981 109162949
Ear infection 61.92 10.04 210 731159 62522 109795408
Dyslipidaemia 61.85 10.04 239 731130 15726 109842204
Prerenal failure 61.69 10.04 108 731261 4351 109853579
Hypocalcaemia 61.28 10.04 682 730687 64684 109793246
Pruritus 60.87 10.04 3184 728185 578376 109279554
Immunodeficiency 60.67 10.04 102 731267 38736 109819194
Abnormal loss of weight 60.60 10.04 177 731192 10080 109847850
Pulmonary vasculitis 60.51 10.04 134 731235 6426 109851504
Thrombotic microangiopathy 60.45 10.04 62 731307 29087 109828843
Choreoathetosis 60.36 10.04 65 731304 1633 109856297
Pancreatic neoplasm 59.79 10.04 67 731302 1762 109856168
Asthenia 59.19 10.04 5308 726061 683691 109174239
Loss of consciousness 59.16 10.04 1709 729660 194597 109663333
Immune reconstitution inflammatory syndrome 58.99 10.04 17 731352 16209 109841721
Diabetic foot infection 58.91 10.04 48 731321 836 109857094
Needle issue 58.76 10.04 254 731115 17586 109840344
Athetosis 58.76 10.04 27 731342 151 109857779
Coma scale abnormal 58.58 10.04 169 731200 9557 109848373
Multiple-drug resistance 58.06 10.04 9 731360 13226 109844704
Neurotoxicity 57.85 10.04 120 731249 42087 109815843
Gait inability 57.01 10.04 601 730768 135775 109722155
Arterial occlusive disease 56.74 10.04 226 731143 15082 109842848
Balanoposthitis 56.68 10.04 57 731312 1319 109856611
Gastrointestinal disorder 56.67 10.04 1194 730175 240758 109617172
Chorea 56.44 10.04 87 731282 3148 109854782
Prescribed underdose 55.96 10.04 231 731138 64943 109792987
Temperature regulation disorder 55.64 10.04 9 731360 12817 109845113
Amnesia 55.60 10.04 438 730931 104970 109752960
Melaena 55.45 10.04 697 730672 68060 109789870
Drug use disorder 55.42 10.04 25 731344 18049 109839881
Overweight 55.13 10.04 128 731241 6336 109851594
Hospitalisation 54.79 10.04 640 730729 141853 109716077
Disability 54.37 10.04 72 731297 30151 109827779
Ischaemic stroke 54.16 10.04 462 730907 40801 109817129
Body temperature decreased 54.11 10.04 424 730945 36511 109821419
Pancytopenia 54.02 10.04 1018 730351 208595 109649335
Joint destruction 54.01 10.04 5 731364 10938 109846992
Polymyalgia rheumatica 53.24 10.04 126 731243 6316 109851614
Pulseless electrical activity 53.23 10.04 236 731133 16521 109841409
Pancreatitis haemorrhagic 53.10 10.04 48 731321 968 109856962
Urine albumin/creatinine ratio abnormal 53.00 10.04 24 731345 129 109857801
Psoriasis 52.68 10.04 1255 730114 138738 109719192
Proctitis 52.55 10.04 23 731346 16904 109841026
Erectile dysfunction 52.05 10.04 252 731117 18304 109839626
General physical health deterioration 51.66 10.04 2292 729077 423003 109434927
Lumbosacral radiculoplexus neuropathy 51.36 10.04 22 731347 101 109857829
Tunnel vision 51.33 10.04 65 731304 1950 109855980
Sedation 50.91 10.04 262 731107 69421 109788509
Abdominal pain 50.82 10.04 3995 727374 508994 109348936
Blood pressure increased 50.71 10.04 2141 729228 256232 109601698
Postprandial hypoglycaemia 50.59 10.04 24 731345 146 109857784
Blood ketone body 50.53 10.04 25 731344 169 109857761
Liver function test increased 50.48 10.04 360 731009 88188 109769742
Walking aid user 50.14 10.04 55 731314 25020 109832910
Diabetic foot 50.06 10.04 94 731275 4001 109853929
Blood pressure systolic increased 49.95 10.04 799 730570 82192 109775738
Naevus flammeus 49.80 10.04 19 731350 60 109857870
Clostridium difficile infection 49.77 10.04 177 731192 51952 109805978
Diabetic coma 49.74 10.04 53 731316 1315 109856615
Macular degeneration 49.72 10.04 42 731327 21617 109836313
Seizure 49.63 10.04 1099 730270 220086 109637844
Food allergy 49.18 10.04 36 731333 19912 109838018
Osteonecrosis 48.76 10.04 93 731276 33648 109824282
Cardiovascular disorder 48.76 10.04 287 731082 22473 109835457
Product substitution issue 48.25 10.04 289 731080 22772 109835158
Bradyarrhythmia 48.03 10.04 103 731266 4831 109853099
Therapy partial responder 47.79 10.04 109 731260 36952 109820978
Palpitations 47.67 10.04 1385 729984 157827 109700103
Unresponsive to stimuli 47.39 10.04 637 730732 63153 109794777
Graft versus host disease in gastrointestinal tract 47.36 10.04 3 731366 8965 109848965
Vitamin B1 deficiency 47.14 10.04 44 731325 926 109857004
C-reactive protein increased 47.13 10.04 1089 730280 216830 109641100
Necrotising myositis 46.96 10.04 62 731307 1940 109855990
Bladder pain 46.94 10.04 74 731295 2731 109855199
Device expulsion 46.54 10.04 83 731286 30808 109827122
Amylase increased 46.54 10.04 185 731184 12334 109845596
Human rhinovirus test positive 46.24 10.04 49 731320 1208 109856722
Hyperlipasaemia 46.05 10.04 53 731316 1436 109856494
Vaginal discharge 45.89 10.04 31 731338 17877 109840053
Necrotising fasciitis 45.82 10.04 132 731237 7459 109850471
Hepatic function abnormal 45.74 10.04 374 730995 88921 109769009
Skin haemorrhage 45.63 10.04 301 731068 24526 109833404
Feeling hot 45.57 10.04 384 730985 90722 109767208
Atrioventricular block complete 45.48 10.04 257 731112 19825 109838105
Epilepsy 45.47 10.04 433 730936 99776 109758154
Treatment noncompliance 45.16 10.04 706 730663 72284 109785646
Hypertensive crisis 45.11 10.04 296 731073 24076 109833854
Immunosuppressant drug level increased 45.06 10.04 11 731358 11713 109846217
Myalgia 45.05 10.04 1849 729520 220532 109637398
Neuritis 44.99 10.04 129 731240 7270 109850660
Base excess negative 44.98 10.04 13 731356 10 109857920
Antipsychotic drug level decreased 44.92 10.04 51 731318 1361 109856569
Injection site erythema 44.86 10.04 402 730967 93774 109764156
Mouth ulceration 44.28 10.04 166 731203 47972 109809958
Azotaemia 44.11 10.04 157 731212 9928 109848002
Hypoglycaemic unconsciousness 43.89 10.04 47 731322 1173 109856757
Total lung capacity abnormal 43.84 10.04 95 731274 4488 109853442
Sinus disorder 43.78 10.04 368 731001 32360 109825570
Radiculopathy 43.77 10.04 38 731331 19298 109838632
Neutrophilia 43.65 10.04 159 731210 10170 109847760
Aplastic anaemia 43.64 10.04 58 731311 24250 109833680
Staphylococcal infection 43.55 10.04 277 731092 69667 109788263
Nail disorder 43.37 10.04 216 731153 57719 109800211
Multiple sclerosis relapse 43.18 10.04 178 731191 50062 109807868
Neurological symptom 43.09 10.04 211 731158 15397 109842533
Blindness 43.03 10.04 398 730971 35961 109821969
Memory impairment 42.91 10.04 983 730386 195961 109661969
Colitis ulcerative 42.91 10.04 317 731052 77046 109780884
Bundle branch block left 42.84 10.04 184 731185 12704 109845226
Pleural effusion 42.77 10.04 873 730496 176836 109681094
Swollen joint count 42.71 10.04 4 731365 8670 109849260
Bladder transitional cell carcinoma 42.64 10.04 71 731298 2745 109855185
Body mass index increased 42.54 10.04 64 731305 2266 109855664
Lymphocyte count decreased 42.52 10.04 214 731155 57029 109800901
Blepharospasm 42.51 10.04 202 731167 54649 109803281
Therapeutic response decreased 42.50 10.04 420 730949 96079 109761851
Optic ischaemic neuropathy 42.02 10.04 88 731281 4059 109853871
Basilar artery thrombosis 41.93 10.04 29 731340 389 109857541
Respiratory disorder 41.78 10.04 288 731081 71094 109786836
Blood mercury abnormal 41.76 10.04 25 731344 257 109857673
Stevens-Johnson syndrome 41.68 10.04 164 731205 46737 109811193
Drug tolerance decreased 41.49 10.04 74 731295 27466 109830464
Animal scratch 41.20 10.04 56 731313 1803 109856127
Delirium 41.19 10.04 636 730733 134389 109723541
Pulmonary fibrosis 40.92 10.04 454 730915 101588 109756342
Anaemia macrocytic 40.28 10.04 123 731246 7180 109850750
Arteriosclerosis 40.05 10.04 291 731078 24476 109833454
Altered state of consciousness 39.79 10.04 568 730801 57058 109800872
Acute painful neuropathy of rapid glycaemic control 39.60 10.04 13 731356 22 109857908
Neuropathy peripheral 39.57 10.04 893 730476 178384 109679546
Hypoglycaemic seizure 39.56 10.04 40 731329 932 109856998
Tenosynovitis 39.35 10.04 30 731339 16253 109841677
Wrong patient received product 39.27 10.04 115 731254 6559 109851371
Left ventricular dysfunction 39.13 10.04 278 731091 23215 109834715
Appendicitis 38.95 10.04 81 731288 28383 109829547
Hyperventilation 38.89 10.04 139 731230 8808 109849122
Electrocardiogram abnormal 38.85 10.04 234 731135 18475 109839455
Oral candidiasis 38.83 10.04 158 731211 44602 109813328
Acute myeloid leukaemia 38.69 10.04 126 731243 37984 109819946
Neoplasm progression 38.61 10.04 259 731110 64336 109793594
Urine ketone body 38.58 10.04 21 731348 177 109857753
Antipsychotic drug level increased 38.55 10.04 118 731251 6897 109851033
Low density lipoprotein increased 38.36 10.04 156 731213 10510 109847420
Respiratory tract infection 38.04 10.04 297 731072 71320 109786610
Anhidrosis 37.77 10.04 27 731342 383 109857547
Haemofiltration 37.73 10.04 19 731350 134 109857796
Cytopenia 37.69 10.04 90 731279 30026 109827904
Urosepsis 37.43 10.04 338 731031 30337 109827593
Microcytic anaemia 37.41 10.04 108 731261 6110 109851820
Unintentional medical device removal 37.09 10.04 7 731362 8916 109849014
Sedation complication 37.06 10.04 46 731323 19809 109838121
No adverse event 37.03 10.04 311 731058 73528 109784402
Hepatojugular reflux 37.00 10.04 34 731335 701 109857229
Autoimmune myositis 36.79 10.04 39 731330 962 109856968
Hypokinesia 36.77 10.04 259 731110 21567 109836363
Medication error 36.77 10.04 935 730434 104431 109753499
Tongue biting 36.60 10.04 68 731301 2871 109855059
Bacterial infection 36.58 10.04 168 731201 45868 109812062
Tongue oedema 36.52 10.04 129 731240 8127 109849803
Ascites 36.39 10.04 415 730954 92393 109765537
Flushing 36.28 10.04 481 730888 104255 109753675
Respiratory syncytial virus test positive 36.18 10.04 47 731322 1447 109856483
Dysentery 36.16 10.04 45 731324 1326 109856604
Electrocardiogram T wave peaked 36.15 10.04 42 731327 1150 109856780
Arteriosclerosis coronary artery 36.06 10.04 287 731082 24831 109833099
Insulin C-peptide increased 36.02 10.04 20 731349 176 109857754
Upper respiratory tract infection 35.96 10.04 631 730738 130697 109727233
Electrolyte imbalance 35.93 10.04 389 730980 36639 109821291
Erythema 35.91 10.04 1568 729801 289879 109568051
Respiratory syncytial virus infection 35.89 10.04 26 731343 14458 109843472
Blood insulin decreased 35.78 10.04 11 731358 13 109857917
Atrioventricular block first degree 35.55 10.04 187 731182 14038 109843892
Injection site reaction 35.43 10.04 397 730972 88673 109769257
Clostridium difficile colitis 35.24 10.04 159 731210 43619 109814311
Dyspepsia 35.19 10.04 977 730392 189988 109667942
Rhinitis allergic 35.08 10.04 40 731329 17882 109840048
Rhinovirus infection 35.08 10.04 17 731352 11772 109846158
Cardiogenic shock 34.87 10.04 553 730816 56785 109801145
Breast cancer stage I 34.84 10.04 4 731365 7383 109850547
Osmolar gap increased 34.74 10.04 20 731349 190 109857740
Dry eye 34.72 10.04 221 731148 55572 109802358
Arrhythmia 34.71 10.04 650 730719 68925 109789005
Myelodysplastic syndrome 34.64 10.04 129 731240 37355 109820575
Vitreous haemorrhage 34.59 10.04 87 731282 4533 109853397
Cutaneous vasculitis 34.37 10.04 171 731198 12558 109845372
Oral herpes 34.11 10.04 123 731246 35957 109821973
Pancreatic neuroendocrine tumour 33.99 10.04 36 731333 887 109857043
Hypertension 33.99 10.04 2907 728462 507177 109350753
Cerebral venous thrombosis 33.97 10.04 70 731299 3192 109854738
Neuropathy vitamin B12 deficiency 33.96 10.04 19 731350 170 109857760
Oedematous pancreatitis 33.93 10.04 48 731321 1606 109856324
Normochromic normocytic anaemia 33.57 10.04 173 731196 12884 109845046
Drug dose omission by device 33.50 10.04 28 731341 14488 109843442
Tumour lysis syndrome 33.28 10.04 99 731270 30702 109827228
Metabolic syndrome 33.02 10.04 69 731300 3178 109854752
Rales 33.00 10.04 278 731091 24461 109833469
Blood calcium decreased 32.71 10.04 124 731245 35721 109822209
Methaemoglobinaemia 32.61 10.04 10 731359 9158 109848772
Weight increased 32.54 10.04 2362 729007 417282 109440648
Rebound effect 32.43 10.04 30 731339 14776 109843154
Cold sweat 32.32 10.04 253 731116 21778 109836152
Foetal death 32.30 10.04 35 731334 16010 109841920
Pneumothorax 32.24 10.04 122 731247 35163 109822767
Seronegative arthritis 32.20 10.04 24 731345 13153 109844777
Congenital hydrocephalus 32.06 10.04 14 731355 68 109857862
Ballismus 31.94 10.04 22 731347 293 109857637
Angina unstable 31.91 10.04 202 731167 16230 109841700
Blood iron decreased 31.79 10.04 227 731142 18987 109838943
Central obesity 31.73 10.04 52 731317 1984 109855946
Ear congestion 31.73 10.04 73 731296 3592 109854338
Pain in jaw 31.70 10.04 203 731166 50974 109806956
Pancreatitis necrotising 31.61 10.04 94 731275 5407 109852523
Obstructive pancreatitis 31.56 10.04 40 731329 1201 109856729
Drug tolerance 31.41 10.04 38 731331 16547 109841383
Phimosis 31.39 10.04 33 731336 806 109857124
Malignant mediastinal neoplasm 31.29 10.04 42 731327 1336 109856594
Wound complication 31.28 10.04 101 731268 6076 109851854
Blood urea increased 31.17 10.04 524 730845 54433 109803497
Immune effector cell-associated neurotoxicity syndrome 31.16 10.04 31 731338 14751 109843179
Asthma 31.15 10.04 1345 730024 248946 109608984
Coronary artery stenosis 31.11 10.04 176 731193 13582 109844348
Drug reaction with eosinophilia and systemic symptoms 31.06 10.04 370 730999 81725 109776205
Asthma-chronic obstructive pulmonary disease overlap syndrome 31.04 10.04 3 731366 6341 109851589
Insulin-like growth factor increased 30.97 10.04 55 731314 2241 109855689
Device related infection 30.94 10.04 145 731224 39374 109818556
Infusion site reaction 30.92 10.04 43 731326 17639 109840291
Diabetes mellitus management 30.80 10.04 10 731359 16 109857914
Interstitial lung disease 30.76 10.04 694 730675 138640 109719290
Mucosal dryness 30.60 10.04 79 731290 4184 109853746
Adrenal cyst 30.58 10.04 20 731349 243 109857687
Herpes zoster 30.56 10.04 518 730851 107861 109750069
Starvation ketoacidosis 30.54 10.04 22 731347 316 109857614
Disorientation 30.49 10.04 646 730723 70025 109787905
Viral test positive 30.15 10.04 33 731336 845 109857085
Enthesopathy 30.14 10.04 23 731346 12455 109845475
Urine albumin/creatinine ratio increased 30.11 10.04 37 731332 1076 109856854
Ear pain 30.04 10.04 217 731152 53009 109804921
Product administered to patient of inappropriate age 30.00 10.04 8 731361 8028 109849902
Insulinoma 29.99 10.04 18 731351 186 109857744
Decreased appetite 29.95 10.04 3590 727779 472256 109385674
Prescription drug used without a prescription 29.79 10.04 92 731277 5404 109852526
Exercise tolerance decreased 29.73 10.04 158 731211 11909 109846021
Peritonitis 29.63 10.04 113 731256 32494 109825436
Glomerular filtration rate abnormal 29.50 10.04 55 731314 2328 109855602
Ischaemic cardiomyopathy 29.47 10.04 118 731251 7893 109850037
Renal tubular acidosis 29.44 10.04 83 731286 4632 109853298
Blood chloride decreased 29.43 10.04 129 731240 8986 109848944
Extrasystoles 29.39 10.04 121 731248 8197 109849733
Pulmonary valve disease 29.36 10.04 22 731347 337 109857593
Hepatic neoplasm 29.14 10.04 73 731296 3794 109854136
Blood cholesterol decreased 29.13 10.04 59 731310 2657 109855273
Cardiac failure congestive 29.09 10.04 1249 730120 149751 109708179
Alcoholic ketoacidosis 28.93 10.04 12 731357 50 109857880
Spirometry abnormal 28.85 10.04 91 731278 5406 109852524
Diabetic complication 28.77 10.04 41 731328 1381 109856549
Device dislocation 28.72 10.04 110 731259 31594 109826336
Retroperitoneal fibrosis 28.62 10.04 30 731339 730 109857200
Venoocclusive disease 28.59 10.04 4 731365 6346 109851584
Spondylitis 28.55 10.04 20 731349 11318 109846612
Respiratory alkalosis 28.48 10.04 93 731276 5628 109852302
Non-alcoholic steatohepatitis 28.43 10.04 56 731313 2471 109855459
Chronic kidney disease 28.41 10.04 683 730686 75608 109782322
Nephropathy 28.32 10.04 169 731200 13298 109844632
Aplasia pure red cell 28.21 10.04 14 731355 9564 109848366
Confusional state 28.20 10.04 3526 727843 465154 109392776
Swollen tongue 28.09 10.04 558 730811 59804 109798126
Hypertriglyceridaemia 27.98 10.04 193 731176 15961 109841969
Device difficult to use 27.91 10.04 51 731318 18754 109839176
Mental status changes 27.89 10.04 680 730689 75442 109782488
5-hydroxyindolacetic acid in urine increased 27.73 10.04 17 731352 183 109857747
Peripheral circulatory failure 27.73 10.04 46 731323 1773 109856157
Anovulatory cycle 27.50 10.04 15 731354 127 109857803
Postmortem blood drug level increased 27.49 10.04 37 731332 1180 109856750
Plasma cell myeloma 27.26 10.04 275 731094 62661 109795269
Skin turgor decreased 27.26 10.04 31 731338 829 109857101
Device use error 27.21 10.04 13 731356 9076 109848854
Neuralgia 27.19 10.04 198 731171 48280 109809650
Fluid retention 27.16 10.04 449 730920 93858 109764072
Hypoperfusion 27.14 10.04 63 731306 3118 109854812
Nasal oedema 27.11 10.04 6 731363 6833 109851097
Albumin urine present 27.08 10.04 29 731340 724 109857206
Urinary tract infection 27.07 10.04 2508 728861 323774 109534156
Blood insulin increased 26.96 10.04 22 731347 384 109857546
Cardiac failure chronic 26.95 10.04 170 731199 13641 109844289
Dyspnoea at rest 26.86 10.04 118 731251 8228 109849702
Rash erythematous 26.84 10.04 380 730989 81452 109776478
Cardiovascular insufficiency 26.84 10.04 64 731305 3224 109854706
Drug dependence 26.77 10.04 207 731162 49813 109808117
Lymphopenia 26.62 10.04 156 731213 40014 109817916
Depression 26.59 10.04 1774 729595 315561 109542369
Blood urine present 26.51 10.04 261 731108 23984 109833946
Cystitis haemorrhagic 26.44 10.04 25 731344 12184 109845746
Substance abuse 26.43 10.04 26 731343 12437 109845493
Cytomegalovirus colitis 26.41 10.04 7 731362 7054 109850876
Hyperinsulinaemic hypoglycaemia 26.37 10.04 19 731350 273 109857657
Lethargy 26.37 10.04 808 730561 92768 109765162
Colitis 26.33 10.04 497 730872 101826 109756104
Hydrops foetalis 26.20 10.04 29 731340 752 109857178
Balanitis candida 26.12 10.04 16 731353 172 109857758
Metabolic alkalosis 26.12 10.04 89 731280 5506 109852424
Leg amputation 26.09 10.04 74 731295 4144 109853786
Arthritis 26.05 10.04 877 730492 166709 109691221
Macular oedema 25.94 10.04 103 731266 6863 109851067
Helicobacter gastritis 25.91 10.04 55 731314 2561 109855369
PO2 increased 25.91 10.04 41 731328 1518 109856412
Adrenal adenoma 25.85 10.04 40 731329 1452 109856478
Apolipoprotein A-I decreased 25.83 10.04 9 731360 20 109857910
Skin exfoliation 25.82 10.04 761 730608 86890 109771040
Nephrogenic systemic fibrosis 25.79 10.04 3 731366 5480 109852450
Obesity 25.76 10.04 562 730807 112789 109745141
Cerebral haematoma 25.73 10.04 129 731240 9503 109848427
Dystonia 25.73 10.04 86 731283 25719 109832211
Forced expiratory volume decreased 25.60 10.04 162 731207 13014 109844916
Coronary artery bypass 25.52 10.04 93 731276 5949 109851981
Injection site mass 25.49 10.04 262 731107 24351 109833579
Pancreatic pseudocyst 25.37 10.04 42 731327 1616 109856314
Metabolic encephalopathy 25.35 10.04 142 731227 10918 109847012
Bacteraemia 25.31 10.04 170 731199 42220 109815710
Viral infection 25.23 10.04 227 731142 52912 109805018
Renal cyst 25.20 10.04 206 731163 17966 109839964
Hepatitis B reactivation 25.15 10.04 9 731360 7475 109850455
Bundle branch block right 25.06 10.04 153 731216 12138 109845792
Ultrasound antenatal screen 25.05 10.04 27 731342 679 109857251
Prostatomegaly 24.87 10.04 73 731296 4169 109853761
Corneal reflex decreased 24.81 10.04 24 731345 529 109857401
Malabsorption 24.74 10.04 96 731273 6329 109851601
Transferrin saturation decreased 24.68 10.04 37 731332 1306 109856624
Blood test abnormal 24.64 10.04 101 731268 28453 109829477
Blood pressure inadequately controlled 24.62 10.04 108 731261 7525 109850405
JC virus infection 24.62 10.04 3 731366 5287 109852643
Catarrh 24.59 10.04 105 731264 7230 109850700
Product administration error 24.57 10.04 364 731005 36853 109821077
Cytomegalovirus test positive 24.45 10.04 8 731361 7028 109850902
Anxiety 24.42 10.04 1957 729412 343121 109514809
Graft versus host disease in skin 24.41 10.04 12 731357 8242 109849688
Low density lipoprotein abnormal 24.37 10.04 24 731345 541 109857389
Drug-disease interaction 24.37 10.04 45 731324 1891 109856039
Pneumatosis intestinalis 24.33 10.04 13 731356 8516 109849414
Wrong dose 24.31 10.04 54 731315 2595 109855335
Anal incontinence 24.29 10.04 237 731132 21727 109836203
Flatulence 24.24 10.04 482 730887 51667 109806263
Miosis 24.23 10.04 70 731299 21913 109836017
Toxic encephalopathy 24.16 10.04 178 731191 15036 109842894
Conjunctivitis 24.15 10.04 128 731241 33664 109824266
Parainfluenzae virus infection 24.11 10.04 8 731361 6966 109850964
Ulcer haemorrhage 24.06 10.04 73 731296 22498 109835432
Cerebral infarction 24.05 10.04 479 730890 51359 109806571
Neuroendocrine tumour 24.01 10.04 40 731329 1547 109856383
Frequent bowel movements 23.95 10.04 330 731039 71060 109786870
Peripheral arterial occlusive disease 23.89 10.04 123 731246 9157 109848773
Pulmonary toxicity 23.86 10.04 51 731318 17695 109840235
Type 2 diabetes mellitus 23.83 10.04 944 730425 176288 109681642
Impaired gastric emptying 23.83 10.04 160 731209 13115 109844815
Enterococcal infection 23.82 10.04 63 731306 20303 109837627
Jaundice 23.81 10.04 536 730833 58700 109799230
Duodenal ulcer 23.80 10.04 215 731154 19299 109838631
Serotonin syndrome 23.78 10.04 263 731106 58890 109799040
Osteonecrosis of jaw 23.73 10.04 203 731166 47814 109810116
Leukocyturia 23.53 10.04 49 731320 2251 109855679
Pyelonephritis 23.46 10.04 263 731106 24987 109832943
Postmenopausal haemorrhage 23.35 10.04 43 731326 1803 109856127
Intercepted product preparation error 23.27 10.04 8 731361 6812 109851118
Liver palpable 23.27 10.04 19 731350 332 109857598
Albuminuria 23.24 10.04 31 731338 980 109856950
Cytomegalovirus chorioretinitis 23.24 10.04 9 731360 7119 109850811
Calculus urinary 23.23 10.04 59 731310 3093 109854837
Temperature perception test abnormal 23.20 10.04 8 731361 17 109857913
Cholecystitis chronic 23.14 10.04 124 731245 9376 109848554
Low density lipoprotein decreased 23.09 10.04 37 731332 1385 109856545
Decreased vibratory sense 22.90 10.04 26 731343 694 109857236
Chronic obstructive pulmonary disease 22.89 10.04 548 730821 108610 109749320
Pericardial disease 22.81 10.04 26 731343 697 109857233
Complication associated with device 22.80 10.04 63 731306 20010 109837920
Acquired phimosis 22.71 10.04 13 731356 122 109857808
Blood sodium decreased 22.71 10.04 368 731001 37951 109819979
Nipple inflammation 22.67 10.04 10 731359 50 109857880
Fluid intake reduced 22.65 10.04 99 731270 6887 109851043
Sinus tachycardia 22.65 10.04 417 730952 44076 109813854
Wound secretion 22.53 10.04 98 731271 6803 109851127
Anti-GAD antibody positive 22.52 10.04 11 731358 72 109857858
Trisomy 18 22.48 10.04 24 731345 597 109857333
Blood lactic acid abnormal 22.47 10.04 12 731357 97 109857833
Necrotising oesophagitis 22.46 10.04 39 731330 1561 109856369
Aggression 22.35 10.04 267 731102 58943 109798987
Status epilepticus 22.34 10.04 120 731249 31451 109826479
Ureterolithiasis 22.31 10.04 72 731297 4330 109853600
Mydriasis 21.98 10.04 74 731295 22083 109835847
Pneumonia fungal 21.91 10.04 40 731329 14714 109843216
Neck pain 21.90 10.04 633 730736 122497 109735433
Hyperphagia 21.89 10.04 62 731307 3469 109854461
Discoloured vomit 21.85 10.04 44 731325 1973 109855957
Dust allergy 21.76 10.04 88 731281 5913 109852017
Sinus congestion 21.74 10.04 302 731067 30157 109827773
Resuscitation 21.72 10.04 55 731314 2878 109855052
Actinic elastosis 21.61 10.04 10 731359 57 109857873
Hyperkinetic heart syndrome 21.60 10.04 13 731356 135 109857795
Throat irritation 21.57 10.04 238 731131 53314 109804616
Cardiotoxicity 21.48 10.04 50 731319 16831 109841099
Intercapillary glomerulosclerosis 21.48 10.04 12 731357 107 109857823
Differential white blood cell count abnormal 21.46 10.04 47 731322 2237 109855693
Therapeutic drug monitoring analysis incorrectly performed 21.45 10.04 25 731344 687 109857243
Ulcer 21.44 10.04 182 731187 42934 109814996
Acidosis hyperchloraemic 21.41 10.04 38 731331 1548 109856382
Blood creatine increased 21.37 10.04 140 731229 11381 109846549
Constipation 21.35 10.04 2056 729313 355730 109502200
Haemolytic anaemia 21.34 10.04 222 731147 20698 109837232
Antineutrophil cytoplasmic antibody positive 21.33 10.04 78 731291 4998 109852932
Carotid arteriosclerosis 21.27 10.04 56 731313 3001 109854929
Cystic fibrosis 21.26 10.04 3 731366 4728 109853202
Mitral valve incompetence 21.24 10.04 324 731045 33005 109824925
Nephrolithiasis 21.20 10.04 581 730788 65631 109792299
Infusion site erythema 21.00 10.04 29 731340 11930 109846000
Ischaemic contracture of the left ventricle 20.97 10.04 13 731356 143 109857787
Peripheral vascular disorder 20.93 10.04 112 731257 8464 109849466
Diabetic ulcer 20.91 10.04 15 731354 214 109857716
Diabetic vascular disorder 20.89 10.04 13 731356 144 109857786
Heart rate increased 20.83 10.04 1157 730212 142677 109715253
Conjunctivitis allergic 20.81 10.04 96 731273 6835 109851095
Urinary retention 20.80 10.04 606 730763 69077 109788853
Sneezing 20.80 10.04 312 731057 31672 109826258
Pneumonia cytomegaloviral 20.73 10.04 10 731359 6944 109850986
Spinal fusion surgery 20.72 10.04 18 731351 9138 109848792
Type V hyperlipidaemia 20.64 10.04 36 731333 1446 109856484
Hypochromic anaemia 20.63 10.04 57 731312 3144 109854786
Laboratory test abnormal 20.62 10.04 189 731180 43890 109814040
Respiratory rate increased 20.53 10.04 255 731114 24828 109833102
Left ventricular hypertrophy 20.50 10.04 154 731215 13090 109844840
Osmolar gap abnormal 20.48 10.04 11 731358 90 109857840
Orbital swelling 20.38 10.04 11 731358 91 109857839
Burns second degree 20.26 10.04 103 731266 7630 109850300
Malignant spinal cord compression 20.23 10.04 13 731356 153 109857777
Vascular device infection 20.15 10.04 50 731319 16462 109841468
Birt-Hogg-Dube syndrome 20.13 10.04 5 731364 0 109857930
Atrioventricular node dysfunction 20.13 10.04 5 731364 0 109857930
Lactate pyruvate ratio abnormal 20.13 10.04 5 731364 0 109857930
Intestinal ischaemia 20.11 10.04 179 731190 16000 109841930
Intestinal perforation 20.07 10.04 71 731298 20873 109837057
Total lung capacity decreased 20.06 10.04 11 731358 7103 109850827
Respiratory tract congestion 20.06 10.04 301 731068 30556 109827374
Hepatic vein dilatation 20.06 10.04 15 731354 229 109857701
Hyperinsulinaemia 20.01 10.04 16 731353 271 109857659
Blood triglycerides abnormal 19.98 10.04 22 731347 567 109857363
Hypogammaglobulinaemia 19.95 10.04 67 731302 20009 109837921
Carcinoid tumour 19.80 10.04 22 731347 573 109857357
Drug specific antibody present 19.80 10.04 16 731353 8418 109849512
Hypomania 19.75 10.04 23 731346 10187 109847743
Genital swelling 19.74 10.04 19 731350 416 109857514
Left atrial dilatation 19.67 10.04 60 731309 3500 109854430
Paraesthesia oral 19.63 10.04 136 731233 33535 109824395
Anaphylactic shock 19.62 10.04 232 731137 51314 109806616
Gastrointestinal toxicity 19.61 10.04 27 731342 11121 109846809
Lip swelling 19.59 10.04 456 730913 50211 109807719
Cleft lip 19.56 10.04 6 731363 7 109857923
Pancreatic mass 19.54 10.04 40 731329 1815 109856115
Autoimmune pancreatitis 19.54 10.04 26 731343 820 109857110
Deformity 19.54 10.04 23 731346 10137 109847793
Prostatitis 19.53 10.04 73 731296 4728 109853202
Electrocardiogram QRS complex prolonged 19.36 10.04 150 731219 12871 109845059
Crush syndrome 19.36 10.04 18 731351 377 109857553
Urogenital infection fungal 19.35 10.04 9 731360 52 109857878
Renal artery thrombosis 19.30 10.04 21 731348 534 109857396
Cleft lip and palate 19.26 10.04 24 731345 708 109857222
Transient ischaemic attack 19.25 10.04 557 730812 63425 109794505
Hypopnoea 19.15 10.04 135 731234 11245 109846685
Vertigo 19.14 10.04 729 730640 86141 109771789
Blood pressure decreased 19.14 10.04 938 730431 114153 109743777
Allergic reaction to excipient 19.14 10.04 25 731344 774 109857156
Musculoskeletal disorder 19.04 10.04 81 731288 22583 109835347
Brain stem infarction 19.02 10.04 43 731326 2091 109855839
Food aversion 19.01 10.04 37 731332 1618 109856312
Pneumonitis 18.99 10.04 374 730995 76157 109781773
Electrocardiogram Q wave abnormal 18.95 10.04 24 731345 720 109857210
Neuropathic arthropathy 18.93 10.04 21 731348 546 109857384
Complications of transplanted kidney 18.91 10.04 13 731356 7429 109850501
Herbal interaction 18.89 10.04 22 731347 604 109857326
Product blister packaging issue 18.88 10.04 17 731352 341 109857589
Drug effective for unapproved indication 18.81 10.04 41 731328 14126 109843804
Synovial cyst 18.81 10.04 29 731340 11401 109846529
Unevaluable event 18.73 10.04 277 731092 58950 109798980
Rheumatoid nodule 18.66 10.04 70 731299 20226 109837704
Leukoencephalopathy 18.57 10.04 20 731349 9175 109848755
Food craving 18.57 10.04 41 731328 1962 109855968
Poisoning 18.57 10.04 283 731086 28822 109829108
Lupus nephritis 18.57 10.04 4 731365 4641 109853289
IIIrd nerve paresis 18.54 10.04 14 731355 217 109857713
Expired product administered 18.53 10.04 106 731263 8214 109849716
Prothrombin consumption time prolonged 18.46 10.04 8 731361 38 109857892
Pulmonary haemorrhage 18.43 10.04 52 731317 16404 109841526
Blood pressure abnormal 18.37 10.04 228 731141 22196 109835734
Ventricular arrhythmia 18.36 10.04 122 731247 9965 109847965
Polyarthritis 18.36 10.04 64 731305 18899 109839031
Alcohol interaction 18.34 10.04 60 731309 3634 109854296
Urine output increased 18.34 10.04 50 731319 2736 109855194
Coronary artery occlusion 18.34 10.04 172 731197 15600 109842330
Osteopenia 18.27 10.04 80 731289 22129 109835801
Blood bicarbonate abnormal 18.27 10.04 12 731357 147 109857783
Diabetic hyperosmolar coma 18.24 10.04 26 731343 876 109857054
Stupor 18.21 10.04 105 731264 8160 109849770
Substance use disorder 18.17 10.04 13 731356 7277 109850653
Hyperphosphataemia 18.17 10.04 52 731317 16329 109841601
Physical examination abnormal 18.15 10.04 20 731349 516 109857414
Pyelonephritis acute 18.15 10.04 95 731274 7118 109850812
Renal abscess 18.14 10.04 35 731334 1521 109856409
Blood growth hormone abnormal 18.13 10.04 8 731361 40 109857890
Impaired work ability 18.08 10.04 260 731109 26159 109831771
Neutropenic colitis 18.07 10.04 16 731353 8049 109849881
Systemic infection 18.02 10.04 119 731250 9700 109848230
Diabetic gangrene 18.02 10.04 14 731355 227 109857703
Labelled drug-drug interaction medication error 17.96 10.04 283 731086 29019 109828911
Neuroglycopenia 17.87 10.04 29 731340 1097 109856833
Product label confusion 17.87 10.04 83 731286 22594 109835336
Metabolic disorder 17.87 10.04 125 731244 10385 109847545
Sudden death 17.87 10.04 243 731126 24152 109833778
Inappropriate antidiuretic hormone secretion 17.84 10.04 319 731050 33532 109824398
Lung opacity 17.83 10.04 31 731338 11621 109846309
Decreased bronchial secretion 17.81 10.04 9 731360 64 109857866
Cholestatic liver injury 17.78 10.04 96 731273 7280 109850650
Hormone receptor positive HER2 negative breast cancer 17.76 10.04 14 731355 232 109857698
Respiratory acidosis 17.72 10.04 154 731215 13672 109844258
Eructation 17.72 10.04 156 731213 13901 109844029
Pneumonia viral 17.71 10.04 29 731340 11128 109846802
Mitochondrial enzyme deficiency 17.70 10.04 7 731362 25 109857905
Duodenal ulcer haemorrhage 17.64 10.04 102 731267 7935 109849995
Periarthritis calcarea 17.64 10.04 10 731359 92 109857838
Adrenal insufficiency 17.63 10.04 187 731182 42203 109815727
Disease recurrence 17.63 10.04 289 731080 60495 109797435
Erythromelalgia 17.61 10.04 18 731351 425 109857505
Eosinophilic granulomatosis with polyangiitis 17.53 10.04 126 731243 10560 109847370
Parosmia 17.52 10.04 148 731221 13032 109844898
Epstein-Barr virus associated lymphoproliferative disorder 17.51 10.04 5 731364 4797 109853133
Lichen planus 17.49 10.04 56 731313 3354 109854576
Epstein-Barr virus infection reactivation 17.42 10.04 3 731366 4081 109853849
Encephalitis toxic 17.42 10.04 15 731354 283 109857647
Pleuritic pain 17.35 10.04 52 731317 16088 109841842
Hypoparathyroidism 17.33 10.04 34 731335 1496 109856434
Hypovitaminosis 17.21 10.04 33 731336 1427 109856503
Product solubility abnormal 17.20 10.04 29 731340 1133 109856797
Pharyngitis streptococcal 17.16 10.04 39 731330 13238 109844692
Papillary thyroid cancer 17.15 10.04 50 731319 2844 109855086
Metastases to central nervous system 17.12 10.04 85 731284 22732 109835198
Tongue injury 17.08 10.04 21 731348 611 109857319
Device malfunction 17.07 10.04 99 731270 25459 109832471
Sinus bradycardia 17.05 10.04 282 731087 29201 109828729
Pseudomonas infection 16.98 10.04 111 731258 27742 109830188
Bronchial secretion retention 16.96 10.04 6 731363 5018 109852912
Neuropathy, ataxia, retinitis pigmentosa syndrome 16.95 10.04 8 731361 48 109857882
Dermatitis artefacta 16.93 10.04 9 731360 72 109857858
Fixed eruption 16.92 10.04 64 731305 4168 109853762
Overlap syndrome 16.90 10.04 21 731348 9038 109848892
Encephalopathy 16.87 10.04 676 730693 80379 109777551
Eyelid bleeding 16.83 10.04 9 731360 73 109857857
Secondary immunodeficiency 16.81 10.04 5 731364 4671 109853259
Blood pressure diastolic decreased 16.79 10.04 332 731037 35553 109822377
Cystitis 16.73 10.04 563 730806 65473 109792457
Clear cell renal cell carcinoma 16.71 10.04 48 731321 2708 109855222
Labelled drug-disease interaction medication error 16.64 10.04 16 731353 350 109857580
Neoplasm malignant 16.63 10.04 161 731208 36982 109820948
Cryptococcosis 16.57 10.04 5 731364 4626 109853304
Carbohydrate metabolism disorder 16.54 10.04 7 731362 31 109857899
Diffuse large B-cell lymphoma 16.53 10.04 52 731317 15846 109842084
Hypoglobulinaemia 16.46 10.04 13 731356 216 109857714
Post-traumatic amnestic disorder 16.43 10.04 8 731361 52 109857878
Mite allergy 16.42 10.04 79 731290 5724 109852206
Pelvic fracture 16.39 10.04 44 731325 14110 109843820
Yellow skin 16.38 10.04 62 731307 4040 109853890
Cellulitis gangrenous 16.37 10.04 17 731352 409 109857521
Steroid dependence 16.37 10.04 104 731265 8365 109849565
Cholangiocarcinoma 16.30 10.04 49 731320 2836 109855094
Chronic gastritis 16.28 10.04 75 731294 5336 109852594
Sputum culture positive 16.27 10.04 3 731366 3886 109854044
Blood growth hormone increased 16.27 10.04 27 731342 1041 109856889
Ureteric haemorrhage 16.26 10.04 11 731358 142 109857788
Acute lymphocytic leukaemia recurrent 16.25 10.04 9 731360 5778 109852152
Heart sounds 16.22 10.04 28 731341 1115 109856815
Non-proliferative retinopathy 16.22 10.04 5 731364 6 109857924
Scrotal cyst 16.22 10.04 5 731364 6 109857924
Blood ketone body present 16.19 10.04 11 731358 143 109857787
Haemorrhage 16.19 10.04 560 730809 106132 109751798
Polyhydramnios 16.18 10.04 38 731331 1895 109856035
Pancreatic disorder 16.15 10.04 60 731309 3874 109854056
Intracranial pressure increased 16.15 10.04 28 731341 10507 109847423
Blood cholesterol abnormal 16.11 10.04 58 731311 3688 109854242
Cataract 16.11 10.04 661 730708 78824 109779106
End stage renal disease 16.10 10.04 80 731289 21393 109836537
Mycotic allergy 16.09 10.04 80 731289 5874 109852056
Atelectasis 16.07 10.04 160 731209 36552 109821378
Malaise 16.07 10.04 4825 726544 666994 109190936
Genital infection 16.07 10.04 13 731356 224 109857706
Glomerular filtration rate increased 16.03 10.04 38 731331 1907 109856023
Base excess 15.94 10.04 8 731361 56 109857874
Red cell distribution width abnormal 15.92 10.04 14 731355 272 109857658
Carbuncle 15.89 10.04 32 731337 1435 109856495
Nodular rash 15.87 10.04 15 731354 321 109857609
Shock hypoglycaemic 15.69 10.04 13 731356 232 109857698
Hypokalaemia 15.66 10.04 1406 729963 181042 109676888
Ototoxicity 15.64 10.04 4 731365 4127 109853803
Diet failure 15.55 10.04 7 731362 37 109857893
Product coating issue 15.54 10.04 10 731359 118 109857812
Amylase decreased 15.51 10.04 13 731356 236 109857694
Hypoxic-ischaemic encephalopathy 15.50 10.04 106 731263 8741 109849189
Troponin T increased 15.50 10.04 63 731306 4243 109853687
Product contamination chemical 15.49 10.04 6 731363 20 109857910
Pancreatic atrophy 15.49 10.04 22 731347 739 109857191
Palmar-plantar erythrodysaesthesia syndrome 15.48 10.04 185 731184 40840 109817090
Blood cholesterol 15.38 10.04 24 731345 878 109857052
Postoperative wound infection 15.36 10.04 53 731316 15700 109842230
Dysgeusia 15.35 10.04 587 730782 69398 109788532
Oxygen saturation decreased 15.34 10.04 865 730504 156117 109701813
Pneumonia bacterial 15.34 10.04 106 731263 26155 109831775
Gingival hypertrophy 15.30 10.04 63 731306 4268 109853662
Electrocardiogram QT prolonged 15.30 10.04 874 730495 108086 109749844
Cardiac discomfort 15.29 10.04 31 731338 1397 109856533
Lacunar infarction 15.28 10.04 82 731287 6204 109851726
Cutaneous T-cell dyscrasia 15.26 10.04 8 731361 62 109857868
Dizziness 15.21 10.04 4996 726373 693197 109164733
Paranasal sinus discomfort 15.19 10.04 83 731286 6322 109851608
Ventricular extrasystoles 15.17 10.04 222 731147 22419 109835511
Ileus 15.15 10.04 130 731239 30599 109827331
Cerebellar ischaemia 15.15 10.04 16 731353 393 109857537
Paradoxical drug reaction 15.13 10.04 26 731343 9791 109848139
Hyperhidrosis 15.12 10.04 1437 729932 185861 109672069
Colorectal cancer 15.12 10.04 23 731346 9091 109848839
Tachyarrhythmia 15.09 10.04 100 731269 8161 109849769
Blindness cortical 15.07 10.04 27 731342 1108 109856822
Helicobacter test false negative 15.05 10.04 8 731361 64 109857866
Pseudohallucination 15.02 10.04 12 731357 203 109857727
5-hydroxyindolacetic acid increased 14.99 10.04 10 731359 126 109857804
Coma uraemic 14.97 10.04 7 731362 41 109857889
Virologic failure 14.95 10.04 7 731362 4945 109852985
Limb injury 14.95 10.04 340 731029 37296 109820634
Cardioactive drug level increased 14.94 10.04 58 731311 3824 109854106
Eye oedema 14.93 10.04 44 731325 2518 109855412
Haematoma 14.93 10.04 499 730870 57977 109799953
Scleroderma 14.92 10.04 12 731357 6329 109851601
Jaundice hepatocellular 14.92 10.04 10 731359 127 109857803
Clostridium test positive 14.90 10.04 31 731338 10862 109847068
Device occlusion 14.87 10.04 51 731318 15134 109842796
Hypertensive heart disease 14.80 10.04 65 731304 4531 109853399
Orthopnoea 14.78 10.04 124 731245 10897 109847033
Granulocyte count decreased 14.75 10.04 4 731365 3970 109853960
Muscle necrosis 14.69 10.04 35 731334 1762 109856168
Vitamin B1 decreased 14.66 10.04 24 731345 915 109857015
Anaesthetic complication 14.63 10.04 3 731366 3603 109854327
Analgesic drug level increased 14.60 10.04 4 731365 3942 109853988
Retinal artery thrombosis 14.60 10.04 9 731360 98 109857832
Hyperoxaluria 14.54 10.04 15 731354 358 109857572
Myoglobin blood increased 14.51 10.04 61 731308 4171 109853759
Pancreatic enzymes increased 14.49 10.04 34 731335 1695 109856235
Fibrillary glomerulonephritis 14.45 10.04 8 731361 70 109857860
Cellulitis of male external genital organ 14.44 10.04 7 731362 45 109857885
Accidental exposure to product 14.42 10.04 238 731131 49770 109808160
Acute myeloid leukaemia recurrent 14.42 10.04 8 731361 5131 109852799
Laryngitis viral 14.35 10.04 8 731361 71 109857859
Nocardiosis 14.34 10.04 17 731352 7469 109850461
Faecal calprotectin increased 14.27 10.04 14 731355 6705 109851225
Serum serotonin increased 14.25 10.04 15 731354 367 109857563
Cardiorenal syndrome 14.24 10.04 36 731333 1882 109856048
Agranulocytosis 14.09 10.04 306 731063 61454 109796476
Lymphoma 14.09 10.04 77 731292 20094 109837836
Herpes simplex 14.08 10.04 55 731314 15709 109842221
Urinary incontinence 14.08 10.04 421 730948 48166 109809764
Periorbital inflammation 14.07 10.04 13 731356 270 109857660
Bladder neoplasm 14.05 10.04 36 731333 1898 109856032
Hypernatraemia 14.05 10.04 180 731189 17653 109840277
General symptom 14.03 10.04 23 731346 8823 109849107
Craniofacial fracture 14.02 10.04 23 731346 878 109857052
Carcinoid tumour of the stomach 14.02 10.04 11 731358 181 109857749
Scrotal abscess 14.00 10.04 19 731350 611 109857319
Body temperature increased 14.00 10.04 266 731103 54447 109803483
Extremity necrosis 13.99 10.04 56 731313 3746 109854184
Skin papilloma 13.93 10.04 15 731354 6881 109851049
Foot amputation 13.92 10.04 26 731343 1102 109856828
Burkholderia pseudomallei infection 13.92 10.04 10 731359 143 109857787
Faeces discoloured 13.90 10.04 308 731061 33640 109824290
Diabetic cheiroarthropathy 13.88 10.04 4 731365 3 109857927
Akathisia 13.87 10.04 62 731307 17051 109840879
Genital tract inflammation 13.86 10.04 10 731359 144 109857786
Embolism venous 13.83 10.04 8 731361 5015 109852915
Pulmonary arterial hypertension 13.82 10.04 143 731226 32425 109825505
Pancreatic enzymes abnormal 13.81 10.04 5 731364 13 109857917
pH urine decreased 13.81 10.04 5 731364 13 109857917
CD30 expression 13.81 10.04 8 731361 77 109857853
Device related thrombosis 13.80 10.04 3 731366 3459 109854471
Diastolic dysfunction 13.79 10.04 134 731235 12270 109845660
Alopecia scarring 13.77 10.04 11 731358 186 109857744
Polyp 13.76 10.04 113 731256 9867 109848063
Scrotal gangrene 13.76 10.04 6 731363 29 109857901
Urine output decreased 13.75 10.04 196 731173 19680 109838250
Ejection fraction decreased 13.74 10.04 361 731008 40519 109817411
Intestinal stenosis 13.73 10.04 7 731362 4708 109853222
Renal replacement therapy 13.72 10.04 11 731358 187 109857743
Autoimmune hepatitis 13.66 10.04 154 731215 14650 109843280
Chronic pigmented purpura 13.65 10.04 13 731356 281 109857649
Gastrooesophageal reflux disease 13.61 10.04 1015 730354 178961 109678969
Conduction disorder 13.56 10.04 58 731311 3997 109853933
Urethral intrinsic sphincter deficiency 13.54 10.04 5 731364 14 109857916
Prolonged expiration 13.53 10.04 31 731338 1521 109856409
Chromaturia 13.52 10.04 271 731098 29089 109828841
Patella fracture 13.51 10.04 41 731328 2385 109855545
Drug withdrawal syndrome 13.46 10.04 174 731195 37880 109820050
Cardiopulmonary failure 13.44 10.04 94 731275 7809 109850121
Vascular purpura 13.44 10.04 55 731314 3716 109854214
Hyperaesthesia 13.40 10.04 51 731318 14676 109843254
Pneumonia haemophilus 13.39 10.04 44 731325 2671 109855259
Femur fracture 13.37 10.04 210 731159 44259 109813671
Obliterative bronchiolitis 13.35 10.04 4 731365 3719 109854211
Genitourinary symptom 13.35 10.04 14 731355 341 109857589
Hunger 13.33 10.04 82 731287 6522 109851408
Medullary thyroid cancer 13.31 10.04 14 731355 342 109857588
Device issue 13.31 10.04 155 731214 34380 109823550
Venous pressure jugular 13.29 10.04 5 731364 15 109857915
Non-high-density lipoprotein cholesterol decreased 13.29 10.04 5 731364 15 109857915
Endometriosis male 13.29 10.04 5 731364 15 109857915
Taste disorder 13.23 10.04 330 731039 65057 109792873
Muscle atrophy 13.21 10.04 140 731229 13114 109844816
Hepatic fibrosis 13.17 10.04 95 731274 7971 109849959
Pleural fibrosis 13.14 10.04 6 731363 4302 109853628
Circumcision 13.14 10.04 6 731363 33 109857897
Pseudodementia 13.14 10.04 6 731363 33 109857897
Renal injury 13.14 10.04 185 731184 18528 109839402
Scleroedema 13.14 10.04 10 731359 157 109857773
Cushingoid 13.12 10.04 37 731332 11675 109846255
Abdominal tenderness 13.09 10.04 133 731236 12324 109845606
Subcutaneous drug absorption impaired 13.02 10.04 19 731350 7640 109850290
Brain oedema 13.01 10.04 137 731232 30961 109826969
Blood magnesium decreased 12.98 10.04 195 731174 19801 109838129
Intracranial haematoma 12.97 10.04 24 731345 1010 109856920
Gallbladder oedema 12.96 10.04 14 731355 353 109857577
Cardiac disorder 12.96 10.04 623 730746 75657 109782273
Joint effusion 12.91 10.04 83 731286 20822 109837108
Orchitis 12.85 10.04 34 731335 1828 109856102
Brain injury 12.81 10.04 141 731228 13335 109844595
Mast cell activation syndrome 12.75 10.04 30 731339 1498 109856432
Product complaint 12.74 10.04 145 731224 13827 109844103
Foreign body in reproductive tract 12.72 10.04 23 731346 951 109856979
Steatohepatitis 12.71 10.04 27 731342 1258 109856672
Ileal stenosis 12.70 10.04 3 731366 3267 109854663
Varicella zoster virus infection 12.70 10.04 14 731355 6354 109851576
Lip oedema 12.69 10.04 90 731279 7510 109850420
Metastases to fallopian tube 12.67 10.04 7 731362 61 109857869
Polycythaemia 12.66 10.04 49 731320 3226 109854704
Optic neuritis 12.65 10.04 35 731334 11112 109846818
Bone disorder 12.65 10.04 85 731284 21107 109836823
Alpha haemolytic streptococcal infection 12.64 10.04 4 731365 3589 109854341
Premature labour 12.63 10.04 26 731343 9146 109848784
B-lymphocyte abnormalities 12.62 10.04 10 731359 167 109857763
Staphylococcal bacteraemia 12.61 10.04 62 731307 16626 109841304
Angioplasty 12.61 10.04 35 731334 1936 109855994
Biliary colic 12.59 10.04 62 731307 4535 109853395
Cholangitis sclerosing 12.58 10.04 4 731365 3578 109854352
Foot operation 12.57 10.04 18 731351 7295 109850635
Pulmonary hilar enlargement 12.57 10.04 9 731360 128 109857802
Cerebellar syndrome 12.57 10.04 78 731291 6224 109851706
Renal transplant 12.52 10.04 3 731366 3235 109854695
Fear of injection 12.50 10.04 25 731344 8886 109849044
Blood pressure systolic decreased 12.49 10.04 140 731229 13301 109844629
Drug dose titration not performed 12.47 10.04 24 731345 1041 109856889
Antipsychotic drug level above therapeutic 12.45 10.04 40 731329 2400 109855530
Presyncope 12.43 10.04 417 730952 48470 109809460
Bladder papilloma 12.41 10.04 5 731364 19 109857911
Bacterial sepsis 12.39 10.04 32 731337 10394 109847536
Varices oesophageal 12.38 10.04 86 731283 7129 109850801
Bronchial wall thickening 12.34 10.04 3 731366 3204 109854726
Atrial enlargement 12.34 10.04 25 731344 1126 109856804
Brain abscess 12.33 10.04 16 731353 6758 109851172
Hypertensive angiopathy 12.32 10.04 8 731361 96 109857834
Carotid artery stenosis 12.31 10.04 104 731265 9159 109848771
Catheter site erythema 12.30 10.04 13 731356 6015 109851915
Focal segmental glomerulosclerosis 12.30 10.04 6 731363 4139 109853791
Stem cell transplant 12.26 10.04 7 731362 4420 109853510
Blood pressure fluctuation 12.23 10.04 389 730980 74435 109783495
Gastrointestinal angiodysplasia 12.23 10.04 26 731343 1212 109856718
Oculogyric crisis 12.23 10.04 5 731364 3827 109854103
Mycobacterial infection 12.21 10.04 7 731362 4410 109853520
Blood glucose normal 12.21 10.04 5 731364 20 109857910
Nipple disorder 12.17 10.04 14 731355 379 109857551
Injection site hypersensitivity 12.15 10.04 40 731329 2431 109855499
Lichenification 12.13 10.04 23 731346 986 109856944
Injection site hypertrophy 12.11 10.04 8 731361 99 109857831
Lichen sclerosus 12.09 10.04 25 731344 1143 109856787
Meningocele 12.08 10.04 3 731366 0 109857930
Fungal balanitis 12.08 10.04 3 731366 0 109857930
Eyelid myokymia 12.08 10.04 3 731366 0 109857930
Babinski reflex test 12.08 10.04 3 731366 0 109857930
Autonomic seizure 12.08 10.04 3 731366 0 109857930
Pseudohypoglycaemia 12.08 10.04 3 731366 0 109857930
Transitional cell carcinoma urethra 12.08 10.04 3 731366 0 109857930
Diabetic dyslipidaemia 12.08 10.04 3 731366 0 109857930
Acute lung injury 12.07 10.04 47 731322 3104 109854826
Therapeutic drug monitoring analysis not performed 12.06 10.04 34 731335 1897 109856033
Hyponatraemic encephalopathy 12.03 10.04 14 731355 384 109857546
Intraductal papillary-mucinous carcinoma of pancreas 12.02 10.04 5 731364 21 109857909
Febrile bone marrow aplasia 12.02 10.04 67 731302 17398 109840532
Echocardiogram abnormal 12.02 10.04 42 731327 2632 109855298
Genital rash 12.01 10.04 27 731342 1308 109856622
Ventricular enlargement 11.98 10.04 19 731350 705 109857225
Vision blurred 11.96 10.04 1000 730369 128022 109729908
Gastrointestinal mucosal necrosis 11.96 10.04 11 731358 227 109857703
Blood glucose 11.95 10.04 6 731363 42 109857888
Large intestinal stenosis 11.95 10.04 5 731364 3775 109854155
Ludwig angina 11.92 10.04 12 731357 278 109857652
Amputation 11.87 10.04 22 731347 927 109857003
Scleritis 11.85 10.04 11 731358 5409 109852521
Pustular psoriasis 11.82 10.04 48 731321 13557 109844373
Generalised bullous fixed drug eruption 11.81 10.04 20 731349 784 109857146
Hypertransaminasaemia 11.78 10.04 103 731266 24152 109833778
Gamma-glutamyltransferase increased 11.78 10.04 507 730862 60802 109797128
Lactate pyruvate ratio increased 11.77 10.04 7 731362 71 109857859
Clonus 11.76 10.04 25 731344 8691 109849239
Expiratory reserve volume decreased 11.73 10.04 9 731360 143 109857787
Diabetic macroangiopathy 11.73 10.04 9 731360 143 109857787
Embolic cerebellar infarction 11.67 10.04 5 731364 23 109857907
Psychogenic tremor 11.67 10.04 5 731364 23 109857907
Exposure via skin contact 11.66 10.04 46 731323 13101 109844829
Haemorrhagic stroke 11.64 10.04 141 731228 13648 109844282
Stenotrophomonas infection 11.55 10.04 13 731356 5845 109852085
Ischaemic hepatitis 11.55 10.04 61 731308 4587 109853343
Eye injury 11.54 10.04 21 731348 7734 109850196
Depressed level of consciousness 11.51 10.04 877 730492 111401 109746529
Vascular cognitive impairment 11.50 10.04 6 731363 46 109857884
Pancreatic failure 11.48 10.04 38 731331 2316 109855614
Sinus arrest 11.46 10.04 57 731312 4185 109853745
Neuropathic ulcer 11.46 10.04 8 731361 109 109857821
Mental impairment 11.46 10.04 212 731157 22427 109835503
Acid base balance abnormal 11.44 10.04 15 731354 466 109857464
Insulin-like growth factor decreased 11.42 10.04 17 731352 596 109857334
Glucose urine 11.39 10.04 6 731363 47 109857883
Retinopathy proliferative 11.37 10.04 9 731360 150 109857780
Granuloma 11.37 10.04 29 731340 9461 109848469
Lipids abnormal 11.36 10.04 18 731351 667 109857263
Infusion site pain 11.35 10.04 68 731301 17351 109840579
Loss of personal independence in daily activities 11.35 10.04 846 730523 149174 109708756
Product appearance confusion 11.34 10.04 8 731361 111 109857819
Suspected suicide attempt 11.33 10.04 13 731356 351 109857579
Drug half-life increased 11.32 10.04 12 731357 296 109857634
Enterocolitis 11.31 10.04 76 731293 18873 109839057
Increased appetite 11.30 10.04 150 731219 14827 109843103
Accidental underdose 11.30 10.04 26 731343 1279 109856651
Leukoplakia 11.30 10.04 10 731359 196 109857734
Pneumomediastinum 11.27 10.04 10 731359 5026 109852904
Hypertensive emergency 11.26 10.04 48 731321 3303 109854627
Gastric ulcer 11.24 10.04 344 731025 39483 109818447
Stress fracture 11.24 10.04 19 731350 7202 109850728
Gingival pain 11.22 10.04 156 731213 15580 109842350
Meningitis cryptococcal 11.22 10.04 9 731360 4753 109853177
Total cholesterol/HDL ratio abnormal 11.22 10.04 7 731362 78 109857852
Nocturia 11.15 10.04 166 731203 16824 109841106
Abdominal pain upper 11.15 10.04 2086 729283 347025 109510905
Lymphadenopathy 11.14 10.04 329 731040 63506 109794424
Injection site bruising 11.12 10.04 256 731113 51007 109806923
Device related sepsis 11.12 10.04 21 731348 7626 109850304
Aplasia 11.12 10.04 22 731347 7851 109850079
Polymerase chain reaction 11.10 10.04 8 731361 115 109857815
Glycosylated haemoglobin 11.08 10.04 6 731363 50 109857880
Vulvovaginitis 11.07 10.04 13 731356 360 109857570
Heat stroke 11.06 10.04 33 731336 1902 109856028
Myasthenia gravis 11.06 10.04 90 731279 21421 109836509
Bone pain 11.04 10.04 337 731032 64796 109793134
Endometrial hyperplasia 11.03 10.04 18 731351 684 109857246
Enterochromaffin cell hyperplasia 10.99 10.04 7 731362 81 109857849
Type 3 diabetes mellitus 10.99 10.04 8 731361 117 109857813
Duplicate therapy error 10.93 10.04 14 731355 425 109857505
Blood thyroid stimulating hormone increased 10.92 10.04 127 731242 12174 109845756
Fistula 10.91 10.04 58 731311 15241 109842689
Hepatobiliary scan abnormal 10.88 10.04 6 731363 52 109857878
Hypernatriuria 10.88 10.04 5 731364 28 109857902
Viral mutation identified 10.86 10.04 8 731361 4411 109853519
Micturition frequency decreased 10.86 10.04 22 731347 991 109856939
Neurofibrosarcoma 10.85 10.04 11 731358 257 109857673
Genital infection female 10.85 10.04 7 731362 83 109857847
Breast cancer female 10.82 10.04 44 731325 12424 109845506
Bile duct stone 10.81 10.04 75 731294 6214 109851716
Electroencephalogram abnormal 10.81 10.04 15 731354 6158 109851772
Diabetic retinal oedema 10.80 10.04 14 731355 430 109857500
Large intestine perforation 10.80 10.04 65 731304 16564 109841366
Thyroid cancer recurrent 10.79 10.04 6 731363 53 109857877
Hypochloraemia 10.78 10.04 50 731319 3568 109854362
Tumour compression 10.77 10.04 10 731359 209 109857721
Hepatic failure 10.76 10.04 557 730812 68182 109789748
Central venous catheterisation 10.75 10.04 6 731363 3836 109854094
Transfusion 10.74 10.04 112 731257 25360 109832570
Neutropenic infection 10.74 10.04 4 731365 3241 109854689
Emphysematous pyelonephritis 10.73 10.04 16 731353 562 109857368
Pneumonia pseudomonal 10.73 10.04 21 731348 7525 109850405
Bacteroides infection 10.72 10.04 3 731366 2916 109855014
Toxoplasmosis 10.71 10.04 4 731365 3235 109854695
Opportunistic infection 10.71 10.04 5 731364 3538 109854392
Arterial spasm 10.71 10.04 9 731360 164 109857766
Thalamic infarction 10.69 10.04 26 731343 1326 109856604
Systemic mycosis 10.68 10.04 6 731363 3823 109854107
Crying 10.68 10.04 113 731256 25515 109832415
Groin abscess 10.68 10.04 33 731336 1939 109855991
Joint arthroplasty 10.68 10.04 5 731364 3532 109854398
Cholecystitis acute 10.67 10.04 155 731214 15627 109842303
Cholecystitis 10.65 10.04 235 731134 25647 109832283
Intestinal transit time decreased 10.65 10.04 8 731361 123 109857807
Acanthosis 10.65 10.04 16 731353 566 109857364
Vulvovaginal pruritus 10.65 10.04 47 731322 3284 109854646
Locomotive syndrome 10.64 10.04 4 731365 12 109857918
Venous aneurysm 10.64 10.04 4 731365 12 109857918
Respiratory symptom 10.59 10.04 148 731221 14797 109843133
Muscle oedema 10.58 10.04 11 731358 265 109857665
Mycobacterium avium complex infection 10.57 10.04 14 731355 5863 109852067
Peritonitis bacterial 10.57 10.04 35 731334 10498 109847432
Haematemesis 10.52 10.04 485 730884 58623 109799307
Creatinine renal clearance 10.51 10.04 6 731363 56 109857874
Parvovirus B19 infection 10.51 10.04 3 731366 2878 109855052
Necrotising soft tissue infection 10.47 10.04 15 731354 508 109857422
Diabetic eye disease 10.46 10.04 10 731359 217 109857713
Maximal voluntary ventilation abnormal 10.46 10.04 5 731364 31 109857899
Head injury 10.45 10.04 365 731004 42652 109815278
Fungaemia 10.44 10.04 15 731354 6071 109851859
Tongue haemorrhage 10.43 10.04 24 731345 1181 109856749
Deprescribing error 10.42 10.04 6 731363 57 109857873
Tooth disorder 10.41 10.04 135 731234 29374 109828556
Intestinal obstruction 10.40 10.04 270 731099 52957 109804973
Supraventricular extrasystoles 10.39 10.04 90 731279 7983 109849947
Anticonvulsant drug level increased 10.38 10.04 3 731366 2855 109855075
Essential hypertension 10.37 10.04 88 731281 7759 109850171
Near death experience 10.36 10.04 21 731348 946 109856984
Hydrocholecystis 10.34 10.04 16 731353 581 109857349
Orchidectomy 10.33 10.04 5 731364 32 109857898
Ventricular dyssynchrony 10.31 10.04 7 731362 91 109857839
Hepatitis acute 10.30 10.04 178 731191 18588 109839342
Insulin autoimmune syndrome 10.30 10.04 18 731351 724 109857206
Cross sensitivity reaction 10.28 10.04 13 731356 5554 109852376
Dermatitis acneiform 10.28 10.04 46 731323 12649 109845281
Device leakage 10.28 10.04 63 731306 15985 109841945
Drug level below therapeutic 10.25 10.04 41 731328 11632 109846298
Benign pancreatic neoplasm 10.25 10.04 6 731363 59 109857871
Vulvovaginal candidiasis 10.23 10.04 46 731323 3239 109854691
Electrocardiogram T wave amplitude decreased 10.23 10.04 19 731350 802 109857128
Dumping syndrome 10.23 10.04 9 731360 175 109857755
Catheter management 10.21 10.04 6 731363 3729 109854201
Foreign body aspiration 10.21 10.04 15 731354 520 109857410
Serum ferritin abnormal 10.20 10.04 14 731355 455 109857475
Venous thrombosis 10.18 10.04 26 731343 8479 109849451
Plasmapheresis 10.18 10.04 19 731350 805 109857125
Vascular encephalopathy 10.18 10.04 19 731350 805 109857125
Acne 10.18 10.04 158 731211 33362 109824568
Focal epithelial hyperplasia 10.18 10.04 4 731365 14 109857916
Muscle twitching 10.17 10.04 138 731231 29797 109828133
Carboxyhaemoglobin increased 10.16 10.04 6 731363 60 109857870
Mood swings 10.16 10.04 99 731270 22713 109835217
Subdural hygroma 10.16 10.04 16 731353 590 109857340
Congestive cardiomyopathy 10.15 10.04 141 731228 14078 109843852
Hepatocellular carcinoma 10.15 10.04 105 731264 9775 109848155
Ankylosing spondylitis 10.15 10.04 61 731308 15551 109842379
Enzyme abnormality 10.14 10.04 13 731356 395 109857535
Leukaemia recurrent 10.13 10.04 4 731365 3127 109854803
Psychiatric decompensation 10.10 10.04 14 731355 5751 109852179
Injection site erosion 10.10 10.04 9 731360 178 109857752
Bladder sphincter atony 10.10 10.04 10 731359 227 109857703
Faeces soft 10.07 10.04 116 731253 11094 109846836
Osteosclerosis 10.07 10.04 9 731360 4506 109853424
Insulin-requiring type 2 diabetes mellitus 10.06 10.04 9 731360 179 109857751
Hypoalbuminaemia 10.05 10.04 133 731236 28841 109829089
Large intestine polyp 10.04 10.04 148 731221 14969 109842961

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD26 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD28 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD31 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD34 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0002471 Biguanides
FDA EPC N0000175565 Biguanide
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35816 leprostatic drug
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:50864 insulin-sensitizing drug
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:74518 anti-obesity agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:145947 antiatherosclerotic agent
CHEBI has role CHEBI:149553 anticoronaviral agent
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

A10BA Biguanides 2 drugs
buforminphenformin
A10BD Combinations of oral blood glucose lowering drugs 19 drugs
acarbosealogliptincanagliflozindapagliflozinempagliflozinertugliflozinevogliptingemigliptinglimepiridelinagliptinlobeglitazonephenformin show all 19 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Induction of ovulation in polycystic ovarian syndrome indication 237055002 DOID:11612
Controlled ovarian stimulation indication 732970000
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Polycystic ovary syndrome off-label use 237055002 DOID:11612
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe Hypoxemia contraindication
Severe Autonomic Insufficiency contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Prolonged-Severe Nausea and Vomiting contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 100MG BASE JANUMET XR MSD SUB MERCK N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MSD SUB MERCK N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MSD SUB MERCK N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12115179 Feb. 11, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 11911388 April 10, 2030 LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 Dec. 19, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 Dec. 19, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 Dec. 19, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 Dec. 19, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12527810 April 22, 2033 USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11666590 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11813275 April 3, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12263153 April 3, 2034 TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12427162 April 3, 2034 DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 12433906 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11833166 April 3, 2034 TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML/MIN/1.73 M2 AND <60 ML/MIN/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 12364700 June 8, 2037 TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML/MINUTE/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
10MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE MSN A211479 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
10MG;500MG DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE MSN A211479 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
5MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE MSN A211479 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
5MG;500MG DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE MSN A211479 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
10MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE SUN PHARM A211491 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
10MG;500MG DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE SUN PHARM A211491 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
5MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE SUN PHARM A211491 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
10MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE ALKEM LABS LTD A211563 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
10MG;500MG DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE ALKEM LABS LTD A211563 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
5MG;1GM DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE ALKEM LABS LTD A211563 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
5MG;500MG DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE ALKEM LABS LTD A211563 April 6, 2026 RX TABLET, EXTENDED RELEASE ORAL Oct. 3, 2026 PATENT CHALLENGE
1GM;EQ 50MG BASE SITAGLIPTIN AND METFORMIN HYDROCHLORIDE SANDOZ A202388 Dec. 2, 2025 RX TABLET ORAL Nov. 24, 2026 PATENT CHALLENGE
500MG;EQ 50MG BASE SITAGLIPTIN AND METFORMIN HYDROCHLORIDE SANDOZ A202388 Dec. 2, 2025 RX TABLET ORAL Nov. 24, 2026 PATENT CHALLENGE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL June 12, 2027 NEW PATIENT POPULATION
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL June 12, 2027 NEW PATIENT POPULATION
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL June 12, 2027 NEW PATIENT POPULATION
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL June 12, 2027 NEW PATIENT POPULATION
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL June 12, 2027 NEW PATIENT POPULATION
1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 DISCN TABLET, EXTENDED RELEASE ORAL Oct. 11, 2027 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 DISCN TABLET, EXTENDED RELEASE ORAL Oct. 11, 2027 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 DISCN TABLET, EXTENDED RELEASE ORAL Oct. 11, 2027 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Dec. 12, 2027 PEDIATRIC EXCLUSIVITY
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Dec. 12, 2027 PEDIATRIC EXCLUSIVITY
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL Dec. 12, 2027 PEDIATRIC EXCLUSIVITY
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Dec. 12, 2027 PEDIATRIC EXCLUSIVITY
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL Dec. 12, 2027 PEDIATRIC EXCLUSIVITY
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Dec. 18, 2027 NEW PATIENT POPULATION
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Dec. 18, 2027 NEW PATIENT POPULATION
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Dec. 18, 2027 NEW PATIENT POPULATION
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL Dec. 18, 2027 NEW PATIENT POPULATION
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 18, 2027 NEW PATIENT POPULATION
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 18, 2027 NEW PATIENT POPULATION
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 18, 2027 NEW PATIENT POPULATION
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 18, 2027 NEW PATIENT POPULATION
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL June 18, 2028 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
D00944 KEGG_DRUG
1115-70-4 SECONDARY_CAS_RN
4020898 VANDF
4023979 VANDF
C0025598 UMLSCUI
CHEBI:6801 CHEBI
MF8 PDB_CHEM_ID
CHEMBL1431 ChEMBL_ID
4091 PUBCHEM_CID
DB00331 DRUGBANK_ID
CHEMBL1703 ChEMBL_ID
D008687 MESH_DESCRIPTOR_UI
965 INN_ID
4779 IUPHAR_LIGAND_ID
9100L32L2N UNII
151827 RXNORM
370164 MMSL
41717 MMSL
5063 MMSL
592 MMSL
d03807 MMSL
003483 NDDF
004534 NDDF
109081006 SNOMEDCT_US
109083009 SNOMEDCT_US
372567009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6225 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 29 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6250 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 29 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6260 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 29 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6270 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 29 sections
XIGDUOXR HUMAN PRESCRIPTION DRUG LABEL 2 0310-6280 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 29 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6001 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 30 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-6002 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 30 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7185 TABLET, FILM COATED 500 mg ORAL ANDA 29 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7186 TABLET, FILM COATED 850 mg ORAL ANDA 29 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-7187 TABLET, FILM COATED 1000 mg ORAL ANDA 29 sections
Saxagliptin and Metformin HUMAN PRESCRIPTION DRUG LABEL 2 0378-8175 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL ANDA 33 sections
Saxagliptin and Metformin HUMAN PRESCRIPTION DRUG LABEL 2 0378-8176 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 33 sections
Saxagliptin and Metformin HUMAN PRESCRIPTION DRUG LABEL 2 0378-8177 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL ANDA 33 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5739 TABLET, FILM COATED 500 mg ORAL ANDA 23 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5745 TABLET, FILM COATED 850 mg ORAL ANDA 23 sections
Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-5746 TABLET, FILM COATED 1000 mg ORAL ANDA 23 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0146 TABLET, FILM COATED 500 mg ORAL NDA 33 sections
Jentadueto HUMAN PRESCRIPTION DRUG LABEL 2 0597-0147 TABLET, FILM COATED 850 mg ORAL NDA 33 sections